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 Summary 
 1 
Summary 
 
 
Cardiovascular disease is the most common mortality risk in the industrialized world. 
Myocardial infarction (MI) results in the irreversible loss of cardiac muscle, triggering 
pathophysiological remodelling of the ventricle and development of heart failure. Insufficient 
myocardial capillary density within the surviving myocardium after MI has been identified as 
a critical event in this process, although the underlying molecular signalling pathways of 
cardiac angiogenesis are mechanistically not well understood. The discovery of microRNAs 
(miRNAs, miRs), small non-coding RNAs with 19-25 nucleotides in length, has introduced a 
new level of the regulation of cardiac signalling pathways. MiRNAs regulate gene expression 
post-transcriptionally by binding to their complementary target messenger RNAs (mRNAs) 
and represent promising therapeutic targets for gene therapy. 
 
Here, it is shown that cardiac miR-24 is primarily expressed in cardiac endothelial cells and 
upregulated following MI in mice and hypoxic conditions in vitro. Enhanced miR-24 
expression induces endothelial cell apoptosis and impairs endothelial capillary network 
formation. These effects on endothelial cell biology are at least in part mediated through 
targeting of transcription factor GATA2, histone deacetylase H2A.X, p21-activated kinase 
PAK4 and Ras p21 protein activator RASA1. Mechanistically, target repression abolishes 
respective and secondary downstream signalling cascades. Here it is shown that endothelial 
GATA2 is an important mediator of cell cycle, apoptosis and angiogenesis at least in part by 
regulation of cytoprotective heme oxygenase 1 (HMOX1). Moreover, additional control of 
endothelial apoptosis is achieved by the direct miR-24 target PAK4. Its kinase function is 
essential for anti-apoptotic Bad phosphorylation in endothelial cells. In a mouse model of MI, 
blocking of endothelial miR-24 by systemic administration of a specific antagonist 
(antagomir) enhances capillary density in the infarcted heart and preserves cardiac function.  
 
The current findings indicate miR-24 to act as a critical regulator of endothelial cell apoptosis 
and angiogenesis. Modulation of miR-24 may be potentially a suitable strategy for therapeutic 
intervention in the setting of ischemic heart diseases. 
 
 Zusammenfassung 
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Zusammenfassung 
 
 
Kardiovaskuläre Erkrankungen sind die häufigste Todesursache in der industrialisierten Welt. 
Nach Myokardinfarkt (MI) kommt es zum Verlust kardialen Gewebes und zu pathologischen 
Umbauprozessen im Herzen, die oftmals in einer Herzinsuffizienz münden. Dabei spielt eine 
insuffiziente Gefäßversorgung im überlebenden Myokard eine wichtige Rolle. Zugrunde 
liegende molekulare Mechanismen oder gentherapeutische Strategien zur Verbesserung der 
Angiogenese nach MI sind jedoch nur unzureichend verstanden und etabliert. Die Entdeckung 
sogenannter microRNAs (miRNAs, miRs), kleiner nicht-kodierender RNAs mit einer Länge 
von 19-25 Nukleotiden, zeigt eine neue Ebene der Komplexität bei der Regulation 
kardiovaskulärer Signalwege auf. So regulieren miRNAs die Genexpression post-
transkriptional durch inhibitorische Bindung an komplementäre messenger RNAs. Die 
Modulation von miRNAs und damit nachfolgenden Gen-Netzwerken könnte daher ein 
wichtiger Baustein bei der Entwicklung neuer Therapiestrategien in der kardiovaskulären 
Medizin werden. In dieser Arbeit wird gezeigt, dass kardiale miR-24 überwiegend in 
kardialen Endothelzellen exprimiert ist und nach Myokardinfarkt im Mausmodell sowie nach 
Hypoxie in vitro hochreguliert wird. Die verstärkte miR-24-Expression induziert endotheliale 
Apoptose und vermindert die Kapillarbildungsfähigkeit endothelialer Zellen in einem 
Angiogeneseassay. Diese funktionalen Defekte werden über die Repression des 
Transkriptionsfaktors GATA2, der Histon-Deacetylase H2A.X, der p21-aktivierten Kinase 
PAK4 und dem p21 Protein-Aktivator RASA1 vermittelt. GATA2 wird in dieser Arbeit als 
wichtiger Faktor für die Zellzykluskontrolle, Apoptose und Angiogenese beschrieben, wobei 
die Regulation direkter Effektoren wie Hämoxygenase 1 (HMOX1) essentiell ist. Weiterhin 
wird über die miR-24-abhängige Modulation von PAK4 endotheliale Apoptose kontrolliert. 
PAK4 weist eine anti-apoptotische Funktion auf, indem es zu einer Phosphorylierung des 
Proteins Bad führt. Die spezifische Repression endogener miR-24 durch einen Antagonisten 
(Antagomir) in einem murinen MI-Modell erhöht die Kapillardichte im infarzierten Gewebe 
und verbessert die kardiale Funktion. Zusammenfassend zeigen die Erkenntnisse dieser Arbeit 
eine wichtige Funktion für miR-24 bei der Regulation endothelialer Apoptose und 
Angiogenese. Die Modulation von miR-24 könnte ein interessantes neues therapeutisches 
Konzept zur Verbesserung der Angiogenese nach MI darstellen. 
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1. Introduction 
 
 
1.1 Cardiac remodelling and heart failure 
 
 
Myocardial infarction (MI) often leading to heart failure is a serious clinical disorder and 
represents a critical health burden worldwide. Cardiovascular disease causes 48% of deaths in 
Europe (European Heart Network, 2008) and 35.3% of deaths in the United States (American 
Heart Association, 2005). Therefore therapeutic interventions regarding prevention and/or 
accute therapy have to be improved. These approaches rely on the current understanding of 
heart failure induced by cardiovascular disease including myocardial infarction (MI), 
coronary artery disease (CAD) or hypertension. 
 
The heart is a complex organ, multi-chambered, built up from different cell types bearing 
specific features. The cardiomyocyte is terminally differentiated and conducts tension by 
shortening. In contrast, the extracellular matrix made up by collagen type I and III synthesized 
from cardiac fibroblasts provides a viscoelastic scaffold preventing sarcomeric deformation 
(Erlebacher et al., 1984). Furthermore it links cardiomyocytes to adjacent vasculature and 
microcapillaries supplying the organ with nutritive blood flow (Weber, 1997). Cell to cell 
interaction, conduction and communication is important in healthy and diseased myocardium. 
Moreover, complex mechanisms regulate the hearts shape and biology thus altering cardiac 
performance. Mechanistically, certain molecular signalling processes are responsible for 
cardiac remodelling transducing fundamental reactions. 
 
Cardiac remodelling relies on diverse stimuli or conditions (figure 1.1). For example, adjacent 
consequences like atrophy or physiologic hypertrophy are less harmful since characterized by 
a reversible state. In contrast, pathologic hypertrophy forced by persistent cardiac stress is the 
precursor for heart failure. Moreover, heart failure can be seen as a progressive disease 
affecting at least the neurohumoral system, genetic factors and global cardiac structure 
(Francis et al., 1984, Mann, 1999, McMurray and Pfeffer, 2002). 
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Figure 1.1: Conditions leading to atropy and physiologic or pathologic hypertrophy. Pathologic hypertrophy is 
accompanied by several circumstances potentially leading to heart failure (Hill and Olson, 2008). 
 
In general, heart failure is accompanied by myocardial hypertrophy. Initially, myocardial 
hypertrophy is characterized by the enlargement of resident cardiomyocytes thereby 
enhancing cardiac muscle power. Thus, this physiological growth reaction should directly 
support cardiac performance and outcome unless other risk factors are abandoned. 
 
Leading factors for the development of maladaptive pathologic hypertrophy include MI and 
prolonged hypertension. Such factors accelerate cardiomyopathy and often disturb myocardial 
conduction. Persistent cardiac stress results in the irreversible loss of cardiac muscle, 
triggering remodelling of the cardiac muscle and the development of heart failure (reviewed 
in Jessup and Brozena, 2003, Hill and Olson, 2008). In addition, alterations in heart structure 
are accompanied by sustained interstitial fibrosis impairing and decreasing cardiac pump 
function. 
 
Basically, cardiac remodelling post-MI is crucially dependent on the infarct size determining 
heart architecture alteration (McKay et al., 1986). Immediately after this ischemic event, 
macrophages, monocytes and neutrophiles infiltrate into the infarcted area contributing to 
local inflammatory response. 
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Infarct remodelling has been divided a long time ago into early phase (within 72 hours) and a 
late phase beginning thereafter. Since the infarct and myocyte death expand in early phase, 
ventricular rupture or aneurysm formation is possible (Erlebacher et al., 1984). In contrast, 
late phase remodelling has to be seen as a more global alteration of ventricular shape resulting 
in dilatation, distortion and hypertrophy (Sutton and Sharpe, 2000 and figure 1.2). The 
underlying mechanisms following infarct expansion are diverse. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2: Time response for ventricular remodelling after myocardial infarction. Ischemic area expands 
within hours to days and finally results in global cardiac remodelling impeding systolic function 
(Jessup and Brozena, 2003). 
 
Immediate infarct expansion is supported by the activation of matrix metalloproteinases 
(MMPs) released from neutrophils degrading extracellular matrix (Cleutjens et al., 1995). 
Therefore infarct area progression is fast and results in wall thinning and ventricular dilatation 
establishing diastolic and systolic wall stress (Warren et al., 1988). Then, wall stress defines a 
stimulus for cardiac hypertrophy which is transduced to intracellular signalling by angiotensin 
II (Ang II) release (Sadoshima et al., 1992). This, in turn, increases the contractile force by 
enhancing protein synthesis of contractile assembly units in the myocyte. In contrast, cardiac 
fibroblasts are also stimulated for protein synthesis and proliferation supporting fibrosis and 
scar formation. Moreover, Ang II reprogrammes cardiac cells to a fetal transcriptome (fetal 
gene reprogramming) by induction of several transcription factors like c-fos, c-jun or c-myc 
further contributing to heart failure (Sadoshima et al., 1993). 
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The noninfarcted zone (remote myocardium) is simultaneously affected by infarct expansion 
responding to preserve stroke volume and to antagonize infarct injury (Lew et al., 1985). 
Additionally, alteration of circulatory hemodynamics triggers further neurohumoral response 
by activation of the renin-angiotension-aldosterone (RAAS) system and increases production 
of atrial and brain natriuretic peptides (ANP and BNP) counteracting Ang II signalling as an 
adaptive response (reviewed in Sutton and Shape, 2000). 
 
The early remodelling phase is dominated by local inflammatory signalling that is transduced 
by mechanical forces throughout the whole ventricle leading over to late remodelling. Here 
myocardial repair is more in focus relying on collagen scar formation that distributes elevated 
wall stresses more evenly (Sutton and Shape, 2000). Deposition of collagen matrix begins at 
day 2 to 4 depending on collagen type and previous signalling (Cleutjens et al., 1995). 
Briefly, the myocyte-released cytokine TGF-β1 modifies fibroblast and macrophage 
chemotaxis and proliferation. Additionally, the phenotypic transition from interstitial 
fibroblasts to myofibroblasts is forced defining expression of receptors to Ang II and TGF-β1. 
Furthermore myofibroblasts encode the ligands for these receptors, thus enabling the 
autoregulation of collagen turnover by MMPs (Desmouliere et al., 1993). Nevertheless, the 
formation of a fibrin-fibronectin matrix is a prerequisite for adherence of myofibroblast 
building up the crescent scar (Knowlton et al., 1992). Ongoing myofibroblast activation 
potentiates scar signalling leading to myocyte substitution within 28 days (Cleutjens et al., 
1995). Afterwards, myofibroblasts become apoptotic leaving behind a greatly increased 
extracellular scaffold. 
 
The different remodelling phases offer various potential therapeutic approaches. Nevertheless 
treatment of heart failure is difficult and novel treatment strategies are warranted. Several 
pathophysiological mechanisms are stimulated upon cardiac dysregulation offering different 
therapeutic approaches. Since primary therapy is based on mechanical or pharmacological 
intervention some of the main counteracting opportunities should be highlighted here. It is 
well know that aldosterone production in the adrenal gland is increasing in heart failure 
leading to ventricular hypertrophy and dysfunction. Aldosterone antagonists are therefore 
powerful compounds to counteract these negative effects.  
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Besides pharmacological intervention, cell transplantation has been investigated in several 
clinical studies such as REPAIR-AMI (acute myocardial infarction) study (Schachinger et al., 
2006; Dill et al., 2009). Here, the researchers questioned whether bone marrow derived 
progenitor cell transplantation inhibits processing of adverse remodelling events after 
myocardial infarction. In summary, cardiac outcome one year after intracoronary cell 
transfusion has been validated beneficial for patients, but the net effect on cardiac 
improvement was rather small and novel therapeutic strategies are needed. 
 
 
1.2 Angiogenesis and apoptotic signalling 
 
 
The generation of blood vessels in the developing embryo or in the adult is determinded by 
two distinct processes: vasculogenesis and angiogenesis. While vasculogenesis comprises the 
de novo formation of blood vessels, angiogenesis involves growth of existing blood vessels. 
Additional de novo postnatal vasculogenesis might occur by progenitor cell differentiation to 
the endothelial lineage (Asahara et al., 1999). 
 
Suppressed oxygen supply results in myocyte necrosis and infarct expansion. Insufficient 
myocardial capillary density within the surviving myocardium after MI has been identified as 
a critical event in pathological remodelling. Myocardial capillaries are formed by endothelial 
cells (ECs) placing a scaffold building up the vasculature. Generally, ECs play fundamental 
roles in vascular development and disease. Formation of new blood vessels by stimulating 
pre-existing ECs (angiogenesis) is crucial for improvement in blood perfusion. Angiogenic 
stimuli activate ECs to migrate and proliferate thereby enhancing generation of primary 
capillaries. Afterwards, these structures undergo remodelling accompanied by sprouting, 
branching or intus-susception . Furthermore smooth muscle cells may be recruited to sites of 
newly formed blood vessels lining the internal bloodstream layer. Angiogenesis can be 
beneficial in terms of ischemic disease, but on the other hand aberrant angiogenesis may be 
responsible for cancer progression (Hanahan et al., 1996). Major angiogenic factors include 
vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF). 
Moreover, VEGF is responsible for progenitor cell mobilization from the bone marrow 
(Asahara et al., 1999). In contrast, anti-angiogenic factors like naturally occurring 
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thrombospondin-1 counteract VEGF and bFGF signalling thus balancing angiogenesis 
(Jimenez et al., 2000).  
 
 
1.2.1 General mechanisms of angiogenesis 
 
 
Angiogenesis is a dynamic process based on extracellular signalling transduced by receptor-
tyrosine kinases (RTKs) to the intracellular compartment thus activating gene transcription. 
VEGF and bFGF are important angiogenic modulators stimulating survival, proliferation, 
migration and differentiation of primary and stable ECs. Essentially, bFGF and VEGF have to 
be activated and sequestered in the extracellular matrix by plasminogen system proteinases of 
different families. Of note, urokinase-type plasminogen activator (u-PA) is essential for 
revascularization upon MI (Heymans et al., 1999). In addition, hypoxia triggers VEGF 
expression by upregulation and stabilization of the transcription factor HIF-1α (Forsythe et 
al., 1996). Mechanistically, both bFGF and VEGF bind their RTK cell surface receptors. 
Ligand binding induces immediate receptor dimerization with subsequent intracellular 
autophosphorylation. This provides a basis for further signalling cascades transduced by Ras 
via mitogen-activated protein kinase (MAPK) to the cell nucleus (Cross and Claesson-Welsh, 
2001). Interestingly, capillaries induced either by bFGF or VEGF show morphological 
differences implicating different roles for both angiogenic factors (Cao et al., 2004). More 
importantly, the FGF system seems to control VEGF signalling during angiogenesis by 
control of VEGF expression (Seghezzi et al., 1998; Presta et al., 2005). 
 
Endothelial cell survival or anti-apoptotic signalling activated by VEGF maintains and 
stabilizes newly formed blood vessels. The underlying mechanisms in human umbilical vein 
endothelial cells (HUVECs) comprise activation of the anti-apoptotic kinase, Akt/PKB, via a 
PI3K-dependent pathway (Gerber et al., 1998). Sustained activation of cellular survival is 
reached by the upregulation of anti-apoptotic proteins like Bcl-2 thus inhibiting downstream 
caspase cascades (Gerber et al., 1998). Furthermore, Akt activation stimulates the 
phosphorylation of the pro-apoptotic protein Bad thereby inhibiting apoptosis signalling 
(Khwaja, 1999). Additionally, sustained Akt activation enhances NO synthase expression 
thereby increasing second messenger NO (Dimmeler et al., 1999; Fulton et al., 1999).  
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Supporting the essential role of VEGF for EC survival, VEGF loss in mice is embryonal 
lethal due to enhanced EC apoptosis and hemorrhage (Carmeliet et al., 1996, Ferrara et al., 
1996). In addition to the aforementioned angiogenic signalling angiogenesis can be routed by 
tiny non-coding RNAs (microRNAs) called “angiomiRs” which have been reviewed recently 
(Wang and Olson, 2009). Thereby, angiogenic factors are post-transcriptionally regulated and 
modulated. 
 
Taken together, angiogenic signalling directly involves pro- or anti-apoptotic cascades. 
Underlying pathways and regulatory mechanisms are tightly embedded in fundamental 
cellular signal transduction networks. 
 
 
1.2.2 Apoptosis signalling 
 
 
The balance of cellular proliferation and apoptosis (programmed cell death) is an essential 
process during embryogenesis, organ development and in the adult regulating tissue 
homeostasis. In contrast to necrosis, apoptosis is characterized by an intact membrane 
structure. Additionally, apoptotic cells condense chromatin and shrink in size (Kerr et al., 
1972). The discovery of apoptotic pathways has led to a well-defined understanding of 
involved signalling cascades. Noteworthy, two pathways sharing common factors of the Bcl-2 
protein family have been identified: An extrinsic guided by cell surface death receptors and an 
intrinsic pathway transduced by various Bcl-2 proteins directly affecting mitochondrial 
remodelling. Overall, both pathways aim towards the activation of cysteinyl aspartate 
proteases (caspases). Once activated, apoptosis cascades develop suicidal character thereby 
conducting substrate proteolysis and cellular destruction. 
 
Briefly, the extrinsic pathway is triggered by the binding of death ligands like Fas or TNFα to 
their receptors therefore known as death receptors. Instantly, ligand binding induces 
conformational changes leading to the formation of an intracellular multiprotein complex 
(death induced signalling complex, DISC) recruiting and activating caspase-8 (Ashkenazi and 
Dixit, 1999). This initiator caspase then transduces death signals towards downstream 
executioner caspase-3 (Scaffidi et al., 1998).  
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Additionally, caspase-8 might cleave Bid protein thus interacting and contributing to the 
intrinsic apoptosis pathway by altering mitochondrial architecture (Yin et al., 1999). The 
mitochondria are the key cellular organelles for the intrinsic pathway (Newmeyer and 
Ferguson-Miller, 2003). Inducing signals comprise DNA damage, oxidative stress and growth 
factor deprivation. Underlying signal transduction is tightly regulated by gatekeeper Bcl-2 
proteins that have opposing functions. Remarkable, pro-survival members like Bcl-2 or Bcl-
xL are inhibited by direct interaction with Bad and Puma pro-apoptotic proteins characterized 
by a BH3 domain (Chen et al., 2005). The direct inhibitory Bad Bcl-xL heterodimerization is 
reverted by kinase-dependent phosphorylation of Bad leading to a cytosolic sequestration with 
14-3-3 proteins (Zha et al., 1996). On the other hand, Bcl-2 and Bcl-xL counteract Bax and 
Bak function. These Bcl-2 proteins can oligomerize and structurally integrate into the 
mitochondrial outer membrane thus promoting pore formation and efflux of pro-apoptotic 
cytochrome c and Smac/Diablo (Mikhailov et al., 2003). Moreover, mitochondria begin to 
fragment linking apoptosis to mitochondrial division machinery (Martinou and Youle, 2006). 
Cytosolic cytochrome c is bound by Apaf-1 thus scaffolding the apoptosome. Afterwards, this 
multimeric protein complex binds and activates caspase-9 (Hakem et al., 1998; Shi, 2006). 
Additionally, Smac/Diablo can bind to caspase inhibitors thereby activating caspases 
independently from apoptosome mechanism (Du et al., 2000). In cardiomyoctes, low levels of 
Apaf-1 require Smac/Diablo release from mitochondria for caspase activation. This 
mechanism delays apoptosis progress especially for post-mitotic cells offering an extra 
protection towards random death (Potts et al., 2005). Interestingly, deregulated apoptotic 
events contribute to origin and progression of cardiovascular disease triggered by myocardial 
infarction for example. Meanwhile, global heart architecture suffers from the loss of 
cardiomyocytes and the decrease of surrounding vessels. 
 
 
1.2.3 Endothelial cell apoptosis in the cardiovascular system 
 
 
Generally, endothelial cells assembled in new vessels become stabilized may survive a long 
time. Therefore, endothelial survival necessarily serves as a potent mediator for the 
vasculature in the cardiovascular system. Nevertheless, programmed cell death (apoptosis) 
coordinates tissue homeostasis in development and adult tissue.  
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During embryonal development, VEGF depletion causes enhanced endothelial cell apoptosis 
(Carmeliet et al., 1996, Ferrara et al., 1996). Thereby, vascular abnormalities like hemorrhage 
appear which perturbate the generation of a proper vascular system. In the adult, pathological 
conditions such as congestive heart failure misbalance regulatory mechanisms in the 
cardiovascular system by inducing apoptosis in ECs thus leading to vessel remodelling 
(Rossig et al., 2000).  
 
Inductors of EC apoptosis include the inflammatory cytokine TNFα, reactive oxygen species 
(ROS), oxidized LDL or others (Robaye et al., 1991; Dimmeler et al. 1997, 1999; Hermann et 
al., 1997). Mechanistically, oxidized LDL and TNFα induce Akt dephosphorylation thus 
disabling the PI3K/Akt pathway (Hermann et al., 2000). Furthermore, a lack of hemodynamic 
force results in EC apoptosis and vessel regression. Exposure of human ECs to laminar flow 
inhibits the activation of apoptotic caspase-3 via shear stress-stimulated release of NO. The 
second messenger NO then deactivates caspase-3 active site by S-nitrosylation (Hermann et 
al., 1997). Pro-survival pathways for the endothelium are mostly mediated by the 
aforementioned pro-angiogenic cytokines VEGF and bFGF. By way of example, direct VEGF 
addition to cultured glucose-stressed ECs reverts the apoptotic phenotype (Yang et al., 2008). 
Mechanistically, VEGF leads to suppression of Bax/Bcl-2 ratio, cleavage of caspase-3, 
reduction in excess ROS and prevention of calcium overload induced by high glucose 
concentration. Additionally, angiopoietin I (Ang I) may bind to Tie2 thus abrogating EC 
apoptosis via activation of PI3K/Akt pathway (Kim et al., 1999, 2000). 
 
In summary, endothelial cell apoptosis is dependent on different stimuli that also guide pro- 
or anti-angiogenic pathways (figure 1.3). Overall, intact capillary structure to provide 
nutrition and oxygen supply is a prerequisite for proper cardiac performance and function. 
The identification of potential genetic regulators is crucial for the development of appropriate 
therapeutics aiming at the modulation of angiogenesis. Besides the classical dogma of gene 
regulation by transcription factors, new gene regulatory pathways have risen offering great 
therapeutic opportunities. 
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Figure 1.3: Regulatory stimuli influencing endothelial cell apoptosis. Diverse pro- or anti- angiogenic factors 
have an impact on the cellular apoptosis network (Dimmeler et al., 2000). 
 
 
1.3 MicroRNAs (miRNAs): regulatory RNAs 
 
 
The discovery of small, 19-25 nucleotide long non-coding RNAs regulating gene expression 
post-transcriptionally in C.elegans in 1993 has established a broad field of research (Lee et 
al., 1993; Wightman et al., 1993). This new class of RNAs has been termed microRNAs 
(miRNAs) later on. Recently some issues about miRNA biology in mammalians have been 
dissected while others are still unclear. More interestingly, miRNAs seem to be key players 
for many biological functions and processes including apoptosis (Brennecke et al., 2003). 
Briefly, miRNAs are endogeneous gene regulators, comprising more than 600 heavily 
conserved members still growing in number (data from miRBase at 
http://microrna.sanger.ac.uk). Thus, miRNAs are capable to regulate more than 30% of all 
protein-coding genes (Lewis et al., 2005; Krutzfeldt and Stoffel, 2006; Griffiths-Jones et al., 
2008). MiRNAs repress target mRNAs through an antisense mechanism binding in the 3´-
untranslated region (UTR) of mRNAs thereby inhibiting protein synthesis. In contrast to 
small inhibitory RNA (siRNA) mediated gene-silencing mammalian miRNAs often show 
partial complementary to respective mRNAs only. In cellular context a single miRNA might 
also be differently expressed.  
 Introduction 
 
  13 
More importantly, one miRNA has usually about at least 200 target mRNAs. Thus, miRNA-
guided regulation of gene networks is quite usual because miRNAs per se affect more than 
one level of regulation. Investigations regarding miRNAs have been employed for various cell 
types and in diverse disease settings. Of note, miRNAs have been reported being dysregulated 
in human pathological disease like cancer or heart failure thereby offering interventional 
therapeutic approaches (Esquela-Kerscher and Slack, 2006; van Rooij and Olson, 2007; Thum 
et al., 2007). 
 
MiRNA biogenesis involves stepwise processes beginning with the transcription of miRNA 
genes, further processing towards functionally active miRNAs finally repressing translation 
(figure 1.4). Initially, miRNA genes characterized are transcribed by RNA polymerase II to 
primary miRNAs (pri-miRNAs) approximately 2 kb in length. Additionally, pri-miRNAs are 
5´ 7-methyl-guanosine (m7G)-capped and polyadenylated (Lee et al., 2004).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4: Overview on miRNA biogenesis and function. In the nucleus, miRNA genes are transcribed to pri-
miRNA structures, processed and translocated by a nucleus export machinery to the cytoplasm. 
Here, miRNA and 3´-UTR target sequence form a heteroduplex leading to translational inhibition 
(Esquela-Kerscher and Slack, 2006). 
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Of note, miRNA geneloci are spread out the whole genome. Precisely, miRNA genes can 
occur within genes (intronic) or just between genes (intergenic). Intronic miRNAs or 
“miRtrons” are thus spliced and generated from primary gene transcripts of their host genes 
thereby offering an alternative mechanism to classical processing of pri-miRNAs (Ruby et al., 
2007). Moreover, miRNA genes are often clustered and transcribed in polycistronic manner 
cooperatively (Altuvia et al., 2005). Nonetheless, the regulation of miRNA expression is 
mostly unclear. Some miRNA geneloci possess unique promoter or enhancer regions. By way 
of example, this scenario has been suggested for transcriptional activation by serum response 
factor (Niu et al., 2007). In contrast, other miRNA gene loci are regulated by regulatory 
elements that are responsible for host gene transcription thus located far away. 
 
In the nucleus, pri-miRNAs are further processed to stem-loop pre-miRNAs. A 500-600 kDa 
microprocessor complex consisting of the nuclear RNaseIII endonuclease Drosha and 
cofactor DiGeorge-syndrome critical region protein 8 (DGCR8, Pasha) is necessary to 
generate 60-70 nucleotide pre-miRNA. Interestingly, pre-miRNAs characterize a 3´ overhang 
of 2 nucleotides being a signal for further recognition (Gregory et al., 2004). Being the key of 
miRNA biogenesis, nuclear exportin-5 mediates translocation of pre-miRNAs to the 
cytoplasm (Lund et al., 2004). In the cytosol, pre-miRNAs are cleaved by a RNaseIII enzyme 
Dicer containing complex along with the transactivating response RNA-binding protein 
(TRBP) (Hutvagner et al., 2001). This step generates the mature hairpin duplex designated as 
miRNA-miRNA*. The inhibition of translation initiation is finally mediated by the RNA-
induced silencing complex (RISC). Thus, one strand of the miRNA duplex is preferentially 
incorporated into RISC while the miRNA* strand is degraded (Gregory et al., 2005). 
Nevertheless, a gene suppressive function for the miRNA* strand has been reported since it 
can associate with RISC proteins (Okamura et al., 2008). The RISC scaffold is built up by 
proteins like aforementioned Dicer-TRBP complex and argonaute (AGO) proteins comprising 
a class of four members (Kim et al., 2009). Essentially, TRBP guides Dicer and miRNA to 
AGO2 assembling RISC (Chendrimada et al., 2005). Noteworthy, AGO2 characterizes 
endonucleolytic activity as well as inhibitory effects on binding of translation initiatory factor 
eIF4E to m7G capped sites. Thus AGO2 can be defined as the catalytic engine of RISC (Liu 
et al., 2004; Kiriakidou et al., 2007). Finally, RISC is guided to the 3´-UTR of potential target 
mRNAs.  
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Here, base pairing between the 5´ seed region of the miRNA (bases two to eight) and target 
mRNA is predominantly crucial for tight binding. Additionally, seed region surrounding 
bases can support target mRNA recognition (Lewis et al., 2005). Subsequently, further 
translation is stopped whereby underlying mechanisms may vary. Besides the aforementioned 
inhibition of translation initiation other mechanistical options include mRNA sequestration in 
cytoplasmic foci called P(processing) bodies or transcript degradation (Pillai et al., 2007; Liu, 
2008).  
 
Interestingly, RNAs can be edited in their nucleotide sequence by adenosine deaminases 
(ADARs) (Bass, 2002). Thus, binding to the stem-loop structure of pre-miRNAs results in 
adenosine to inosine nucleotide change. In turn, inosine mimicks guanosine base thereby 
affecting miRNA target recognition as it has been reported for miR-22 (Luciano et al., 2004). 
Furthermore, RNA editing at position 1 or 2 of the predicted mature miRNA strand in the 
stem-loop of pre-miR-22 influences strand choice for assembling RISC by altering 
thermodynamic parameter (Khvorova et al., 2003; Schwarz et al., 2003). 
 
In summary, the field of miRNA biology opens a new level of cellular regulation, especially 
in regard to certain organ or cell-type specific mechanisms in disease. The biology of 
miRNAs bears a great potential to target and balance whole gene networks. As a result, 
understanding these effects is more complicated since the pluripotency of target recognition 
and regulation has to be kept in mind. 
 
 
1.3.1 MiRNAs in the cardiovascular system 
 
 
MicroRNAs contribute to both physiological and pathophysilogical reactions in the 
cardiovascular system. Initially work has focused on miRNA deregulation in different cardiac 
stress models. Van Rooij et al. applied transverse aortic constriction (TAC) and a transgenic 
calcineurin mouse model both resulting in maladaptive responses of the heart. Performing 
microarrays from miRNAs, these disease model systems revealed several deregulated 
miRNAs. Additionally, in vitro transfection of selected miRNAs to cultured cardiomyocytes 
resulted in hypertrophic growth further underlying the deep impact on cardiac structure. 
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Noteworthy, some of the stress-model enhanced miRNAs have also been upregulated in end-
stage heart failure hearts (van Rooij et al., 2006). These important observations emphasize a 
potential role of miRNAs in settings of human cardiovascular disease. 
 
Stress-conditions like persistent cardiac hypertrophy leading to cardiac failure have been 
described to rely on fetal gene expression (Izumo et al., 1988). Recently, investigators have 
linked this fetal gene reprogramming to the expression of miRNAs in the heart. By the use of 
microarray analysis researchers have shown that the miRNA expression profile in failing 
hearts was comparable to that of fetal hearts. In addition, down- and upregulated target 
mRNAs matched the profile for up- and downregulated miRNAs. Therefore, combination of 
miRNA expression pattern and target prediction could explain fetal gene reprogramming in 
heart failure as our group has shown before (Thum et al., 2007). 
 
Next to different cardiac stress models transgene research has highlighted the importance of 
miRNAs in the cardiovascular system. In addition to the initial finding that miRNAs are 
deregulated upon cardiac stress van Rooij et al. constructed a transgene with cardiomyocyte 
specific overexpression of miR-195. Mice suffered from cardiac hypertrophy and heart failure, 
highlighting that one single deregulated miRNA can induce cardiac failure (van Rooij et al., 
2006). 
 
Moreover, the miRNA processing factor Dicer has been manipulated in animal model by da 
Costa Martins et al. Hence, inducible cardiac Dicer knockout animals were generated because 
Dicer null knockouts per se are embryonal lethal due to misbalanced cardiogenesis (Zhao et 
al., 2007). Both young and old mice developed cardiac failure when shutting down Dicer 
expression. More importantly, young mice died shortly after Dicer knockdown whereas older 
mice survived for a longer time. Hence, cardiac failure in younger mice was not accompanied 
by strong alterations in the myocardium as it appeared in the elderly. Obviously, this finding 
might be explained by an essential and stronger miRNA impact on cardiac structure in 
younger mice (da Costa Martins et al., 2008). 
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DGCR8, another important factor of the miRNA processing machinery upstream of Dicer has 
recently been investigated in a knockout model. Cardiac-specific deletion led to dilated 
cardiomyopathy characterized by enhanced fibrosis and survial in median 31 days post birth. 
In contrast to the aforementioned conditional Dicer knockout, no hypertrophy was detectable 
(Rao et al., 2009). 
 
These in vivo observations implicate a principal modus operandi of miRNAs in the 
cardiovascular system. Moreover, cardiac-specific impact of several miRNAs has been 
reported. Thus, dissecting cardiac cells into cardiomyocytes, cardiac fibroblasts and 
endothelial cells may help to understand miRNA-guided gene regulation in the heart. 
 
 
1.3.1.1 Cardiomyocyte miRNAs 
 
 
Cardiomyocytes have a central role for cardiac function. Several miRNAs have been 
identified to be important for cardiomyocyte biology. MiR-1 possesses an outstanding role 
based on its relative abundance in cardiac tissue covering 40% of all present miRNAs (Rao et 
al., 2009). Initially, Zhao et al. showed that miR-1 comprising the microRNAs miR-1-1 and 
miR-1-2 is primarily localized in the heart and skeletal muscle. The microRNA expression is 
regulated by serum response factor (SRF) which can bind to enhancer elements in the 
promoter region of miR-1-2 stimulating transcriptional activity. Functional ovexpression of 
miR-1 with the use of β-myosin heavy chain (MHC) promoter in the developing heart caused 
a decrease in cardiomyocyte proliferation. This, in turn, misbalanced and inhibited correct 
ventricular function. On the molecular level, this observation could be explained by the 
regulative effect of miR-1 towards the cardiac transcription factor Hand2 which is important 
for functional cardiogenesis (Zhao et al., 2005). The group of Zhao et al. also constructed a 
miR-1-2 mouse knockout transgene to analyze loss of a specific miRNA. Indeed, cardiac 
morphogenesis and performance was altered strikingly. Histological analysis revealed 
ventricular septum defects as wells as cardiac edema which led to 50% embryonal lethality.  
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The aforementioned transcription factor Hand2 was induced on protein level giving again a 
clue for fatal cardiogenesis because Hand2 dosage is crucial for functional cardiac 
development (McFadden et al., 2005). Moreover, electrical conduction was disturbed. The 
correct transducing mechanism is a prerequisite for ventricular depolarization in healthy state. 
Mechanistically, investigators found the miR-1-2 target Irx5, a regulator of cardiac potassium 
channeling, is deregulated in mutant mice suggesting a commitment to the phenotype. 
 
MiR-1 knockout mice exhibited a prolonged phase of mitotic adult cardiomyocytes inducing 
cardiac hyperplasia. Loss of miR-1-2 might losen inhibitory cell cycle control in differentiated 
cardiomyocytes (Zhao et al., 2007). These in vivo studies provides evidence for a superior 
role of miR-1 in the regulation of cardiac performance and function. 
 
Since miR-1 is transcribed in a bicistronic gene cluster with miR-133, this miRNA has also 
been investigated intensively. Indeed, miR-133 also regulates cardiomyocyte signalling (Care 
et al., 2007). Likewise, miR-133 is highly expressed specifically in skeletal muscle and 
cardiac myocytes. Carè et al. also observed decreased levels of miR-1 and miR-133 in 
different models of murine cardiac hypertrophy as well as in human samples of heart failure. 
Therefore, investigators proposed that microRNA expression pattern is inversely correlated to 
cardiac hypertrophy. In line, in vitro experiments further emphasized the regulative role of 
miR-133 for cardiomyocyte hypertrophy. Cardiomyocytes overexpressing miR-133 were 
capable to inhibit hypertrophic response to stimulative phenylephrine. Furthermore, this 
inhibitory reaction was observed in modulated neonatal and adult cardiomyocytes. Again, 
miR-133 expression was found to be low in phenylephrine-induced hypertrophic 
cardiomyocytes further supporting the idea of an inverse correlation of miR-133 expression 
level towards progression of cardiac hypertrophy. Indeed, in vitro antagonizing miR-133 
caused quick progression of a hypertrophic response (induction of fetal genes, increase in 
protein synthesis and cell size). To analyze a functional relationship between miR-133 and 
miR-1, experiments for miR-133 were substituted to miR-1. These experiments pointed to a 
tight cooperation of these two miRNAs for the regulation of cardiac hypertrophy. Mice 
receiving osmotic minipumps delivering an antagonist for miR-133 displayed that miR-133 
downregulation resulted in the formation of hypertrophic hearts. In addition, hypertrophic 
marker genes were upregulated in this setting.  
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To further explain downstream miR-133 signalling bioinformatic and in vitro reporter gene 
assays validated potential miR-133 targets. Substantial target regulation was reported for 
RhoA, Cdc42 and Whsc2 which are proteins linked to hypertrophic biology. Taken together, 
the observations describe a crucial and regulative role of miR-133 for in vitro and in vivo 
cardiac hypertrophy. 
 
The aformentioned induction of fetal genes in hypertrophic hearts comprises the well-known 
switch of the α-MHC ATPase to the expression of β-MHC ATPase (Lowes et al., 1997; 
Nakao et al., 1997). This modulation results mainly in decreased cardiac contractility. The 
group of van Rooij et al. deciphered a miR-208 based mechanism that controls the α/β-MHC 
switch (van Rooij et al., 2006). Noteworthy, miR-208 is encoded by the intron 27 of the α-
MHC gene and is also highly expressed in cardiac tissue compared to other organs. Specific 
blockade of T3-hormone signalling in wild-type mice led to a decrease in α-MHC, a 
subsequent increase in β-MHC and finally to a more slower decrease in miR-208 expression 
suggesting high stability of this miRNA. In vivo, a mouse miR-208 knockout showed a 
stunning reaction towards cardiac stress applied by trans-aortic banding: The typical 
hypertrophic response in wild-type animals was abandoned in the transgene. In addition, the 
transgene could not upregulate β-MHC but other cardiac stress markers indicating that miR-
208 is essential for the hypertrophy response but not for the expression of further cardiac 
stress proteins. These implications were further emphasized by the finding that transgenic 
overexpression of miR-208 could upregulate β-MHC. Again, pharmacogenetic inhibiton of 
T3-hormone signalling was applied to test for phenotypic transgene analysis. MiR-208 
knockout animals failed to induce β-MHC whereas induction was prominent in wild-type 
animals suggesting that miR-208 interferes with specific transcriptional repressors of β-MHC. 
Mechanistically, THRAP1, a transcriptional co-regulator of hormone recpetor signalling 
involved in β-MHC regulation at the transcriptional level was validated to be a direct miR-208 
target. These findings claim a substantial role of miR-208 for cardiomyocyte stress response. 
More recently, these observations were extended by the finding that miR-208 is also required 
for correct cardiac transcription factor GATA4 expression being a direct target for miR-208 
(Callis et al., 2009). Additionally, gain- and loss-of function experiments for miR-208 pointed 
to a role in cardiac biology. 
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1.3.1.2 Fibroblast miRs 
 
 
Fibrosis is a maladaptive tissue response reaction existing in different disease conditions. A 
hallmark of cardiac fibrosis is the accumulation of collagens and extracellular matrix proteins 
impairing cardiac contractility and ventricular function.  
 
Mechanistically, TGF-β signal transduction possesses a key function for extracellular 
remodelling during cardiovascular injury triggering extracellular remodelling (Khan and 
Sheppard, 2006). Besides the role of miRNAs for cardiomyocyte biology, several miRNA-
based mechanisms have been deciphered for fibrotic cardiovascular events. Primarily, cardiac 
disease deregulated miRNAs have been chosen for mechanistical investigations aiming at 
fibrotic modulation. 
 
Among the highly upregulated miRNAs in heart failure, miR-21 action in cardiac failure 
could be described recently by our group (Thum et al., 2008). More interestingly, in situ 
hybridization showed a specific upregulation in cardiac fibroblasts. This indicates cell-type-
dependent impact of miR-21. Unravelling fibroblast-specific mechanisms in vitro, miRNA 
modulation was capable to modulate apoptotis. Antagonizing miR-21 led to reduced survival 
of cardiac fibroblasts. Reduced cell survival was explained by a derepression of direct miR-21 
target Sprouty-1 which is primarily localized to fibroblast-enriched areas of the heart. 
Moreover, derepressing Sprouty-1 increased inhibition of pro-survival ERK signalling. 
Transferring these observations into an in vivo cardiac stress model, transverse aortic 
constriction was applied. Both prevention and treatment therapy aimed at antagonizing miR-
21 by sequestering endogenous miRNA with a complementary cholesterol-modified 
oligonucleotide (antagomir). Cardiac performance improved markedly in treatment groups 
and most remarkably, cardiac fibrosis was diminished (prevention strategy) or reversed 
(treatment strategy). The effective therapy has proven a promising approach for the 
modulation of cardiac fibrosis upon cardiac stress. 
 
While investigating miRNAs found to be dysregulated upon myocardial infarction, van Rooij 
et al. concentrated on the mechanistic role of miR-29 (van Rooij et al., 2008).  
 Introduction 
 
  21 
In the group of downregulated miRNAs post MI, miR-29 was found to be a critical regulator 
for the in vivo fibrotic response during cardiac remodelling. miR-29 is also enriched in the 
fibroblast cell population in the heart. Moreover, predicted targets comprise extracellular 
matrix proteins and collagens. Thus, theoretically, downregulation of miR-29 should 
derepress these mediators leading to enhanced fibrotic activity. Indeed, several collagens and 
matrix proteins were validated as direct miR-29 targets supporting this theory. Further 
evidence was taken from animal experiments using a miR-29 mimic post myocardial 
infarction. In this situation, enhancing miR-29 decreased the fibrotic response. Additionally, 
aforementioned direct miR-29 targets were downregulated. On the whole, this therapeutic 
approach reveals a tool to modulate fibrosis via impairing its fundamental factors. 
 
Another crucial regulator of extracellular remodelling is connective tissue growth factor 
(CTGF) (Duisters et al., 2009). Duisters et al. showed an increased CTGF expression upon 
cardiac stress in vivo which correlated to decreased amounts of miR-30 and miR-133. As 
mentionded before, miR-133 is cardiomyocyte enriched, whereas researchers found miR-30 in 
a higher expression level in fibroblasts. Bioinformatic analysis revealed that both miRNAs 
might target CTGF. The origin of CTGF is diverse: fibroblasts produce CTGF, but also 
stressed cardiomyocytes secrete CTGF stimulating extracellular protein synthesis. In vitro 
assays established the direct CTGF regulation by miR-30 and miR-133 either in 
cardiomyocytes or fibroblasts. Hence, cell-type specific miRNA expression and target 
availability determines the impact of modulation in cardiomyocytes or fibroblasts. Although a 
concrete therapeutic therapy is missing in this study, useful clues are given for the modulation 
of cardiac fibrosis balanced by CTGF. 
 
 
1.3.1.3 Endothelial miRs (angiomiRs) 
 
 
The blood vessel network in the heart is responsible to provide sufficient nutrition and oxygen 
supply. Disturbance of endothelial biology may result in severe disorders of the heart. The 
importance of miRNAs for blood vessel formation was primarily shown in Dicer transgenic 
mice. Here, alteration of miRNA-processing Dicer led to embryonal lethality due to impaired 
vasculature in the developing embryo (Yang et al., 2005).  
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Moreover, endothelium-specific and conditional Dicer knockout mice resulted in decreased 
angiogenic response to VEGF-stimulation. This underscores an in vivo requirement for 
endothelial miRNAs in angiogenesis (Suarez et al., 2008). In addition, silencing Dicer or 
Drosha in cultured endothelial cells impaired angiogenic properties (Kuehbacher et al., 2007; 
Suarez et al., 2007).  
 
The first study describing a miRNA profile in endothelial cells was done by Poliseno et al. 
Here, investigators found a distinct miRNA signature of highly expressed miRNAs. In 
addition, bioinformatic analysis revealed that important angiogenic transmembrane receptors 
may be targeted by abundant miRNAs. To assess functional impact, in vitro overexpression of 
miR-221 and miR-222 mixture impaired tube formation and migratory capacity. Furthermore, 
the angiogenic receptor c-kit was downregulated in miRNA-modulated cells. These findings 
emphasize that miRNA-modulation of ECs specifically regulates angiogenic mechanisms 
(Poliseno et al., 2006). 
 
Until now only one miRNA was suggested to be exclusively expressed in ECs. This pivotal 
feature belongs to miR-126. In 2008, three independent groups analyzed and reported vascular 
defects in miR-126 deficient zebrafish and mice (Fish et al., 2008; Wang et al., 2008; Kuhnert 
et al., 2008). In zebrafish, antagonizing experiments induced hemorrhage in the developing 
organism. miR-126 morphants displayed collapsed endothelial lumens highlighting the role of 
miR-126 for establishing vascular structure in development. Mechanistically, Spred1 which is 
a negative regulator of cell survival was validated as a direct miR-126 target being 
theoretically derepressed in miR-126 deficient zebrafish. To analyze this hypothesis, Spred1 
was overexpressed in the developing zebrafish. Indeed, Spred1 upregulation caused a similar 
vascular phenotype also seen in the miR-126 morphant (Fish et al., 2008). In mice miR-126 
knockouts, miRNA-deletion caused a phenotype also characterized by severe vascular defects 
with hemorrhage and edema (Wang et al., 2008). Remarkable, 40% of knockout animals died 
in embryonal phase or perinatally. Functional analysis further showed a reduced angiogenic 
response in knockout animals when considering EC migration into implanted matrigel plugs. 
More interestingly, in a model of myocardial infarction, miR-126 deficient mice were not able 
to survive a three week time span upon MI. This emphasizes the need of miR-126 dependent 
regulation for neovascularization supporting cardiac healing.  
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Again, Spred1 was reported being the crucial miR-126 target. Downregulation of Spred1 by 
miR-126 is necessary to transduce pro-survial signalling in endothelial cells thus inducing 
angiogenic events. The complexity of the miR-126 genelocus has further been of potential 
interest. Since miR-126 is located within an intron of the Egfl7 gene, questions aroused 
whether the vascular abormalities seen in miR-126 mice are due to the loss of miR-126 or 
Egfl7. 
 
Egfl7 knockout mice also suffer from vascular abnormalities which were proposed to rely on 
impaired angiogenic signalling mediated by chemoattractant Egfl7 (Schmidt et al., 2007). To 
address the question if miR-126 or Egfl7 is the key player for proper conductive vasculature, 
Kuhnert et al. generated mice delitious for minimal miR-126 sequence and compared the 
phenotype to whole Egfl7 knockouts. Finally, the aforementioned vascular defects were only 
observable in mice deficient of miR-126 highlighting the requirement of miR-126 for the 
developing and postnatal vasculature (Kuhnert et al., 2008). 
 
Combinatorial action of clustered miRNAs is another option for miRNA-guided regulation of 
angiogenesis. The oncogenic miR-17~92 cluster was first described for inductive tumor 
expansion. The augmentation in tumor growth was explained by the direct downregulation of 
cluster targets thrombospondin-1 (Tsp1) and CTGF. Both targets are well-known negative 
angiogenic regulators. Thus, targeting miR-17~92 cluster may serve as a promising approach 
in cancer research (Dews et al., 2006). Besides its role in cancer, cluster member miR-92 was 
recently attributed to anti-angiogenic function in ischemic disease and therefore was 
suggested to be a relevant therapeutic target (Dimmeler et al., 2009). 
 
 
1.3.2 MiRNA antagonists (“antagomirs”) for in vivo application 
 
 
The abundance of miRNAs and the deregulation of miRNAs in many diseases opened a field 
of research to eliminate cellular miRNAs thereby derepressing miRNA targets. In 2005, 
Krutzfeldt et al. investigated the application of a modified RNA oligo (figure 1.5) 
complementary to a specific miRNA in mice (Krutzfeldt et al., 2005, 2006). The so-called 
“antagomir” was injected in the tail vein and could specifically eliminate miRNA of interest 
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in several tissues except the brain. Moreover, the antagomir itself was not degraded by the in 
vivo exonuclease machinery since its sugar backbone is modified by stabile phosphothioate 
bonds at 5´ and 3´ prime ends. Antagomir target recognition is importantly dependent on 
precise nucleotide sequence bearing a perfect match to miRNA of interest. Finally, the target 
miRNA:antagomir duplex is degraded in a cytosolic compartment which does not overlap 
with P(processing)-bodies indicating that this process is different from the small-inhibitory 
RNA (siRNA) pathway (Krutzfeldt et al., 2005, 2007). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5: Chemical structure of an antagomir (Krutzfeldt et al., 2006). The partially phosphothioate- and 2´-
O-methyl-modified RNA oligo is linked to a cholesterol support. 
 
 
Since this initial application several antagomirs have been tested for outcome on cardiac 
function. Essentially, deregulated miRNAs have been mostly chosen for further investigation. 
Antagonizing miR-133 resulted in sustained cardiac hypertrophy, implicating a control 
mechanism for cardiac hypertrophy (Carè et al., 2007). Antagomirs have also been used in 
therapeutic settings upon pathologic stress. Investigators have shown miR-21 upregulation 
post MI. Consequently, mimicking pathologic stress, mice underwent trans-aortic constriction 
(TAC) and were treated with constant doses against miR-21. Treatment resulted in beneficial 
effects for cardiac performance measured by reduced fibrotic area and improved pump 
function compared to control antagomir treatment (Thum et al., 2008). Although miR-92a has 
not been reported to be deregulated under pathological conditions in the heart, antagonizing 
this miRNA in a mouse model of hind limb ischemia and MI has showed an interesting 
finding. Angiogenesis improves in animals receiving antagomir-92a indicating a potential 
therapeutic value in ischemic diseases (Bonauer et al., 2009). 
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Collectively, application of antagomirs in vivo can be a valuable tool to support healing or 
wounding processes. Nonetheless application has to be done carefully, since antagomirs can 
reach nearly every tissue which is connected to the blood stream. Side-effects in other organs 
might occur quite often. As a result, investigators try to modify antagomirs by cell type 
specific antibodies minimizing unwished off-target effects. 
 
 
1.4 MiR-24 genelocus and miR-24 function 
 
 
The human miR-24 genelocus is encoded by two distinct chromosomal sites and is clustered 
with miR-23a/b and miR-27a/b (data from miRBase at http://www.mirbase.org/ and figure 
1.6). Mature sequences are identical but specified as miR-24-1/2 since the genelocus for miR-
24-2 is intergenic, whereas miR-24-1 is transcribed intronically from the host-gene encoding 
an aminopeptidase (data from Entrez Gene at http://www.ncbi.nlm.nih.gov). In addition, two 
minor mature miRNA sequences can be proccessed from the pre-miRNA stem loop structure 
designated as miR-24-1/2*. The asteristik describes the complementary sequence to the 
mature miRNA sequence which is in 5´→3´ direction. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6: Overview on distribution of genomic miR-24 loci. miR-24 is transcribed with clustered miRs miR-
23a/b and miR-27a/b from chromosome 9 and 11 (Chan et al., 2010). 
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For the first time, detailed investigations regarding the clustered genelocus for miR-23a-27a-
24-2 revealed RNA Polymerase II-driven transcription of miRNA genes. Additionally, a 
promoter region has been defined comprising sequences with no obvious regulatory elements 
despite GC-boxes (Lee et al., 2004). In addition, miR-24-1 has been described to be 
potentially activated by hypoxic conditions probably through hypoxia-inducible factor-1 
(HIF-1) in cancer cells, although the HIF-1 responding regulatory elements are located within 
5 kb upstream. Therefore, miR-24 has been classified as a hypoxia-regulated miRNA (HRM) 
besides others (Kulshreshtha et al., 2007).  
 
In contrast to the aforementioned miR-24-2 genecluster, miR-24-1 cluster is located 
intronically. Expression of the clustered miR-23b-27b-24-1 miRNAs has been induced by 
BMP2 signalling in mice. Noteworthy, differential expression of clustered miRNAs has been 
observed indicating specific pri-miRNA processing (Sun F et al., 2009). Moreover, and of 
interest, miR-24 is upregulated by cardiac hypertrophy and in end-stage failing hearts (van 
Rooij, 2006). Additionally, in vitro overexpression in cardiomyocytes led to hypertrophic 
growth implicating a role in heart remodelling and interestingly, a cardiomyocyte-specific 
overexpressing miR-24 transgene is embryonal lethal, suggesting a pivotal role for proper 
heart development. 
 
MiR-24 expression has not been reported to be cell type specific (figure 1.7). Moreover this 
miRNA is expressed ubiquitously with highest expression level in heart and lung tissue 
assessed by Northern Blot and its expression was found to be repressed by SMADs (Sun Q et 
al., 2008).  
 
 
 
 
 
 
 
 
Figure 1.7: miR-24 expression in different organs measured by Norhern blot analysis (Sun Q et al., 2008). miR-
24 expression is normalized to house keeping small nuclear RNA U6 (RNU6b). 
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Downstream target analysis for miR-24 has revealed some interesting issues about miR-24 
function. MiR-24 has been investigated in the context of erythropoeisis in erythroleukemic 
K562 cells. Gain-of function experiments show the human activin type I receptor ALK4 
(hALK4) to be a direct target. Consequently, SMAD2 signalling cascades are disturbed as 
well as downregulation of hemoglobin causing a delay in erythroid differentiation. 
Furthermore, miR-24 expression level has also been observed to be inversely correlated with 
erythroid differentiation progress in CD34+ progenitor cell population (Wang et al., 2008). 
 
Another group has observed upregulation of miR-24 when inducing blood cell differentiation 
with hemin. Here, the histone variant H2A.X involved in DNA repair is negatively regulated 
(Lal et al., 2009). In vitro, H2A.X modulation causes higher susceptibility towards genotoxic 
insults, whereby overexpressing a miR-24 insensitive H2A.X, variant could rescue the 
deficient phenotype. More importantly, the miR-24 target H2A.X has recently been described 
to have a substantial role in neovascularization events (Economopoulou et al., 2009). In vitro, 
hypoxic treatment of HUVECs led to the activation of H2A.X by phosphorylation. This 
activation was counteracted by the transient knockdown of H2A.X which decreased 
endothelial proliferation capacity under hypoxic conditons. Additionally, an in vivo model of 
hindlimb ischemia in endothelium specific H2A.X knockout animals validated and 
emphasized reduced neovascularization upon implantation of tumor cells. Thus, H2A.X 
seems to be a key player for hypoxia-driven neovascularization. Recent work also suggested 
that miR-24 influences cell cycle progression thereby regulating cellular proliferation state 
(Lal et al., 2009). Global transcriptome analysis in naturally miR-24 low-expressing Hep2G 
cells revealed several cell cycle and DNA repair important factors being modulated when 
overexpressing miR-24. In line, cell cycle analysis showed an inhibitory effect for miR-24 on 
cell cycle progression. Interestingly, downregulated targets like Myc contained a miR-24 
binding site (seed region), whereas others like E2F did not. Both transcription factors were 
validated by luciferase assay to be direct miR-24 targets thus orchestring gene networks. The 
downmodulation of Myc implicates that further microRNA responsive elements (MREs) are 
responsible for target recognition in the 3´-UTR of Myc which lack a seed region. Detailed 
investigation of myoblast development has revealed upregulation of miR-24 which could be 
inhibited by TGF-β1 forced SMAD3 signalling binding directly to proposed miR-24 promoter 
region site (Sun Q et al., 2008).  
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Moreover, TGF-β1 repressed myogenesis can be modulated by overexpressing miR-24 
leading to enhanced myoblast differentiation. On the whole the authors suggest that this 
modulation is supported by simultaneous expression of miR-24 clustered miRNAs. 
Nevertheless, miR-24 has also been reported to have an impact on TGF-β signalling itself in 
fetal mouse liver development (Rogler et al., 2009). Here, upregulation of the miR-23b cluster 
including miR-23b, miR-27b and miR-24-1 targets SMAD proteins SMAD3, 4, 5 thereby 
diminishing TGFβ signalling and influencing cell fate choice. 
 
In fibroblast or carcinoma cells ectopic overexpression of miR-24 regulates the tumor 
suppressor protein p16(INK4a) thereby affecting replicative senescence of these cells (Lal et 
al., 2008). Additionally, antagonizing miR-24 enhances p16(INK4a) protein level. MiR-24 has 
been described to prevent retina apoptosis in developing Xenopus laevis (Walker and Harland, 
2009). In vivo, antisense nucleotides (morpholinos) against miR-24 induced retina cell 
apoptosis. In contrast, injecting miR-24 in the developing Xenopus reverted malformation of 
the eye. Apoptosis modulation has also been observed while overexpressing the miR-23a-27a-
24-2 genecluster in human embryonic kidney cells (Chhabra et al., 2009). Here, enhanced 
cluster expression induced apoptosis suggesting an impact on apoptosis signalling. 
Nevertheless, miR-24 is not the only mediator but participates in coordinated pro-apoptotic 
regulation. 
 
In summary, the current findings on miR-24 indicate that this microRNA is an important 
regulator in diverse cellular types having an impact on development, differentiation and 
certain cellular signalling processes. In addition, miR-24 clustered and genetically 
neighbouring miRNAs may support the impact on target regulation. Nevertheless, the role of 
miR-24 in the cardiovascular system remains elusive. 
 
 
1.5 Scope and aim of this study 
 
 
Pathological cardiac remodelling post MI involves many signalling pathways being 
dysregulated. Genetic pathways in numerous cardiac cell types are subsequently altered with 
deleterious outcome. MiRNAs target several mRNAs thus regulating complex gene networks. 
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In diseased states, several cardiac miRNAs are deregulated and contribute to mRNA 
transcriptome alterations and cardiovascular disease (van Rooij et al., 2006; Thum et al., 
2007). Underlying miRNA-guided molecular mechanisms in cardiac angiogenesis are less 
defined. Thus, in this study, the role of cardiac miRNAs in MI-induced cardiac remodelling is 
investigated. Moreover, potential regulatory mechanisms for cardiac angiogenesis are 
dissected. Specifically in this work, effects of MI-deregulated miR-24 on endothelial function 
in vitro and in vivo are investigated. In context of MI miR-24 function is unclear, especially in 
regard to neovascularization. Thus, miR-24 guided mechanisms and characteristics in 
response to MI have to be investigated. In addition, endothelial miR-24 targets have to be 
found and validated by in vitro assays. For in vivo translational research a disease setting of 
murine myocardial infarction is applied. Hence, miR-24 is antagonized by a specific 
compound (antagomir) upon MI. Following a therapeutic periode basic heart parameters are 
determined and validated. Additionally, other aspects regarding in vivo heart remodelling are 
investigated, especially focusing on cardiac angiogenesis. Taken together, this work aims 
towards further functional clues, understanding and transparency of MI-deregulated miR-24. 
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2. Material and Methods 
 
 
2.1 Material  
 
 
2.1.1 Equipment 
 
Table 2.1: Devices used for this work 
 
Device Type Manufacturer 
Autoclave VARIOKLAV® H+P Labortechnik, 
Oberschleissheim, Germany 
Bioanalyzer Agilent 2100 Bioanalyzer Agilent, Böblingen, Germany 
Bioanalyzer software Agilent 2100 Expert Agilent, Böblingen, Germany 
Blotting apparatus Mini Trans-Blot® Electrophoretic 
Transfer Cell 
Bio-Rad, Munich, Germany 
Bunsen burner Campingaz Labogaz 206 Camping Gaz, Hungen-
Inheiden, Germany 
CellQuest software CellQuest software BD Biosciences, Franklin 
Lakes, USA 
Centrifuge Biofuge fresco Thermo Fisher Scientific, 
Langenselbold, Germany 
Centrifuge Heraeus Megafuge 1.0R Thermo Fisher Scientific, 
Langenselbold, Germany 
ChemiImager ChemiImager 5500 Alpha Innotech, San Leandro, 
USA 
Chemi5500 software Chemi5500 Alpha Innotech, San Leandro, 
USA 
Cryotome Leica CM1850 Leica Microsystems, Wetzlar, 
Germany 
Echo device Toshiba PowerVision 6000 Toshiba Medical Systems, 
Neuss, Germany 
Electrophoresis chamber 
agarose gels 
Mini Sub-Cell® GT Bio-Rad, Munich, Germany 
Electrophoresis chamber 
SDS-PAGE 
Mini Protean® Tetra Cell Bio-Rad, Munich, Germany 
Electrophoresis chamber 
western blot 
Mini Trans Blot Cell Bio-Rad, Munich, Germany 
ELISA reader Multiplate reader 550 Bio-Rad, Munich, Germany 
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Device Type Manufacturer 
FACS FACS Calibur BD Biosciences, Franklin 
Lakes, USA 
Fluorescence microscope Axiovert 135 Zeiss, Jena, Germany 
Freezer (-20°C) Liebherr comfort Liebherr, Biberach an der Riss, 
Germany 
Freezer (-80°C) HERA freeze Thermo Fisher Scientific, 
Langenselbold, Germany 
Fridge (4°C) BioCompact II 200 Gram-Bioline, Vojens, 
Denmark 
Heating block Thermomixer compact Eppendorf, Hamburg, Germany 
Incubator HERA cell 150 Thermo Fisher Scientific, 
Langenselbold, Germany 
Incubator Function line Thermo Fisher Scientific, 
Langenselbold, Germany 
Incubator bacterial culture INB400 Memmert, Schwabach, 
Germany 
Laminar flow Type UVF BDK, Sonnenbühl-Genkingen, 
Germany 
MACS cell sorter MACS Multistand, OctoMACS 
Separation Unit 
Miltenyi Biotech, Bergisch-
Gladbach, Germany 
Magnetic stirrer RCT basic IKA® Werke, Staufen, 
Germany 
Microwave MW7823 Severin, Sundern, Germany 
Microscope Wilovert 30 Hund, Wetzlar, Germany 
Multi-plate reader Synergy HT BIO-TEK, Bad Friedrichshall, 
Germany 
PCR cycler T personal combi Biometra, Göttingen, Germany 
pH measurement device Microprocessor pH Meter pH537 WTW, Weilheim, Germany 
Photometer Ultrospec3000 Pharmacia Biotech/Amersham, 
Piscataway, USA 
Pipettes 0.1-2.5 µl /0.2-10 µl /10-100 µl/ 
100-1000 µl 
Eppendorf, Hamburg, Germany 
Pipettor Accu-jet® pro BRAND, Wertheim, Germany 
Power supply Power Pac200 Bio-Rad, Munich, Germany 
Real-time PCR device iCycler® Bio-Rad, Munich, Germany 
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Device Type Manufacturer 
Real-time PCR software iCycler® iQ™ software 3.1 Bio-Rad, Munich, Germany 
Scale Kern 440-45N Kern, Balingen, Germany 
Special accuracy weighing 
machine 
TP214 Denver instrument, Göttingen, 
Germany 
SigmaStat® software SigmaStat software 2.03 SPSS, Chicago, USA 
Rolling shaker RM50 Via Hartenstein, Würzburg, 
Germany 
ScanAlyze software ScanAlzye 2.50 Eisen lab, Berkeley, USA 
Scanner Epson Perfection V500 photo Epson, Meerbusch, Germany 
ScionImage Software Release Alpha 4.0.3.2 Scion, Frederick, USA 
Shaker Vibro-Shaker 50 Via Hartenstein, Würzburg, 
Germany 
Shaker for bacterial 
culture 
TH 30/SM-30 Edmund Bühler, Hechingen, 
Germany 
Sonifier Sonifier GM70, sonotrode MS72 Bandelin, Berlin, Germany 
Table centrifuge C1301, Labnet Via neoLab, Heidelberg, 
Germany 
Vacuum pump N811KN.18, Neuberger Via neoLab, Heidelberg, 
Germany 
Vortexer MS3 basic IKA® Werke, Staufen, 
Germany 
Water bath WNB7 Memmert, Schwabach, 
Germany 
X-ray film developer Optimax Protec, Oberstenfeld, Germany 
 
 
2.1.2 Consumable material and chemicals 
 
Table 2.2: Material applied 
 
Material Manufacturer 
Blotting paper GE Healthcare, Munich, Germany 
Cell culture flasks Greiner Bio-one, Frickenhausen, Germany 
Cell culture plates Thermo Fisher Scientific (Nunc), Langenselbold, 
Germany 
Cryo tubes Greiner Bio-one, Frickenhausen, Germany 
FACS tubes BD Biosciences, Franklin Lakes, USA 
Falcon tubes Greiner Bio-one, Frickenhausen, Germany 
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Material Manufacturer 
Gas cartouche Camping Gaz, Hungen-Inheiden, Germany 
Glas ware Schott, Wertheim, Germany 
Gloves Semper care/Flexam 
Pipette tips Sarstedt, Nümbrecht, Germany 
Plastic pipettes Costar® Stripette via Materiallager Uniklink 
Würzburg 
Primer TIB MOLBIOL, Berlin, Germany 
PVDF membrane Bio-Rad, Munich, Germany 
Sequencing reactions MWG Biotech, Munich, Germany 
Sterile filter Schleicher & Schuell, Dassel, Germany 
Tubes Eppendorf, Hamburg, Germany or Sarstedt, 
Nümbrecht, Germany 
X-ray film developer reagents Agfa, Cologne, Germany 
X-ray films Fuji, Düsseldorf, Germany 
 
 
All listed chemicals were purchased in pro analysi (p.a.) grade. 
 
Table 2.3: Chemicals applied 
 
Chemical/summ formular Manufacturer 
Acetic acid Merck, Darmstadt, Germany 
Acrylamide/Bisacrylamide 37.5:1 Roth, Karlsruhe, Germany 
Agar Roth, Karlsruhe, Germany 
Agarose Sigma-Aldrich, Taufkirchen, Germany 
Ampicillin Sigma-Aldrich, Taufkirchen, Germany 
APS Sigma-Aldrich, Taufkirchen, Germany 
Braunol™ Braun, Melsungen, Germany 
BSA Sigma-Aldrich, Taufkirchen, Germany 
Chloroform Fluka, Steinheim, Germany 
Chloroform/Isoamylalcohol Roth, Karlsruhe, Germany 
Cell lysis buffer Cell Signaling, Danvers, USA 
DAPI Sigma-Aldrich, Taufkirchen, Germany 
Dextrose Merck, Darmstadt, Germany 
Desferrioxamine Sigma-Aldrich, Taufkirchen, Germany 
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Chemical/summ formular Manufacturer 
Dihydroethidium Invitrogen, Karlsruhe, Germany 
Dithiothreitol Sigma-Aldrich, Taufkirchen, Germany 
DMSO Roth, Karlsruhe, Germany 
Donkey serum Invitrogen, Karlsruhe, Germany 
Ethanol Merck, Darmstadt, Germany 
Ethylendiaminotetraacetat Fluka, Steinheim, Germany 
Formaldehyde Merck, Darmstadt, Germany 
Glycogen Sigma-Aldrich, Taufkirchen, Germany 
H2O2 30% Sigma-Aldrich, Taufkirchen, Germany 
Heparin Fresenius, Bad Homburg, Germany 
Hepes Merck, Darmstadt, Germany 
Salmon sperm DNA Sigma-Aldrich, Taufkirchen, Germany 
Hydrochloric acid Merck, Darmstadt, Germany 
Isopropanol Fluka, Steinheim, Germany 
KCl Sigma-Aldrich, Taufkirchen, Germany 
KH2PO4 Sigma-Aldrich, Taufkirchen, Germany 
LB powder Roth, Karlsruhe, Germany 
L-Glutamine Sigma-Aldrich, Taufkirchen, Germany 
Lipofectamine2000™ Invitrogen, Karlsruhe, Germany 
Liquemin™ Roche, Penzberg, Germany 
Loading buffer [3x] Cell Signaling, Danvers, USA 
Loading buffer [6x] Fermentas, St. Leon-Rot, Germany 
Luminol Roth, Karlsruhe, Germany 
Matrigel™ BD Biosciences, Franklin Lakes, USA 
Matrigel™ high concentration BD Biosciences, Franklin Lakes, USA 
Methanol Merck, Darmstadt, Germany 
Methylbutan Merck, Darmstadt, Germany 
MgSO4 Sigma-Aldrich, Taufkirchen, Germany 
NaCl Sigma-Aldrich, Taufkirchen, Germany 
NaHCO3 Sigma-Aldrich, Taufkirchen, Germany 
NaH2PO4 Merck, Darmstadt, Germany 
NP40 Sigma-Aldrich, Taufkirchen, Germany 
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Chemical/summ formular Manufacturer 
PIPES Sigma-Aldrich, Taufkirchen, Germany 
Propidiumiodide Sigma-Aldrich, Taufkirchen, Germany 
Protein G sepharose GE Healthcare, Munich, Germany 
Sarkosyl Sigma-Aldrich, Taufkirchen, Germany 
Skim milk powder Roth, Karlsruhe, Germany 
Para-cumaric acid Roth, Karlsruhe, Germany 
Para-formaldehyde Sigma-Aldrich, Taufkirchen, Germany 
PBS GIBCO/Invitrogen, Karlsruhe, Germany 
Pefabloc™ Roche, Penzberg, Germany 
Phenol/Chloroform/Isoamylalcohol Roth, Karlsruhe, Germany 
Protease blocker tablet 25x Roche, Penzberg, Germany 
RotiQuant™ Roth, Karlsruhe, Germany 
SDS Roth, Karlsruhe, Germany 
Sodium hydroxide solution Merck, Darmstadt, Germany 
SYBR Safe™ Invitrogen, Karlsruhe, Germany 
TEMED Roth, Karlsruhe, Germany 
TissueTek® SAKURA via Hartenstein, Würzburg, Germany 
TRIS, Trizma Sigma-Aldrich, Taufkirchen, Germany 
TritonX100 Merck, Darmstadt, Germany 
Trizol™ Invitrogen, Karlsruhe, Germany 
Trypsine BD Biosciences, Franklin Lakes, USA 
Tween20™ Roth, Karlsruhe, Germany 
Vectashield™ Linaris, Bettingen, Germany 
Vitamine B12 SERVA, Heidelberg, Germany 
 
 
2.1.3 Provided kit systems 
 
 
Table 2.4: Provided kit systems, ELISAs and arrays 
 
Kit name Catalogue number Manufacturer 
Agilent RNA 6000 nano 
reagents/RNA nano chips 
#5067-1511 Agilent, Böblingen, Germany 
Annexin-V-FLUOS staining 
kit 
#11-858-777-001 Roche, Penzberg, Germany 
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Kit name Catalogue number Manufacturer 
β-galactosidase assay kit #E2000 Promega, Madison, USA 
CD146 MicroBeads #130-092-007 Miltenyi Biotec, Bergisch-Gladbach, 
Germany 
DNeasy Blood & Tissue Kit #69504 Qiagen, Hilden, Germany 
GeneChip® Human 1.0 ST 
array 
#901147 Affymetrix, High Wycombe, UK 
HotStar Taq Mastermix kit #203443 Qiagen, Hilden, Germany 
iQ™ Supermix #170-8860 Bio-Rad, Munich, Germany 
iScript select™ cDNA 
synthesis kit 
#170-8897 Bio-Rad, Munich, Germany 
Luciferase assay kit #E1500 Promega, Madison, USA 
Mouse hemoglobin ELISA #E-90HM Immunology Consultants Laboratory 
Inc, Newberg USA 
PathScan® Phospho-Bad 
(Ser112) Sandwich ELISA kit 
#7182 Cell Signaling, Danvers, USA 
PCR purification kit #28104 Qiagen, Hilden, Germany 
Plasmid purification kit #12125, 12143 Qiagen, Hilden, Germany 
pMIR-REPORT Kit #AM5795 Ambion/Applied Biosystems, 
Carlsbad, USA 
Proteome profiler apoptosis 
array 
#ARY009 R&D Systems, Minnesota, USA 
RNeasy mini kit  #74104 Qiagen, Hilden, Germany 
Vector M.O.M basic kit #BMK-2202 Vector Laboratories, Burlingame, 
USA 
 
 
2.1.4 Solutions and buffers 
 
 
2.1.4.1 Cell culture media, components and used cells 
 
 
Table 2.5: Cell culture media and components 
 
Medium/component name Catalogue number Manufacturer 
Cryo-SFM #C-29910 PromoCell, Heidelberg, Germany 
DMEM #C-71220 PromoCell, Heidelberg, Germany 
EGM-2 plus supplements #CC-4147 Cambrex Lonza, Basel, Switzerland 
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Medium/component name Catalogue number Manufacturer 
FCS #C-37360 Biochrome/Promocell 
MEM Eagle (Joklik 
modification) 
#M8028 Sigma-Aldrich, Taufkirchen, 
Germany 
MEM #1-33 V12-K Amimed 
OPTI-MEMI® #51985-026 GIBCO/Invitrogen, Karlsruhe, 
Germany 
Pen/Strep #C-42010 Promocell 
Trypsine/EDTA #L-2163 Biochrome, Berlin, Germany 
 
 
Table 2.6: Cardiomyocyte medium MEM (Minimal Essential Medium) 
 
Component Stock Amount/l MEM  Final concentration 
MEM  10.5 g  
BrdU 20 mM 5 ml 0.1 mM 
Vitamin B12 2 mg/ml 1 ml 2 µg/ml 
L-Glutamine  292 mg 2 mM 
NaHCO3  350 mg 4.2 mM 
Ad 1000 ml dH2O 
Sterile filtration 
Pen/Strep 1000x 1 ml 1x 
 
 
Table 2.7: Cell types/cell lines used in this work 
 
Cell type Catalogue number Manufacturer 
HEK293 (Human Embryonic 
Kidney) 
 Kind gift from Anahia-Paula 
Arias-Loza (AG Pelzer, 
cardiology, University Hospital 
Würzburg) 
HUVEC (Human Umbilical Vein 
Endothelial cells) 
#CC-2519 Cambrex Lonza, Basel, 
Switzerland 
H9C2 (Rat Cardiomyocyte Cell 
Line) 
#CRL-1446 LGC Standards GmbH, Wesel, 
Germany  
NRCM (Neonatal Rat 
Cardiomyocytes) 
 Own preparation 
NRCF (Neonatal Rat Cardiac 
Fibroblasts) 
 Own preparation 
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2.1.4.2 Cardiomyocyte preparation and fractionation of cardiac cells 
 
 
Table 2.8: Cardiomyocte preparation medium CBFHH (Calcium- and Bicarbonate-Free  
 Hanks´ solution with HEPES) 
 
Component Stock Amount/l CBFHH 
[ml] 
Final concentration 
NaCl 3.42 M 40 ml 137 mM 
KCl 0.53 M 10 ml 5.36 mM 
MgSO4*7H2O 81 mM 10 ml 0.81 mM 
Dextrose 555 mM 10 ml 5.55 mM 
KH2PO4 44 mM 10 ml 0.44 mM 
Na2HPO4  34 mM 10 ml 0.34 mM 
HEPES pH 7.4 0.206 M 100 ml 20.06 mM 
Ad 1000 ml dH2O 
Sterile filtration 
Pen/Strep 1000x 1 1x 
 
 
Table 2.9: T&D (Trypsin and Dnase) solution 
 
Component Stock Amount/100 ml CBFHH Final concentration 
DNase 2 mg/ml in 0.15 M 
NaCl 
1 ml 0.02 mg/ml 
Trypsine 1.5 mg/ml 100 ml 1.5 mg/ml 
 
 
Table 2.10: Collagenase solution for fractionation of cardiac cell types 
 
Component Final concentration 
Butanedione 
monoxime 
10 mM 
Calcium chloride 20 µM 
Collagenase II 1 mg/ml 
Ad Joklik medium 
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2.1.4.3 DNA Electrophoresis 
 
 
Table 2.11: 50x TAE (Tris-Acetate-EDTA) buffer for DNA electrophoresis 
 
Component Stock Amount/l  Final concentration 
Tris  242 g 2 M 
Acetic acid (glacial)  57.1 ml  
EDTA 0.5 M pH 
8.0 
100 ml 0.05 M 
Ad 1000 ml dH2O 
 
 
2.1.4.4 Chromatin Immunoprecipitation (ChIP) 
 
 
Table 2.12: Buffers for ChIP 
 
Cell lysis buffer 
Component Stock Amount/100 ml  Final concentration 
KCl 1 M 8.5 ml 85 mM 
NP40 100% (w/v) 0.5 ml 0.5% (w/v) 
PIPES pH 8.0 1 M 0.5 ml 5 mM 
Ad 100 ml dH2O 
IP dilution buffer 
Component Stock Amount/100 ml Final concentration 
EDTA 0.5 M 0.24 ml 1.2 mM 
NaCl 5 M 3.34 ml 167 mM 
Tris-HCl pH 8.1 1 M 1.67 ml 16.7 mM 
TritonX100 100% (w/v) 1.1 ml 1.1% (w/v) 
Ad 100 ml dH2O 
Dialysis buffer 
Component Stock Amount/500 ml Final concentration 
EDTA 0.5 M 2 ml 2 mM 
Sarkosyl 10% (w/v) 10 ml 0.2% (w/v) 
Tris-HCl pH 8.0 1 M 25 ml 50 mM 
Ad 500 ml dH2O 
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IP wash buffer 
Component Stock Amount/500 ml Final concentration 
DOC 10% (w/v) 50 ml 1% (w/v) 
LiCl 2.5 M 100 ml 500 mM 
NP40 100% (w/v) 5 ml 1% (w/v) 
Tris-HCl pH 9.0 1 M 50 ml 100 mM 
Ad 500 ml dH2O 
Elution buffer 
Component Stock Amount/10 ml Final concentration 
SDS 10% (w/v) 1 ml 1% (w/v) 
NaHCO3 500 mM 2 ml 100 mM 
Ad 10 ml dH2O 
Proteinase K buffer 5x 
Component Stock Amount/10 ml Final concentration 
EDTA pH 8.0 0.5 M 0.5 ml 25 mM 
SDS 10% (w/v) 1.25 ml 1.25% (w/v) 
Tris-HCl pH 7.5 1 M 0.5 ml 50 mM 
Ad 10 ml dH2O 
TE buffer 
Component Stock Amount/100 ml Final concentration 
EDTA 0.5 M 0.2 ml 1 mM 
Tris-HCl pH 7.5 1 M 1 ml 10 mM 
Ad 100 ml dH2O 
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2.1.4.5 SDS-PAGE and Western blot 
 
 
Table 2.13: Gel recipe for separating gel (SDS-PAGE), 2 gels 
 
Component 10% 12% 15% 
dH2O 10.42 ml 8.75 ml 6.25 ml 
1.5 M Tris-HCl pH 8.8, 
0.4% (w/v) SDS 
6.25 ml 6.25 ml 6.25 ml 
30% (w/v) 
Acrylamide/Bisacrylamide 
8.33 ml 10 ml 12.5 ml 
10% (w/v) APS 100 µl 100 µl 100 µl 
TEMED 10 µl 10 µl 10 µl 
 
 
Table 2.14: Gel recipe for 5% (v/v) stacking gel (SDS-PAGE), 2 gels 
 
Component Volume 
dH2O 3.81 ml 
1 M Tris-HCl pH 6.8, 
0.4% (w/v) SDS 
1.6 ml 
30% (w/v) 
Acrylamide/Bisacrylamide 
820 µl 
10% (w/v) APS 50 µl 
TEMED 5 µl 
 
 
Table 2.15: 10x SDS-PAGE electrophoresis buffer 
 
Component Amount/l Final concentration (10x) Final concentration 
(1x) 
Glycin 144 g 1.92 M 192 mM 
SDS 10 g 1% (w/v) 0.1% (w/v) 
Tris 30 g 250 mM 0.81 mM 
Ad 1000 ml dH2O 
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Table 2.16: 10x Western blot transfer buffer 
 
Component Amount/l Final concentration (10x) Final concentration 
(1x) 
Glycin 144 g 1.92 M 192 mM 
Tris 30 g 250 mM 0.81 mM 
Ad 1000 ml dH2O 
 
 
Table 2.17: TBST western blot washing buffer 
 
Component Amount/l Final concentration 
NaCl 16 g 274 mM 
Trizma 1 M pH 7.6 40 ml 40 mM 
Tween20 2 ml (v/v) 0.2% (v/v) 
Ad 2000 ml dH2O 
 
 
Table 2.18: Luminol reagent for Western blot detection 
 
Solution Amount 
25 mg Luminol in 50 
ml 0.1 M Tris-HCl pH 
8.6 
2 ml 
10 mg p-cumaric acid 
in 10 ml DMSO 
0.8 ml 
H2O2 (30% v/v) 2.4 µl 
dH2O 3 ml 
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2.1.5. Plasmids 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1: Plasmids supplied from Ambion in the Luciferase assay kit 
 
 
The supplied pMIR-REPORT Luciferase plasmid from Ambion was further used for cloning 
vector constructs bearing human-GATA2-3´-UTR, mouse-GATA2-3´-UTR, human-PAK4-3´-
UTR, human-RASA1-3´-UTR and human H2AX-3´-UTR. 
 
 
2.1.6 Oligonucleotides and probes 
 
 
Table 2.19: siRNAs applied in this work 
 
siRNA Catalogue number Manufacturer 
GATA2 (human) sc-37228  Santa Cruz Biotechnology, Santa Cruz, USA 
H2AX (human) sc-62464 Santa Cruz Biotechnology, Santa Cruz, USA 
PAK4 (human) sc-39060 Santa Cruz Biotechnology, Santa Cruz, USA 
RASA1 (human) sc-29467 Santa Cruz Biotechnology, Santa Cruz, USA 
Scrambled siRNA 
control-A 
sc-37007 Santa Cruz Biotechnology, Santa Cruz, USA 
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Table 2.20: miRNAs applied in this work 
 
miRNA Catalogue number Manufacturer 
hsa-miR-24 PM10737 Applied Biosystems, Foster City, USA 
hsa-anti-miR-24 AM10737 Applied Biosystems, Foster City, USA 
hsa-miR-22 PM11752 Applied Biosystems, Foster City, USA 
hsa-miR-210 PM10516 Applied Biosystems, Foster City, USA 
pre-miR miRNA 
precursor 
molecules-negative 
control #2  
AM17111 Applied Biosystems, Foster City, USA 
anti-miR miRNA 
precursor 
molecules-negative 
control #1 
AM17010 Applied Biosystems, Foster City, USA 
Cy3 pre-miR 
negative control #1 
AM17120 Applied Biosystems, Foster City, USA 
 
 
Table 2.21: TaqMan miRNA detection assays applied in this work 
 
miRNA Catalogue number Manufacturer 
hsa-miR-24 #4373072 Applied Biosystems, Foster City, USA 
RNU6B #4373381 Applied Biosystems, Foster City, USA 
 
 
Table 2.22: Antagomirs applied in this work 
 
Antagomir Sequence Manufacturer 
Antagomir-24 5’-CTGTTCCTGCTGAACTGAGCCA-
chol-3’ 
Regulus Therapeutics, 
Carlsbad, USA 
Scrambled 
antagomir 
5’-
ACAAACACCAUUGUCACACUCCA-
chol-3’ 
Regulus Therapeutics, 
Carlsbad, USA 
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Table 2.23: Primer sequences used for pMIR-REPORT cloning with restriction sites underlined 
 
3´-UTR Primer (forward, reverse) Product size [bp] 
GATA2 (human) forward:  
5´-AAAACTAGTGGAACAGATGGACGTCGAG-3´ 
reverse: 
5´-AAAAAGCTTGCAGCTTCGGCCTCAAAG-3´ 
700 
GATA2 (mouse) forward:  
5´-AAAACTAGTACTTCCTCCTGCCAGCCTA-3´ 
reverse: 
5´-AAAAAGCTTCCGAGGGTTTAGCAGAAAAG-3´ 
700 
H2A.X (human) forward:  
5´- AAAACTAGTGCCCCATTTCCCTTCCAG-3´ 
reverse: 
5´- AAAAAGCTTGGTGTTAAGAGCCCTTGCAG-3´ 
1360 
PAK4 (human) forward:  
5´-AAAACTAGTTTGCTGGGGGTAGATGAGAC-3´ 
reverse: 
5´-AAAAAGCTTGGTTCTTCAGGCAGTGGTTC-3´ 
620 
RASA1 (human) forward:  
5´-AAAACTAGTTCCAAGATTCTGCTGGTGAA-3´ 
reverse: 
5´-AAAAAGCTTGGCAGCTGATGAGGTTGTCT-3´ 
750 
 
 
Table 2.24: Primer sequences used for ChIP-PCR 
 
Promoter region Primer (forward, reverse) Product size [bp] 
BMP and activin 
membrane-bound 
inhibitor (BAMBI) 
forward: 
5´-TCTCAGGTTTTGGAGGGAGA-3´ 
reverse: 
5´-GGCCGAGACTGACACTCAAT-3´ 
259 
Endothelial cell 
specific molecule 1 
(ESM1) 
forward: 
5´-CAAGTGATATGCCAGGGTCA-3´ 
reverse: 
5´-TGGTTGTTTTGCATGAGGAC-3´ 
136 
 
 
 
Promoter region Primer (forward, reverse) Product size [bp] 
Heme oxygenase 1 
(HO1) 
forward: 
5´-CATCACCAGACCCAGACAGA-3´ 
reverse: 
5´-AAGGCCGACTTTAAGGGAAG-3´ 
133 
Netrin 4 (NTN4) forward: 180 
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5´-GAGCCAGTTATTCAGCAAAGAAA-3´ 
reverse: 
5´-ATGCAGAGGCCATGCTAATC-3´ 
Sirtuin 1 (SIRT1) forward: 
5´-GGAGTCACAGTGTGCCAGAA-3´ 
reverse: 
5´-CCTTCCTTTCTAGCGTGAGC-3´ 
201 
 
 
2.1.7 Antibodies, enzymes and standard markers 
 
 
Table 2.25: Primary antibodies applied in this work (Western blot and ChIP) 
 
Antibody/Antigen Catalogue number Manufacturer 
Akt #9272 Cell Signaling Technology, Danvers, USA 
Bad Ab28840 Abcam, Cambridge, USA 
GAPDH ab8245 Abcam, Cambridge, USA 
GATA2 arp31855 Aviva Systems Biology, San Diego, USA 
GATA2 ab22849 Abcam, Cambridge, USA 
GATA2 (ChIP) sc-267x Santa Cruz Biotechnology, Santa Cruz, USA 
GFP ab1218 Abcam, Cambridge, USA 
H2.AX ab11175 Abcam, Cambridge, USA 
HIF1α sc-10790 Santa Cruz Biotechnology, Santa Cruz, USA 
HMOX1 (HO1) AF3776 R&D Systems, Minnesota, USA 
Lamin A/C sc-6215 Santa Cruz Biotechnology, Santa Cruz, USA 
Mouse control-
IgG (ChIP) 
sc-2025 Santa Cruz Biotechnology, Santa Cruz, USA 
PAK4 ab19007 Abcam, Cambridge, USA 
p44/42 MAP 
Kinase 
#9102 Cell Signaling Technology, Danvers, USA 
 
 
 
Antibody/Antigen Catalogue number Manufacturer 
phospho-Akt #9271 Cell Signaling Technology, Danvers, USA 
phospho-p44/42 
MAP Kinase 
(Thr202/Tyr204) 
#9101 Cell Signaling Technology, Danvers, USA 
RASA1/GAP ab2922 Abcam, Cambridge, USA 
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SIRT1 ab32441 Abcam, Cambridge, USA 
TBP ab818 Abcam, Cambridge, USA 
 
 
Table 2.26: Secondary antibodies applied in this work (Western blot) 
 
Antibody Catalogue number Manufacturer 
Anti-rabbit-IgG-HRP #7074 Cell Signaling Technology, Danvers, 
USA 
Anti-mouse-IgG-HRP #7076 Cell Signaling Technology, Danvers, 
USA 
Anti-goat-IgG-HRP sc-2020 Santa Cruz Biotechnology, Santa Cruz, 
USA 
Precision Protein™ 
StrepTactin-HRP 
#161-0380 Bio-Rad, Munich, Germany 
 
 
Table 2.27: Primary antibodies applied in this work (Immunocyto-/histochemistry) 
 
Antibody Catalogue number Manufacturer 
CD31 ab28364 Abcam, Cambridge, USA 
CD31 ab24590 Abcam, Cambridge, USA 
CD31 MCA2388 Serotec 
GATA2 arp31855 Aviva Systems Biology, San Diego, USA 
PAK4 ab19007 Abcam, Cambridge, USA 
RASA1/GAP ab2922 Abcam, Cambridge, USA 
Troponin I sc-15368 Santa Cruz Biotechnology, Santa Cruz, 
USA 
 
 Material and Methods 
 
48 
Table 2.28: Secondary Alexa Flour ® antibodies applied in this work (Immunocyto/histo-chemistry) 
 
Alexa Fluor®  Catalogue number Manufacturer 
Donkey anti-rabbit 488 A21206 Invitrogen, Karlsruhe, Germany 
Donkey anti-rat 488 A21208 Invitrogen, Karlsruhe, Germany 
Donkey anti-mouse 
488 
A21202 Invitrogen, Karlsruhe, Germany 
Donkey anti-rabbit 594 A21207 Invitrogen, Karlsruhe, Germany 
Donkey anti-mouse 
594 
A21203 Invitrogen, Karlsruhe, Germany 
 
 
Table 2.29: Enzymes applied in this work 
 
Enzyme Catalogue 
number 
Manufacturer 
Collagenase C0130 Sigma-Aldrich, Taufkirchen, Germany 
DNase DN25 Sigma-Aldrich, Taufkirchen, Germany 
HindIII (+buffer) R0104S 
 
New England Biolabs, Frankfurt, 
Germany 
Proteinase K P2308 Sigma-Aldrich, Taufkirchen, Germany 
RNAse A R6513 Sigma-Aldrich, Taufkirchen, Germany 
SpeI (+ buffer) R0133L New England Biolabs, Frankfurt, 
Germany 
T4 DNA Ligase (+ 
buffer) 
M0202S + 
B0202S 
New England Biolabs, Frankfurt, 
Germany 
 
 
Table 2.30: Standard markers applied in this work 
 
Standard marker Catalogue number Manufacturer 
DNA electrophoresis 
standard 
#SM0241 Fermentas, St. Leon-Rot, Germany 
Precision Plus Protein 
standard 
#161-0374 Bio-Rad, Munich, Germany 
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2.1.8 FACS solutions 
 
 
Table 2.31: Annexin-V-FLUOS staining solution for apoptosis detection 
 
Component Amount/1 ml 
Annexin-V-FLUOS solution 20 µl 
Incubation buffer 1 ml 
Propidium iodide solution 20 µl 
 
 
Table 2.32: Propidium iodide (PI) solution for cell cycle analysis 
 
Component Final 
concentration 
Propidium iodide 50 µg/ml 
RNase A 0.1 mg/ml 
Triton X-100 0.05% (v/v) 
 
 
2.1.9 Components for bacteria culture and bacteria strains 
 
 
Table 2.33: LB and LB-agar media 
 
LB-media 
Component Amount/l LB 
LB 25 g 
Ad 1000 ml dH2O, then autoclave 
LB-agar 
Component Amount/l LB 
LB 25 g 
Agar (separate 
bottle) 
15 g 
Ad 1000 ml dH2O (split for LB and agar),  
then autoclave 
 
The desired antibiotic ampicillin (final concentration 100 µg/ml) was added after autoclaving 
and cooling down of solutions to 50-60 °C. Afterwards, LB-agar plates were spilled. 
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Table 2.34: Applied bacteria strain 
 
Name genotype Catalogue 
number 
Manufacturer 
One Shot® TOP10 
Chemically 
Competent E. coli 
F- mcrA ∆(mrr-hsdRMS-mcrBC) 
φ80lacZ∆M15 ∆lacX74 recA1 
araD139 ∆(araleu) 
7697 galU galK rpsL (StrR) endA1 
nupG 
#C4040-10 Invitrogen, 
Karlsruhe, 
Germany 
 
 
2.1.10 Animals 
 
 
All animal experiments were approved by local authorities and conducted according to the 
German law of animal protection. 
 
Mice were purchased from Harlan-Winkelmann (Borchen, Germany). Inbred C57BL/6 mice 
were male, 8-10 weeks old and approximately 20-25 g in weight. 
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2.2 Methods 
 
 
2.2.1 Cell culture 
 
 
2.2.1.1 Cultivation of endothelial cells (ECs) 
 
Human umbilical vein endothelial cells (HUVECs) were cultured in EGM-2 media 
supplemented with 20% (v/v) fetal calf serum (FCS) and supplements. Cells were grown in a 
humidified atmosphere at 5% CO2 and 37°C. Hypoxic conditions were simulated by 
incubating HUVECs with 1% O2, 5% CO2 for 24 h. Furthermore, cells were splitted up to 
passage 10. 
 
2.2.1.2 Isolation and cultivation of neonatal rat cardiomyocytes and 
cardiac fibroblasts 
 
Hearts were removed from newborn rats (day 0), put into calcium- and bicarbonate-free 
HEPES-buffered Hanks’ medium, cut into pieces and digested with trypsin/DNase under 
constant stirring. The collected primary cells were passed through a cell strainer (40 µm) and 
then seeded in a pre-plating step onto uncoated plastic dishes dishes and incubated for 60 min 
at 37°C. The supernatant (containing the cardiomyocytes) was collected and the adherent cells 
were washed several times and cultured in minimal essential medium (MEM) containing 5% 
(v/v) FCS. These cultures contained almost exclusively primary cardiac fibroblasts. The cells 
in the supernatant that was collected were plated in MEM containing vitamin B12, NaHCO3 
and 5% (v/v) FCS. This cell population was almost exclusively cardiomyocytes. After 1 d in 
culture medium was replaced to DMEM with 10% (v/v) FCS and antibiotics. Cardiac 
fibroblasts were cultured at 5% CO2, cardiomyocytes at 1% CO2. 
 
The rat cardiomyocyte cell line H9C2 was cultured in DMEM media supplemented with 10% 
(v/v) FCS and antiobiotics in a humidified atmosphere at 5% CO2 and 37°C. 
 
2.2.1.3 Cultivation of other applied cell types 
 
The human embryonic kidney cell line HEK-293 was cultured in DMEM media with 10% 
(v/v) FCS and antiobiotics in a humidified atmosphere at 5% CO2 and 37°C. 
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2.2.1.4 Transfection assays 
 
Transient liposomal transfection of small-inhibitory RNAs (siRNAs) or microRNAs was done 
according to manufacturers´ instructions. Therefore cells were splitted into 6wells one day 
before transfection to reach 60-70% confluence on day of transfection. Specific 
siRNAs/miRNAs, control siRNA/miRNA and 4 µl Lipofectamine2000 per 6well were mixed 
separately and incubated for 5 min with Opti-MEM I media. Complexes were added together 
and incubated for 20 min. Media was changed to antibiotic-free media before adding 
liposomal siRNA complexes (final concentration 150 nM for siRNA and 100 nM for 
miRNAs). Cells were incubated for 4 h before changing the media to fresh medium. Silencing 
of proteins or miRNA targets was monitored 48 h (siRNA) or 72 h (miRNAs) post 
transfection by western blot analysis. Specific details about the used siRNAs and miRNAs are 
given in tables 2.19/20. 
 
2.2.1.5 Luciferase reporter assay 
 
A luciferase reporter assay system was applied to validate potential miRNA targets. luciferase 
gene expression can be downregulated by binding of certain miRNAs in 3´-UTR of luciferase 
reporter gene. The cloned constructs were co-transfected with miRNAs of interest (table 2.20) 
and beta-galactosidase control plasmid (figure 2.1) into HEK293 reporter cells in 48wells by 
use of Lipofectamine2000. 0.2 µg plasmid DNA each, 100 nM miRNA and 0.5 µl of 
Lipofectamine2000 were applied. Cells were incubated for 24 h before measuring luciferase 
and β-galactosidase activity on a multi-plate reader according to manufacturers´ instructions. 
 
2.2.1.6 In vitro tube formation assay for ECs 
 
A matrigel based assay was applied to test capillar formation of ECs in vitro. Therefore ECs 
were pre-treated by siRNA or miRNA modulation as mentioned before. Then cells were 
harvested and 15000 cells in 200 µl EGM-2 media with supplements were seeded on Matrigel 
coated 8well chamber slides. After 6 and 24 h pictures were taken on a Zeiss Axiovert 
microscope. Experimental outcome was measured qualitatively. 
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2.2.1.7 Viral transduction 
 
The generation of a murine N-terminal GFP tagged GATA2 adenovirus was done by the 
laboratory of Prof. Stefan Engelhardt (Pharmacology, Rudolf-Virchow Center, Würzburg, 
Germany). Following biosafety level 2 experiments were done in the laboratory of Prof. 
Stefan Engelhardt. 
 
For viral transduction experiments cells were grown to subconfluence and infected with viral 
particles in a multiplicity of infection (m.o.i.) of 40 for 24-48 h. Additionally, a YFP control 
virus was also applied with same m.o.i.. 
 
 
2.2.2 Molecular biology 
 
 
2.2.2.1 RNA isolation 
 
RNA isolation of cell culture cell pellets or animal tissue was done either with Qiagen 
RNeasy mini kit or TRIzol reagent. For TRIzol RNA isolation samples were homogenized 
with 1 ml TRIzol for 5 min at RT. 200 µl chloroform was added, samples were mixed and 
incubated for 2-3 min at RT. Samples were centrifuged at 11900 x g for 15 min at 4°C. 
Afterwards the upper phase was taken and mixed with 500 µl isopropyl alcohol following 10 
min incubation at RT. Then samples were centrifuged at 11900 x g for 10 min at 4°C. The 
resulting RNA pellet was washed with 70% (v/v) ethanol and centrifuged at 7370 x g for 5 
min at 4°C. Afterwards RNA pellet was suspended in appropriate amounts of DEPC-treated 
water. 
 
2.2.2.2 DNA isolation 
 
Genomic DNA from cell pellets was isolated with the Qiagen DNeasy Blood & Tissue Kit. 
 
2.2.2.3 Determination of RNA and DNA concentration 
 
RNA and DNA concentrations were determined by measurement of absorption at 260 nm 
(A260) and 280 nm (A280) in a UV-spectralphotometer versus dH2O as reference. The 
absorption of suspended DNA or RNA is proportional to concentration at A260.  
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For DNA 1.0 A260 unit equals 50 µg/ml DNA and for RNA 1.0 A260 unit equals 40 µg/ml 
RNA. The A260/A280 ratio was measured and only preparations with a ratio between 1.8 and 
2.0 were considered to be pure. 
 
2.2.2.4 Agarose gel electrophoresis 
 
For qualitative analysis of DNA band pattern agarose gel electrophoresis was applied. 
Therefore, 1.8% (m/v) agarose gels were prepared by heating agarose in 0.5 TAE buffer. 
Samples were mixed with 6x loading dye solution and loaded onto the gel with an appropriate 
DNA ladder. Electrophoresis run was performed for 60 min at 90 V in 0.5 TAE buffer. 
 
2.2.2.5 Luciferase pMIR-REPORT cloning 
 
A putative 3´-UTR miRNA binding sequence was cloned into SpeI and HindIII cloning site of 
pMIR-REPORT vector (figure 2.1). In advance, 3´-UTR of mRNA containg the miRNA 
binding site was PCR amplified from whole genomic DNA (human or mouse) with 
appropriate primers (table 2.23). Primers were designed with Primer3 
(http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi). 
 
PCR setup 
 
10 µl HotStarTaq-Mix  
2.5 µl primerpair (forward/reverse) [4 µM] 
2.5 µl genomic DNA (human/mouse) [100 ng/µl] 
 
PCR protocol: 
94°C 10 min, [94°C 1 min, 57°C 30 sec, 72°C 1 min]x40, 72°C 10 min, 4°C hold 
 
PCR products were purified with Qiagen PCR purification kit and analyzed for correct band 
pattern on a 1.8% (m/v) agarose gel. The amplified 3´-UTR sequences and pMIR-REPORT 
vector were double-digested for 2 h at 37°C with appropriate restriction enzymes before 
purification with Qiagen PCR purification kit. 
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Restriction digestion setup 
 
A) Insert (3´-UTR) 
 
20 µl PCR product  
2 µl SpeI [10 U/µl] 
1 µl HindIII [20 U/µl] 
3 µl NEB buffer 2 [10x] 
4 µl dH2O 
 
B) Vector 
 
1 µl vector pMIR-REPORT [3 µg/µl] 
6 µl SpeI [10 U/µl] 
3 µl HindIII [20 U/µl] 
2 µl NEB buffer 2 [10x] 
8 µl dH2O 
Afterwards insert and vector were ligated with T4 DNA ligase o/n at 16°C before T4 DNA 
ligase inhibition for 15 min at 65°C. 
 
Ligation setup 
 
20 µl 3´-UTR 
0.5 µl vector 1:10 diluted 
3 µl 10x T4 buffer 
1.5 µl T4 DNA ligase 
5 µl dH2O 
 
Finally, E. coli TOP10 cells were heat-transformed with the ligation sample. Therefore, 50 µl 
competent were thawed on ice and 10 µl ligation mix was added. After 20 minutes incubation 
on ice, cells were heat-shocked for 90 seconds at 42°C. Cells were then cooled on ice for 2 
minutes. Afterwards 500 µl SOC media was added and cells mixed on a vortexing platform 
for 45 min at 37°C. Then 100-200 µl cell suspension were plated on LB-Amp plates and 
incubated o/n at 37°C. The next day transformants were picked and inoculated to LB-Amp-
media o/n at 37°C. Plasmid preparation was done the next day with Qiagen mini plasmid kit. 
For verification of positive transformants double-digestion with SpeI and HindIII was 
performed for 1 h at 37°C. 
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Qualitative restriction digestion setup 
 
5 µl isolated plasmid DNA (pDNA) 
0.5 µl SpeI [10 U/µl] 
0.5 µl HindIII [20 U/µl] 
2 µl NEB buffer 2 [10x] 
12 µl dH2O 
 
Afterwards samples were analyzed for positive band pattern on a 1.8% (m/v) agarose gel. The 
constructs were further subjected to sequencing for final validation. For greater amounts of 
pDNA plasmid preparation was done with the Qiagen midi plasmid kit. 
 
2.2.2.6 Real-time PCR analysis 
 
For detection of miRNAs in samples different TaqMan MicroRNA assays were applied. 
Specific details about the used assays are given in table 2.21. In a first step, total RNA was 
reverse transcribed. 
 
cDNA reaction setup for miRNA detection 
 
2 µl sample total RNA [100-1000 ng/µl] 
3 µl iScript reaction mix [5x]  
1 µl reverse transcriptase  
3 µl miRNA primer for reverse transcription  
6 µl dH2O 
 
Cycler protocol: 
25°C 5 min, 42°C 30 min, 85°C 5 min, 4°C hold 
 
Afterwards, Real-time PCR analyis was performed in an ICycler. Data analysis was supported 
by a standard curve created from a mixture of all analyzed samples and a subsequent 5-fold 
dilution series. Analysis was performed with ICycler Software 3.0. 
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Real-time PCR reaction setup for miRNA detection 
 
1.33 µl sample 1:2 diluted 
10 µl iQ Supermix [2x] 
7.67 µl dH2O 
 
Cycler protocol: 
95°C 10 min, [95°C 15 sec, 60°C 1 min]x40, 15°C hold 
 
 
2.2.2.7 ChIP 
 
Chromatin immunoprecipitation (ChIP) is a technique to detect protein-DNA interactions. 
Here, transcription factor GATA2 controlled target DNA sequences were investigated. In 
advance, Protein G Sepharose beads were blocked o/n at 4°C with 100 µg salmon sperm 
DNA and 100 µg BSA per 100 µl 50% (v/v) beads. HUVECs from confluently grown T75 
flasks were first cross-linked by adding 1% (v/v) formaldehyde for 10 min at RT. Cross-
linking was stopped by addition of 2.5 M Glycin to a final concentration of 125 mM for 5 min 
at RT. Cells were washed once with ice-cold PBS before scraped and harvested. The pellet 
was lysed in lysis buffer on ice for 10 min with interval vortexing. Next, the lysate was 
sonified to yield DNA fragments from 100-1000 bp in length. Therefore, 12 intervalls for 
each 30 seconds were applied (Bandelin Sonifier GM70, sonotrode MS72, cycle 0.5, 
maximum amplitude strength). Samples were kept on ice for the whole procedure. 
Afterwards, samples were centrifuged at maximum speed (10 min, RT). From these cleared 
lysates 100 µl aliquots were separately taken to measure sonification efficiency. Therefore 
samples were heated o/n at 65°C. Then, 100 µl dH2O and Proteinase K (0.5 mg/ml final) were 
added and samples are incubated for 3 h at 42°C. Finally, total DNA after sonification was 
purified with Qiagen PCR purification kit before agarose gel analysis. To reduce non-specific 
background cleared lysates were pre-cleared on 50 µl 50% (v/v) blocked Protein G Sepharose 
beads twice for 2 h at RT. Afterwards, samples were divided into 500 µl aliquots and filled up 
with 1 ml IP dilution buffer. Samples were subjected to either immunoprecipitation with 5 µg 
GATA2 antibody or control mouse IgGs o/n at 4°C.  
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To block non-specific background 250 µg BSA and 24 µg salmon sperm DNA were added. 
One sample with cell lysis and IP dilution buffer was named “mock” control. The next day 
GATA2-DNA cross-links were collected by 15 min incubation with 50 µl 50% (v/v) Protein 
G beads at 4°C on a rotating wheel. Samples were centrifuged (3000 x g, 1 min, 4°C) and 
beads were washed twice with dialysis buffer and four times with IP wash buffer. Finally 
beads were washed twice with TE-buffer. Antibody-GATA2-DNA complexes were eluted 
from the beads by adding 150 µl IP elution buffer. Samples were heated at 65°C and kept on a 
vortexing platform for 10 min. The elution step was repeated and combined eluates were 
reverse crosslinked by addition of 5 M NaCl (0.3 M final concentration) for 4 hours at 65°C. 
Samples were cooled on ice and subjected to RNA degradation by adding 10 µg RNase A and 
incubation for 30 min at 37°C. Next samples were mixed with 2.5 volumes 100 % (v/v) 
ethanol and incubated o/n at -20°C. On the following day DNA was pelleted (maximum 
speed, 20 min, 4°C) and protein was digested from the samples by addition of 100 µl TE 
buffer, 25 µl 5x proteinase K buffer and 6.25 µl (20 µg/µl) proteinase K (2 h, 55°C). DNA 
was further extracted by phenol-chloroform-isoamylalcohol (PCI) extraction (1 volume 
sample on 1 volume PCI, maximum speed, 10 min, RT). The upper phase was mixed with 1 
volume chloroform-isoamylalcohol and centrifuged (maximum speed, 10 min, RT). Again, 
the upper phase was taken and 1/10 volume 5 M NaCl and 5 µg glycogen were added. 
Samples were mixed with 2.5 V 100% (v/v) ethanol and incubated o/n at -20°C. The next day 
DNA was pelleted (maximum speed, 10 min, 4°C) and washed with 70% (v/v) ethanol. 
Pellets were air-dried and solved in 60 µl TE buffer before purification with Qiagen PCR 
purification kit. 
 
For ChIP primer design 2000-2500 bp upstream promoter region of candidate target genes 
was identified by Ensembl Genome Browser (http://www.ensembl.org/index.html). Then the 
promoter region was screened for potential GATA2 binding sites by the use of ALLGEN-
Promo (http://alggen.lsi.upc.es/cgibin/promo_v3/promo/promoinit.cgi?dirDB=TF_8.3). 
Afterwards, primers were designed to amplify potential GATA2 binding site. Finally, PCR 
analysis of chipped DNA fragments was done with appropriate primers (table 2.24). 
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PCR setup 
 
2.5 µl chipped DNA 
2.5 µl primerpair [4 µM] 
10 µl HotStarTaq Mix 
 
PCR protocol: 
94°C 10 min, [94°C 1 min, 57°C 30 sec, 72°C 1 min]x33, 72°C 10 min, 4°C hold 
 
 
2.2.2.8 Affymetrix gene chips 
 
To assess RNA integrity number (RIN) for downstream array analysis total RNA was 
subjected to capillar chromatography in an Agilent bioanalyzer 2100 according to 
manufacturers´ instructions. Therefore 1 µl of isolated total RNA was analyzed with Agilent 
RNA nano chips for 18 and 28 S RNA peaks in an electropherogramm. 
 
Afterwards total RNA underwent microarray (Human Exon Gene ST array) analysis in the 
laboratory of Dr. Susanne Kneitz (IZKF Microarray Core Facility, University of Würzburg). 
Data acquisition was done with a R programmed software (Dr. Paolo Galuppo, Cardiology, 
University Hospital Würzburg) or Affymetrix expression console. 
 
 
2.2.3 Protein biochemistry 
 
 
2.2.3.1 Protein isolation 
 
Total protein was isolated from samples by 10 min incubation with cell lysis buffer plus 4 
mM protease-blocker Pefabloc on ice. Lysis was supported by interval vortexing. Samples 
were then centrifuged (8000 x g, 10 min, 4°C) to obtain soluble protein. 
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2.2.3.2 Determination of protein concentration 
 
Protein concentration was measured by Bradford assay quantification (Bradford, 1970). 
Therefore 1 µl sample was mixed with 800 µl dH2O and 200 µl RotiQuant reaction mix. The 
mixture was incubated for 5 min at rt before measuring absorbance at 595 nm (A595) in a UV-
spectralphotometer versus reference. Protein concentration was obtained by comparing A595 to 
a protein standard curve of BSA [0.2-20 mg/ml]. 
 
2.2.3.3 SDS-PAGE 
 
Samples were mixed with sample buffer and DTT and heat-denatured for 5 min at 95°C. Then 
denatured proteins were separated by discontinous SDS-PAGE. Therefore, 10-15% 
acrylamide gels were prepared. Electrophoretic separation was performed in a mini gel 
apparatus for 90-120 min at 20-30 mA. Afterwards gels were blotted onto PVDF-membranes. 
 
2.2.3.4 Western blot 
 
Western blot was applied in a wet blot technique. Prior to electrophoretic transfer, PVDF 
membrane was activated in methanol for 1 min. Then it was washed in distilled water for 2 
min before 5 min equilibration in transfer buffer. Western blot was performed o/n at constant 
30 V. 
 
The next day membranes were blocked with 5% (w/v) skim milk powder for 30 min. After 
three times washing with TBST membranes were incubated with appropriate antibodies 
diluted in 5% (w/v) skim milk powder in TBST for 3 h at RT or o/n at 4°C. Details about the 
used primary antibodies are in table 2.25. Following antibody incubation membranes were 
again washed three times with TBST before incubation with appropriate secondary antibodies 
linked to horseradish peroxidise (HRP) (see table 2.26) for 1 h at RT. The secondary 
antibodies were 1:10.000 diluted in 5% (w/v) skim milk powder in TBST. Afterwards 
membranes were washed three times with TBST. For antigen detection luminol reagent was 
added to the membranes. Finally membranes were covered with X-ray films. Time for 
developing X-ray films was depending on antigen. Bands on X-ray films were quantified by 
the use of Scion Image Alpha 4.0.3.2. 
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2.2.3.5 Apoptosis array 
 
The apoptosis array system was supplied by R&D Systems (Proteome profiler array) and was 
performed by manufacturers´ instructions. Briefly, cell pellets were lysed in lysis buffer and 
200 µg total protein was incubated with the array membrane. For detection membranes were 
incubated with antibody cocktail/Streptavidin-HRP secondary antibody. Chemiluminescent 
reaction was performed and exposition to X-ray films was done for 30 sec to 10 min. Details 
about the spotted antigens are in table 2.35. 
 
Table 2.35: Overview on the spot distribution of the apoptosis array (R&D, Minnesota, USA) 
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2.2.3.6 Phospho-Bad ELISA 
 
For detection of intracellular phosphorylated Bad protein (Ser112) a phospho-Bad ELISA 
(R&D Systems) was applied according to manufacturers´ instructions. Therefore, cells in 
6wells were harvested and lysed with cell lysis buffer. Protein concentration was determined 
and samples were adjusted to 0.3 µg/µl protein. Then 100 µl sample were diluted with 100 µl 
sample buffer and incubated to antibody-coated wells for 2 h at 37°C. Afterwards plates were 
washed and incubated with 100 µl detection antibody for 1 h at 37°C. Again, plate was 
washed before incubation with 100 µl HRP-linked secondary antibody for 30 min at 37°C. 
Washing was repeated and finally wells were incubated with 100 µl substrate solution for 10 
min at 37°C. Detection reaction was stopped by addition of 100 µl stop solution. Plates were 
immediately measured in an ELISA reader for A450. Measurements wered adjusted to total 
BAD protein determined by Western blot. 
 
 
2.2.4 Fluorescence-activated cell sorting (FACS) 
 
FACS measurements were performed on a FACS Calibur (BD Biosciences, Germany) flow 
cytometer. Data acquisition and analysis was performed with CellQuest software (BD 
Biosciences, USA). 
 
2.2.4.1 Apoptosis staining 
 
Apoptosis was measured with the Annexin-V-Fluos kit (Roche, Germany) according to 
manufacturers´ instructions. Here necrotic cells can be separated from apoptotic cells by 
double staining of PI and Annexin-V-Fluorescein. Only Annexin-V-Fluorescein single 
positive cells can be named apoptotic. Briefly, cells were harvested and washed. Afterwards 
cell pellets were incubated with 100 µl staining solution for 15 min at RT. Then 500 µl 
incubation buffer was added and samples underwent FACS analyis. 
 
2.2.4.2 Cell cycle propidium iodide (PI) stain 
 
Cell cycle analysis was performed by propidium iodide staining. Therefore cells were 
harvested, suspended in 500 µl PI staining solution and incubated at 37°C for 40 min. 
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Afterwards cells were washed with PBS. Finally cell pellets were resupended in 300-500 µl 
PBS and subjected to FACS analysis. 
 
2.2.4.3 Reactive oxygen species (ROS) detection 
 
The redox-sensitive, cell-permeable fluorophore dihydroethidium (DHE) becomes oxidized in 
the presence of O2- to yield fluorescent ethidium. Thus, dye oxidation is an indirect measure 
of the presence of reactive oxygen intermediates. MiRNA-transfected HUVECs were 
incubated with DHE (2.5 µM) for 30 min at rt. After washing, HUVECs were immediately 
analyzed with FACS. 
 
2.2.5 Immunocytochemistry and immunohistochemistry 
 
Immunofluorescent detection of samples was done with an Axiovert microscope (Zeiss, 
Germany). Pictures were taken with the support of Axiovision 4.5 software (Zeiss, Germany). 
 
2.2.5.1 Immunocytochemistry 
 
Cells were grown to confluence in 4 or 8well chamber slides for analysis. Confluent cells 
were fixed with 4% (w/v) p-formaldehyde in PBS for 15 min at RT. Then cells were 
permeabilized with 0.1% (v/v) Triton X-100 in PBS for 10 min at RT. After washing samples 
were blocked with 5% (v/v) donkey serum for 30 min at RT. Next, cells were washed and 
incubated with specific antibodies diluted in 5% (v/v) donkey serum (table 2.27). Again, 
samples were washed and then incubated with appropriate Alexa fluorophore secondary 
antibodies (table 2.28) for 30 min at RT. Finally cells were washed and stained with DAPI 
(1:1000 dilution) for 5 min at RT. 
 
2.2.5.2 Immunohistochemistry 
 
For immunohistochemistry frozen hearts were mounted in tissue tek and slowly frozen by the 
use of methylbutan. Then, frozen hearts were sliced into 10 µm sections and air-dried for 30 
min. Samples were fixed by acetone for 3 min at RT and dried for 10 min. After washing with 
PBS samples were blocked with 5% (v/v) donkey serum for 30 min at RT. Incubation with 
appropriate primary antibodies in 1% (v/v) donkey serum was performed o/n at 4°C.  
Material and Methods 
 64 
Optionally, mouse on mouse (MOM) kit was applied to detect mouse antigens with mouse 
primary antibodies. The next day samples were washed and incubated with appropriate Alexa 
fluorophore secondary antibodies diluted in 1% (v/v) donkey serum for 30 min at RT. Finally 
slides were washed and stained with DAPI (1:1000 dilution) for 5 min at RT. Finally slides 
were mounted with Vectashield. Details about the used antibodies are in table 2.27/28. 
 
 
2.2.6 In vivo methods 
 
 
2.2.6.1 Fractionation of cardiac cells from heart tissue  
 
The thorax of mice was opened and the aorta was cannulated. After washing with 37°C PBS, 
the heart together with the cannula was removed and perfused with a collagenase solution in 
Joklik medium for 5 min. Then the heart was placed in 37°C pre-warmed collagenase solution 
for further 25 min and was subsequently minced and filtered through a nylon mesh (200 µm 
pore size). Then, cardiomyocytes were separated by a sedimentation step in 15 ml falcon 
tubes. The noncardiomyocyte cell fraction retained in the supernatant was incubated with 
CD146-antibodies coupled to MicroBeads and subjected to magnetic affinity cell sorting 
according to the manufacturers’ recommendations. 
 
2.2.6.2 Antagomir injection 
 
Antagomirs were designed and provided by Regulus Therapeutics (USA). Details on 
sequence information can be found in table 2.22. Antagomirs were diluted in nuclease-free 
water and 100 µl at concentrations of 5 mg/kg and 80 mg/kg were applied to mice via 
retroorbital injection. 
 
2.2.6.3 Myocardial infarction 
 
Male mice underwent coronary artery ligation for the production of MI. Briefly, mice were 
anesthetized, placed on a heating pad, intubated and ventilated with a mixture of oxygen and 
isoflurane. After left lateral thoracotomy and exposure of the heart by retractors, the left 
anterior descending coronary artery (LAD) was permanently ligated. For control reasons, 
mice were also subjected to surgery without application of MI (sham-operated animals). 
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Successful production of MI was checked by measurements of ST-elevation in 
electrocardiograms as well as impaired left ventricular wall motion by echocardiography. 
Animals that did not show ST-elevation and impaired left ventricular wall motion after 
myocardial infarction were excluded from further studies. Fourteen days after MI, additional 
echocardiography measurements were performed and finally hearts were excised and cut into 
transverse sections. From the middle ring, sections were cut and stained with appropriate 
antibodies (see above). Cardiac dimensions and function were analyzed by pulse-wave 
Doppler echocardiography essentially. 
 
2.2.6.4 Echocardiography 
 
Echocardiographic studies were performed under light anesthesia with spontaneous 
respiration using isoflurane. An ultrasonographer experienced in rodent imaging performed 
the echocardiography, operating a Toshiba PowerVision 6000 and a 15 MHz transducer. 
Short-axis two-dimensional echocardiographic images were obtained at the midpapillary and 
apical levels of the left ventricle and stored as digital loops. Frame acquisition rates using the 
loop mode reached 100 MHz, allowing excellent temporal resolution for two-dimensional 
analysis. At the same anatomic levels, short-axis M mode images were obtained with a sweep 
speed of 100 mm/s. Echocardiographic studies were performed after the surgical procedure at 
weeks four and eight. Endocardial borders were traced at end-systole and end-diastole 
utilizing a prototype off-line analysis system (NICE, Toshiba Medical Systems, The 
Netherlands). Using the end-systolic and -diastolic areas, fractional area changes were 
calculated at both levels as [(end-diastolic area - end-systolic area)/end-diastolic area] (Merkle 
et al., 2007). 
 
2.2.6.5 Matrigel implantation and determination of vascularization  
 
300 µl Matrigel™ Basement Membrane Matrix High Concentration supplemented with 600 
ng/ml bFGF, 300 ng/ml VEGF and 25 U/ml Heparin were injected subcutaneously into 
wildtype C57BL/6 mice and harvested two weeks later. Animals were treated post 
implantation with Antagomir-24 or a scrambled control antagomir (5 mg/kg at day 0 and day 
2) by retroorbital injection. Half of the plug was lysed in cell lysis buffer and samples were 
measured for haemoglobin amount with a Mouse Hemoglobin ELISA.  
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Hemoglobin amount was normalized to total protein. Additionally, plugs were frozen in 
TissueTek, sliced, stained with CD31 antibodies and investigated by fluorescence 
microscopy. 
 
 
2.2.7 MicroRNA target prediction 
 
The miRNA databases and target prediction tools miRBase (http://microrna.sanger.ac.uk/, 
Griffiths-Jones et al., 2004, 2006, 2008), PicTar (http://pictar.mdc-berlin.de/, Krek et al., 
2005) and TargetScan (http://www.targetscan.org/index.html, Lewis et al., 2005; Grimson et 
al., 2007; Friedman et al., 2009) were used to screen and identify in silico potential miRNA 
targets. 
 
 
2.2.8 Statistical analysis 
 
Average data are presented as mean and s.e.m. unless stated different. Statistical analysis was 
carried out using SigmaStat (SPPS, Chicago, USA). For statistical comparison of two groups, 
unpaired, two-tailed Student’s t-test or Mann-Whitney Rank Sum test was used. In case of 
comparison of more than two groups one-way ANOVA was applied. 
 
Differences were considered significant when p < 0.05. Otherwise, p values were described as 
n.s. (not significant). In the figures, significant p values are indicated by asterisk (* = p < 
0.05; ** = p < 0.01; *** = p < 0.001). 
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3. Results 
 
 
3.1 MiR-24 is induced post myocardial infarction (MI) 
 
 
MiRNA-dependent regulation of target proteins has been described in different organs and 
cell types thus highlighting a potential therapeutic value for disease. More interestingly, 
several studies indicated that miRNAs are deregulated upon cardiac failure (Thum et al., 
2007; van Rooij et al., 2008). The up- or downregulation of cardiac miRNAs was also 
suggested to be a critical regulatory step for cardiac wound healing (Care et al., 2007; Thum 
et al., 2008; Bonauer et al., 2009). Thus, miRNA deregulation may impact on essential 
cardiac signalling cascades which result in reduced cardiac function. Previously, upregulation 
of miR-24 in a murine hypertrophy model was reported (van Rooij et al., 2006). Other data 
gained in our group also indicated miR-24 upregulation to be induced by cardiac stress in a rat 
MI model. 
 
To validate these data, miR-24 expression level was profiled in the left ventricle (LV) of 
infarcted mice hearts and compared to control animals. Mice underwent permanent coronary 
ligation, whereas controls received sham-operation only. Successful performance of infarcts 
was validated by ECG analysis and measured by impaired wall motion using 
echocardiography. After 14 d of intervention, hearts were prepared, total LV RNA was 
isolated, reverse transcribed and analyzed by real-time quantitative PCR with specific primers 
to miR-24 and the house-keeping miRNA RNU6b. RT-PCR revealed a significant increase of 
miR-24/RNU6b ratio in infarcted versus sham operated animals (2.34 ± 0.44 vs. 1 ± 0.16, p < 
0.05; figure 3.1). This indicates that miR-24 is regulated in cardiac remodeling post MI. 
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Figure 3.1: Ratio of miR24/RNU6b in sham versus infarcted (MI) mice hearts. Hearts were prepared 14 d after 
coronary ligation and LV underwent total RNA isolation and miRNA detection. N = 6 to 7 animals 
per group. * = p < 0.05 
 
 
3.1.1 MiR-24 profiling reveals an ubiquitous expression panel 
 
 
MiRNA-dependent effects crucially depend on their cellular expression level. Cardiac injury 
changed miR-24 expression in the infarcted heart. Since the heart comprises different cell 
types, the cellular source of miR-24 upregulation is unclear. To test for possible differences in 
basal miR-24 expression, an expression screen profiling endogeneous miR-24 was performed. 
This might give an initial clue to a possible cell type enriched expression, which has been 
reported for some miRNAs, e.g. miR-126 for endothelial cells (ECs) (Fish et al., 2008; Wang 
et al., 2008; Kuhnert et al., 2008). Therefore, real-time PCR detection of miR-24 was 
performed in total RNA samples from different cell types and organs (figure 3.2). The 
resulting qualitative profile verified miR-24 expression in endothelial cells as wells as in 
cardiomyocytes which are key cellular components in the heart. Comparing the organ panel, 
higher miR-24 signals were found in muscle, brain, spleen and heart. On the whole, miR-24 
screening revealed ubiquitious abundance of this microRNA. This indicates that miR-24 is not 
a cell-type or organ specific miRNA based on human samples. 
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Figure 3.2: Ratio of miR24/RNU6b in various cell types and organs. Total RNA was prepared or provided from 
cell and organ samples and underwent miRNA detection with specific primers to miR-24 and 
RNU6b. 
 
 
3.1.2 MiR-24 is induced in ECs post hypoxia and in cardiac ECs post MI 
 
 
The regulation of miRNA expression depends on transcriptional activities occuring in the 
whole genome. Therefore, recruitment of transcription factors to its DNA binding sites is the 
trigger for induction or repression of transcription sites. Thus, identification of transcription 
factors regulating miRNA expression would be favorable to understand upstream miRNA 
signalling. Transcriptive regulation of the miR-24-1 genelocus has been observed during 
hypoxic conditions by hypoxia-inducible factor α (HIF1α) (Kulshreshtha et al., 2007). A 
hypoxic environment is a major hallmark of myocardial infarction. Indeed, miR-24 was found 
to be upregulated in the infarcted heart. To test the hypothesis if hypoxia induces miR-24 in 
ECs or neonatal rat cardiomyocytes, cells were subjected to 1% (v/v) O2 for 24 h and 
thereafter miRNA expression level was monitored. Interestingly, the expression level of miR-
24 was induced by hypoxic treatment in endothelial cells compared to normoxic environment 
(2.16 ± 0.12 vs. 1 ± 0.15, p < 0.01; figure 3.3) but not in cardiomyocytes (data not shown).  
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Figure 3.3: Relative miR-24 expression during hypoxia in vitro. Endothelial cells were incubated in normoxic 
(21% v/v O2) or hypoxic (1% O2 v/v) conditions for 24 h before miRNAs were detected by 
TaqMan RT-PCR. RNU6b served as a house-keeping miRNA. N =3 experiments per group. ** = p 
< 0.01 
 
A key player for hypoxic signalling is the aforementioned HIF1α which mediates 
transcriptional control during hypoxic conditions (Kvietikova et al., 1995; Huang et al., 
1996). In vitro, this transcription factor can be stabilized by a chemical agent, desferrioxamine 
(DFA), thus inhibiting its proteosomal degradation (Wang and Semenza, 1993). To test for 
potential HIF1α-dependent transcriptional regulation of miR-24 in ECs, HIF1α was stabilized 
chemically by desferrioxamine (DFA) in vitro. In Western Blot experiments, HIF1α 
upregulation was observable 6 h after DFA treatment in EC nuclear extract (figure 3.4).  
 
 
 
 
 
 
 
Figure 3.4: Representative Western Blot of HIF1α in control or desferrioxamine (DFA, 150 µM) treated 
HUVECs. Control and DFA-treated group were incubated for 6 h before protein isolation. Nuclear 
extracts were blotted onto PVDF membrane, followed by detetction with appropriate antibodies. 
TATA-box binding protein (TBP) was used as a loading control. 
 
Next, miR-24 expression was investigated in DFA-treated, HIF1α stabilized ECs. RT-PCR 
was applied to measure endogenous miRNA expression in isolated total RNA.  
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Nevertheless, the induction of HIF1α protein measured by Western Blot before was not 
accompanied by a synergistic induction in miR-24 expression compared to control level (0.85 
± 0.08 vs. 1 ± 0.05, p = n.s.; figure 3.5). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5: miR-24 expression analysis in control and desferrioxamine (DFA) treated HUVECs. HUVECs 
were cultured for 6 h with or without the presence of 150 µM DFA. Afterwards, total RNA was 
isolated and RT-PCR analysis was performed. N = 4 per group. 
 
 
Whether the miR-24 expression pattern varies at different time points remains to be 
determined. 
 
Myocardial infarction (MI) upregulated miR-24 expression in total hearts 14 d after 
intervention (figure 3.1). The cellular source mostly contributing to enhanced expression is so 
far unclear. To address this issue, sham-operated and infarcted animals underwent cellular 
fractionation of heart tissue two days after intervention. In a first step, cardiomyocytes were 
separated from the non-cardiomyocyte fraction by sedimentation as described (Thum et al., 
2008). Afterwards, cardiac endothelial cells were isolated and enriched by incubation with 
magnetically-labeled CD146 beads. Finally, total RNA from cardiomyocytes and endothelial 
cells was subjected to miRNA-expression analysis. Endogeneous miR-24 expression was 
higher in cardiac ECs compared to cardiomyocytes (3.45 ± 0.40 vs. 1 ± 0.18, p = < 0.001; 
figure 3.6). Of great importance, miR-24 expression level remained constant in 
cardiomyocytes either isolated from sham-operated or infarcted animals (1 ± 0.18 vs. 0.73 ± 
0.22, p = n.s.; figure 3.6).  
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In contrast, expression in cardiac endothelial cells increased post MI compared to sham 
control (7.17± 0.35 vs. 3.45± 0.40, p = <0.001; figure 3.6). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6: MiR-24 expression analysis in murine cardiomyocytes or cardiac endothelial cells in sham-operated 
or animals post MI. Total hearts were isolated 2d after myocardial infarction or sham-operation. 
Then fractionation of cardiomyocytes and endothelial cells followed. MiR-24 and relevant house-
keeping RNU6b level was calculated by real-time PCR analysis. N =4 animals per group. *** = p < 
0.001 
 
Taken together, hypoxia or myocardial infarction induces expression of miR-24 in cardiac 
endothelial cells. Its transcriptional regulation, however, remains unclear. 
 
 
3.2 MiR-24 modulation in different cell types 
 
 
The availability of synthetic miR-24 precursors or antagonists offers the possibility to perform 
in vitro gain- and loss-of function experiments. Therefore, we modulated miR-24 expression 
in the most prominent cardiac cells, namely cardiomyocytes, fibroblasts and endothelial cells. 
Cardiomyocytes and fibroblasts were prepared and isolated from young-born rats whereas 
HUVECs served as an endothelial cell model. Synthetic scrambled (scr), precursor (pre) or 
antagonist (anti) miRNA oligonucleotides were transfected liposomally for 72 h. Afterwards, 
transfection efficiency was measured by miRNA-specific real-time PCR. In addition, Cy3-
labeled miRNAs were transfected to monitor transfection efficiacy. 
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As can be seen in figure 3.7, neonatal rat cardiomyocytes exhibited the strongest ability to 
incorporate exogeneous Cy3-miRNA due to their large size in comparison to endothelial cells 
or fibroblasts.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7: Liposomal transfection of Cy3-labeled miRNA precursor oligonucleotides in different cardiac 
cells. 100 nM of miR-Cy3 (red) was transfected for 72 h before fluorescent imaging was 
performed. Nuclei were stained with DAPI (blue). 
 
 
Quantitative miRNA expression analysis further characterized the modulation of miR-24 
expression level (figure 3.8). While pre-miR-24 transfection increased miR-24 levels in 
endothelial cells (521.81 ± 147.96 vs. 10 ± 3.04; p < 0.05), fibroblasts (399.31 ± 69.08 vs. 10± 
1.17; p < 0.05) and cardiomyocytes (3391.29 ± 570.43 vs. 10 ± 0.52; p < 0.001), transfection 
of anti-miR-24 significantly repressed endogeneous miR-24 in endothelial cells (1.52 ± 0.81 
vs. 10± 3.04; p < 0.05), fibroblasts (5.78 ± 1.24 vs. 10± 1.17; p < 0.05) and cardiomyocytes 
(0.14 ± 0.07 vs. 10 ± 0.52; p < 0.001). These experiments prove the general capability to 
modulate miR-24 expression in different cardiac cell types in vitro. 
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Figure 3.8: Transfection efficieny of miR-24 precursor or antagonist in cardiomyocyte, fibroblast and 
endothelial cells. 100 nM of scrambled (scr) miRNA, pre-miR-24 or anti-miR-24 was transfected 
for 72 h before total RNA isolation and subsequent miRNA RT-PCR analysis. N = 4 per group. * = 
p < 0.05; *** = p < 0.01 
 
 
3.2.1 MiR-24 overexpression induces apoptosis specifically in ECs 
 
 
The functional consequences of miR-24 upregulation upon MI are unclear. It is well 
established that MI-dependent cardiac remodeling includes changes such as apoptosis, fibrosis 
and neoangiogenesis. Thus, modulating miR-24 expression level might lead to severe 
functional changes in cardiac cells. To dissect the impact of miR-24 modulation in the 
different cardiac cell types (cardiomyocytes, fibroblasts and endothelial cells) changes in 
apoptosis were tested by FACS. Annexin-V was used to mark early apoptotic cells since this 
protein binds with hight affinity to phosphatidylserine (PS) which flips from the inner to the 
outer membrane side while apoptosis is initiated (Koopman et al., 1994). In addition, cells 
were stained with propidium iodide (PI) to discriminate between necrotic and apoptotic cells 
because a prominent hallmark of apoptosis is the integrity of cellular membrane so only 
necrotic cells can incorporate PI.  
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While analyzing Annexin-V positive and PI-negative cells, only miR-24 overexpressing ECs 
but not cardiomyocytes or cardiac fibroblasts showed a significant increase (2.78 ± 0.38 vs. 1 
± 0.016; p < 0.05) in apoptosis rate (figure 3.9). Moreover, even antagonizing endogeneous 
miR-24 in ECs reduced cell death (0.62 ± 0.04 vs. 1 ± 0.016; p < 0.001). Since cardiac 
fibroblasts and cardiomyocytes were uneffected in terms of apoptosis measurement, the 
proceeding experiments focused on miR-24 function in ECs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9: Apoptosis analysis in miR-24 modulated ECs, cardiac fibroblasts and cardiomyocytes. Cells were 
miRNA-transfected for 72 h (100 nM each) and then underwent Annexin-V-FITC/PI staining. 
Samples were then analyzed on a FACS Calibur. Cells were gated on Annexin-V positive, PI-
negative cells. N =4 per group. * = p < 0.05; *** = p < 0.001 
 
 
Hypoxia-induced upregulation of miR-24 in ECs raised the question, if antagonizing miR-24 
would reduce apoptosis rate induced by oxygen depletion. Therefore miR-24 was either up- or 
downregulated in ECs for 72 h. Afterwards cells underwent hypoxic treatment (1% O2) for 24 
h. Finally apoptosis analysis was performed. Indeed, antagonizing miR-24 in ECs reduced the 
apoptosis rate (1.54 ± 0.12 vs. 2.58 ± 0.12; p < 0.001) in hypoxic atmosphere (figure 3.10). 
Thus, miR-24 downregulation is beneficial under stress conditions. For ECs, this observation 
implicates a shelter mechanism towards reduced oxygen concentration and cellular stress. 
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Figure 3.10: Apoptosis analysis in miRNA modulated ECs that were additionally exposed to hypoxic stress. 
ECs were miRNA transfected (100 nM each) for 72 h and then incubated in 1% O2 for 24 h. 
Afterwards samples underwent Annexin-V-FITC/PI staining and were analyzed by FACS. N = 4 
experiments per group. *** = p < 0.001 
 
 
3.2.2 Apoptosis array post miR-24 modulation reveals dysregulation of 
anti-apoptotic HMOX1 and pBAD protein 
 
 
Cellular death induced by the extrinsic or intrinsic apoptosis pathway is mediated by diverse 
factors. Obviously, in ECs an apoptotic programme is initiated by upregulation of miR-24 
(figure 3.8). Nervertheless, underlying signal pathways remain elusive. To monitor the 
changes in the expression of key apoptotic players and to gain a better understanding for miR-
24 induced EC apoptosis, miR-24 overexpressing HUVECs were analyzed using a specified 
apoptosis protein array (figure 3.11).  
 
Here, the expression of 35 apoptosis-related factors was investigated simultaneously on a 
protein array. Control and miR-24 modulated cell lysates were incubated to this array (figure 
3.11). Finally, comparison of protein expression levels revealed deregulated protein levels 
induced by forced expression of miR-24 (figure 3.12). 
 
The strongest upregulation in protein levels was found for HIF-1α (1.5-fold upregulation), 
FAS (+1.46-fold upregulation), SMAC/DIABLO (+1.42-fold upregulation), HSP27 (+1.38-
fold upregulation) and HTRA2 (+1.32-fold upregulation) protein.  
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In contrast, a prominent reduction was observed for total Bad (0.54-fold downregulation) and 
HMOX1 protein (0.57-fold downregulation). 
 
 
 
 
 
 
 
 
 
Figure 3.11: Apoptosis array membrane analyzed with control and miR-24 modulated (100 nM each) cell 
lysates. 35 different antibodies to apoptosis markers were spotted and hybridized in duplicate to the 
membrane. 200 µg of total cell lysates were incubated with membranes and developed with a 
chemiluminescent method. Group lysates were a pool of three different experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12: Quantitative summary of the protein profiler apoptosis array. A selection of up- or downregulated 
apoptosis-related proteins upon miR-24 modulation in ECs is plotted. 
 
 
To delineate mechanisms involved in miR-24 mediated apoptosis we focused on 
downregulated proteins related to anti-apoptotic function or cardiovascular protection. 
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Therefore, two candidate proteins, BAD and HMOX1, were further investigated to validate 
the array result. BAD belongs to the BCL2 family and either stimulates apoptosis by 
heterodimerization at mitochondrial membran sites (Zha et al., 1997) or protects towards cell 
death in phosphorylated state (Zha et al., 1996). Cardioprotective heme-oxygenase 1 
(HMOX1) has been characterised as an outstanding factor for heme metabolism thereby 
mediating anti-oxidant effects (Clark et al., 2000). Endothelial cells were modulated either by 
precursor or antagonistic miR-24 transfection. MiR-24 dependent HMOX1 downregulation 
was confirmed by Western Blot in HUVECs (0.19 ± 0.09 vs. 1 ± 0.25; p < 0.05; figure 3.12). 
In line, antagonizing endogeneous miR-24 increased HMOX1 expression compared to control 
level (1.42 ± 0.37 vs. 1 ± 0.25; p = n.s.; figure 3.13). 
 
 
 
 
 
 
 
 
 
 
Figure 3.13: Western Blot analyis of HMOX1 protein in scr-miR, pre-miR-24 or anti- miR-24 modulated (100 
nM each) HUVECs. Loading control is GAPDH. HMOX1 signal density was normalized to 
GAPDH, N = 3 experiments per group. * = p < 0.05 
 
 
In contrast to direct quantification of HMOX1 by Western Blot, BAD expression level was 
investigated differently since its prominent anti-apoptotic characteristic depends on its 
phosphorylation status controlled by kinases (Datta et al., 1997). Thus, post-translational 
modification might also contribute to decreased BAD expression in the protein apoptosis 
array. To dissect this issue, Western Blot in combination with phospho-Bad specific ELISA 
was performed. This approach showed that the level of unphosphorylated BAD was slightly 
decreased in miR-24 overexpressing ECs (0.74 ± 0.11 vs. 1 ± 0.17; p = n.s.; figure 3.14). 
Repression of miR-24 also decreased total BAD protein (0.57 ± 0.14 vs. 1 ± 0.17; p = n.s.; 
figure 3.14). 
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Figure 3.14: Representative Western Blot analysis of BAD protein in scr-miR, pre-miR-24 or anti-miR-24 
modulated (100 nM each) HUVECs. Loading control is GAPDH. BAD signal density was 
normalized to GAPDH, N = 3 experiments per group. 
 
Further normalizing the total BAD protein values to relevant BAD phosphorylation status at 
serine residue 112 revealed a massive downregulation by miR-24 overexpression (0.31 ± 0.03 
vs. 1 ± 0.16; p < 0.05, figure 3.15). This indicates loss of anti-apoptotic phospho-BAD (p-
BAD) function induced by miR-24. In contrast, inhibiting miR-24 increased phosphorylated 
BAD levels (1.76 ± 0.34 vs. 1 ± 0.16; p = n.s.).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.15: Summary of phospho-BAD ELISA data (p112) normalized to total BAD protein values. HUVECs 
were miRNA modulated (100 nM each), lysed and analyzed by phospho-BAD specific ELISA. N = 
3 experiments per group. * = p < 0.05 
 
 
The data indicate the involved factors to trigger apoptotic pathways by miR-24 overexpression 
in ECs. Underlying molecular mechanisms are therefore potentially mediated by p-BAD and 
HMOX1 downregulation. However, these proteins are no predicted miR-24 targets.  
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Thus, regulative impact should be mediated by other modulators that are direct miR-24 targets 
(see section 3.3). 
 
 
3.2.3 Elevated reactive oxygen species (ROS) upon miR-24 
overexpression in ECs 
 
 
In ECs, miR-24 overexpression induces apoptosis. The cellular consequences are cell 
shrinkage, chromatin condensation and the induction of proteolytic cascades. Apoptosis 
progression can be accompanied by certain side reactions, enhancing the apoptotic signalling 
(Johnson et al., 1996). As validated before, miR-24 overexpressing ECs have a deficit in anti-
oxidant HMOX1. To answer the question, if increased reactive oxygen species (ROS) are 
present in miR-24 overexpressing and apoptotic ECs, cells underwent dihydroethidiume 
(DHE) staining and FACS analysis. Shown in figure 3.16, ROS levels were significantly 
increased in miR-24 overexpressing ECs (1.86 ± 0.03 vs. 1 ± 0.01; p < 0.001). This finding 
implies that the generation of ROS may contribute to miR-24 mediated apoptosis. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.16: Measurement of reactive oxygen species (ROS) by dihydroethidiume (DHE) staining in scr-miR 
and miR-24 modulated (100 nM each) ECs. Cells were miRNA-transfected for 72 h, stained with 
2.5 µM DHE and analyzed on a FACS Calibur. N = 4 experiments per group. *** = p < 0.001 
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3.2.4 Capillary tube formation is impaired in miR-24 overexpressing ECs 
 
 
A major characteristic of ECs is the capability to form tube-like capillaries supporting 
angiogenic response in vivo. This feature can be investigated in vitro by monitoring tube-
formation in matrigel-coated wells (Grant et al., 1989). To answer the question if miR-24 
modulation influences angiogenic properties in vitro, a tube-formation assay was performed. 
To test this, cells are seeded onto matrigel-coated slides where tube formation is favoured. 
Again, HUVECs were miR-24 modulated and then analyzed for tube-formation qualitatively. 
As can be seen in figure 3.17, control and anti-miR-24 modulated ECs show comparable 
capillary formation. Nevertheless, angiogenic response is impaired in miR-24 overexpressing 
ECs indicated by the lack of proper capillary density. In summary, this assay reveals a first 
functional defect for miR-24 overexpressing ECs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.17: Tube formation assay on matrigel coated wells. HUVECs were miRNA-modulated (100 nM each) 
for 72 h. Then, 15000 cells were put on matrigel for up to 24 h. Qualitative pictures were taken at 8 
h. N = 3 experiments per group. 
 
 
3.3 MiR-24 regulates endothelial GATA2, H2A.X, PAK4 and RASA1 
 
 
The major hallmark of miRNA biology is the post-transcriptional regulation of miRNA-
specific target genes. Thus, binding of miRNAs to the 3´-UTR of target mRNA can inhibit 
translation or induce degradation of the mRNA:miRNA heteroduplex.  
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Noteworthy, miRNA-guided protein regulation crucially depends on the abundant expression 
of miRNA and its target gene within the same cell. The aforementioned miR-24 mediated 
defects in endothelial cell biology should be explained by exploring and validating direct miR-
24 targets in endothelial cells. More insight into the network of miRNA and its targets is 
provided by different miRNA target prediction tools available online. The miRNA prediction 
databases miRBase (www.mirbase.org), PicTar (www.pictar.mdc-berlin.de) and TargetScan 
(www.targetscan.org) were applied to screen for putative miR-24 target genes potentially 
involved in fundamental EC biology processes, e.g. apoptosis or angiogenic response. In table 
3.1, four putative miR-24 targets are listed which are predicted by at least two databases. The 
genes H2AFX, GATA2, PAK4 and RASA1 are commonly expressed in endothelial cells. 
 
Table 3.1: Selection of predicted miR-24 targets provided by different databases. 
 
Gene 
symbol 
Gene name Evolutionary 
conservation, 
no. of species 
(miRBase) 
Predicted 
target 
(miRBase) 
Predicted 
target 
(PicTar) 
Seed match 
for miR-24 
(TargetScan) 
GATA2 Endothelial 
transcription factor 
GATA-2 (GATA-
binding protein 2) 
4 yes no 8mer (poorly 
conserved) 
H2AFX Histone 2A family 
member X (H2A.X) 
5 yes yes 7mer-m8 (two 
sites 
conserved) 
PAK4 Serine/threonine-
protein kinase PAK 4 
(p21-activated kinase 
4) (PAK-4) 
5 no yes 8mer 
(conserved) 
RASA1 Ras GTPase-
activating protein 1 
(GTPase-activating 
protein) (GAP) (Ras 
p21 protein activator) 
(p120GAP) 
(RasGAP) 
10/1 no yes (2 
transcript 
variants) 
7mer-m8 
(conserved) 
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To validate the prediction of miR-24 targets, endothelial cells overexpressing miR-24 were 
analyzed for target protein expression by Western Blot (figure 3.18). GATA2, an endothelial-
specific transcription factor that also is known to control hematopoiesis (Tsai et al., 1994), is 
decreased while miR-24 expression is forced (0.57 ± 0.06 vs. 1 ± 0.09; p < 0.05). The histone 
2 family member H2A.X is involved in DNA double strand repair and has recently been 
reported to have an essential role in postnatal angiogenesis (Lal et al., 2009). In ECs, miR-24 
overexpression represses expression of nuclear H2A.X measured by Western Blot analysis 
(0.56 ± 0.13 vs. 1 ± 0.05; p = 0.05). In addition, the anti-apoptotic kinase PAK4 regulating 
Bad phosphorylation status (Gnesutta et al., 2001) is decreased (0.31 ± 0.02 vs. 1 ± 0.10; p < 
0.01). Finally, RASA1, a family member of the Ras GTPases essential for the formation of 
vasculature (Henkemeyer et al., 1995), is downregulated upon miR-24 overexpression (0.56 ± 
0.04 vs. 1 ± 0.12; p < 0.05). 
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Figure 3.18: Western Blot analysis of putative miR-24 targets in ECs. HUVECs were transfected with 100 nM 
scr control miRNA or pre-miR-24 for 72 h, harvested and lysed. 10-50 µg total protein, in case of 
H2A.X a nuclear fraction, was loaded onto 12% (v/v) SDS-Polyacrylamide gels and SDS-PAGE 
was performed. Gels were blotted onto PVDF-membranes, blocked with 5% (w/v) skim milk 
powder, incubated with appropriate primary antibodies, secondary antibodies linked to HRP and 
developed using chemiluminescent reaction. GAPDH was used as a loading control for GATA2, 
PAK4 and RASA1, whereas nuclear Lamin A+C was the normalizing factor for H2A.X. For each 
target, Western Blot results were normalized and validated statistically. N = 3 experiments each. * 
= p < 0.05; ** = p < 0.01 
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Cumulatively, in vitro overexpression of miR-24 suggests H2A.X, GATA2, PAK4 and 
RASA1 to be potential miR-24 targets. Investigated targets are expressed in endothelial cells 
and linked at least to cellular apoptosis or angiogenic signalling. To further proof these 
targets, reporter gene assays were performed to validate bona fide targets for miR-24. 
 
 
3.3.1  Luciferase reporter gene assays confirm miR-24 targets GATA2, 
H2A.X, PAK4 and RASA1 
 
 
MiRNAs target mRNAs specifically at the 3´-untranslated region (3´-UTR) leading to 
transcript degradation or subsequent ribosome inhibition. As a direct consequence, target 
protein level decreases. A genetic tool to observe miRNA:mRNA interaction is a luciferase 
reporter gene assay. Therefore, 3´-UTR of interest is cloned adjacent to the luciferase gene in 
a reporter vector. In vitro, reporter vector, miRNAs of interest and a normalizing beta-Gal 
containing vector are co-transfected in HEK293 reporter cell line. Theoretically, interaction 
with an appropriate, specific miRNA should downregulate luciferase gene expression in 
respect to the aforementioned mechanism. For control reasons, different miRNAs with no 
binding prediction (non-related miRNAs) are also co-transfected. Thus, luciferase expression 
should be unaffected here. 
 
In this work, human GATA2-, H2A.X-, PAK4- and RASA1-3´-UTR bearing miR-24 binding 
site were cloned into a luciferase reporter vector and analyzed. Remarkably, H2A.X-3´-UTR 
contained two miR-24 binding sites. As can be seen in figure 3.19, the investigated luciferase 
constructs were specifically downregulated in the presence of miR-24 compared to control 
group (H2A.X: 0.63 ± 0.01 vs. 1 ± 0.03; p < 0.001; GATA2: 0.68 ± 0.02 vs. 1 ± 0.01; p < 
0.001; PAK4: 0.68 ± 0.01 vs. 1 ± 0.07; p = 0.005; RASA1: 0.52 ± 0.04 vs. 1 ± 0.02; p < 0.001). 
However, luciferase activity for non-related miRNAs with no predicted binding site in 3´-
UTR like miR-1, miR-22 and miR 210, remained basically unchanged. 
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Figure 3.19: Luciferase assays to validate the potential miR-24 targets GATA2, H2.AX., PAK4 and RASA1. 
HEK293 reporter cells were transfected for 24 h with cloned reporter vector bearing the predicted 
miR-24 binding site, miRNA and for normalizing reasons, beta-galactosidase expression vector. 
Finally, cells were lysed and analyzed for luminescence and beta-galactosidase activity. N = 4 
experiments per group. ** = p < 0.05; *** = p < 0.001 
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3.3.2 Transient knockdown of miR-24 targets GATA2, PAK4 and RASA1 
induces apoptosis in ECs 
 
 
As mentioned before, GATA2, H2A.X, PAK4 and RASA1 were validated as direct miR-24 
targets through its recognition sites in 3´-UTR. In addition, overexpression of miR-24 was 
pro-apoptotic implicating a role of its target genes in regulating apoptosis outcome. To test for 
an impact on apoptosis, validated targets were transiently downregulated and analyzed by 
Annexin-V-FITC/PI staining. Noteworthy, as can be seen in figure 3.20, all targets were 
efficiently repressed by their specific siRNA. 
 
 
 
 
 
 
 
 
 
 
Figure 3.20: Western Blot analysis for transient knockdown of GATA2, H2A.X, PAK4 and RASA1 in ECs. 
HUVECs were transfected with 100 nM scr control siRNA or target specific siRNA, harvested 
and lysed. 10-50 µg total protein, in case of H2A.X a nuclear fraction, was loaded onto 12% 
(v/v) SDS-Polyacrylamide gels and SDS-PAGE was performed. Gels were blotted onto PVDF-
membranes, blocked with 5% (w/v) skim milk powder, incubated with appropriate primary 
antibodies, secondary antibodies linked to HRP and developed using chemiluminescent reaction. 
GAPDH was used as a loading control for GATA2, PAK4 and RASA1, whereas nuclear Lamin 
A+C was the normalizing factor for H2A.X. N = 3 experiments each. 
 
 
Modulated endothelial cells were then analyzed for an apoptotic phenotype. In case of 
GATA2, PAK4 and RASA1, knockdown increased apoptosis compared to scrambled control 
siRNA transfected ECs (GATA2: 2.40 ± 0.07 vs. 1 ± 0.03; p < 0.001; PAK4: 1.79 ± 0.03 vs. 1 
± 0.03; p < 0.001; RASA1: 1.41 ± 0.10 vs. 1 ± 0.04; p < 0.05; figure 3.21). In contrast, 
transient H2A.X silencing had no effect on apoptotic events (0.85 ± 0.07 vs. 1 ± 0.13; p = 
n.s.). 
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To sum up, three out of four identified direct miR-24 targets, namely GATA2, PAK4 and 
RASA1 directly foster apoptosis in ECs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.21: Apoptosis analysis in siRNA modulated ECs. ECs were transfected with gene specific siRNA (150 
nM each) for 48 h. Afterwards samples underwent Annexin-V-FITC/PI staining and were analyzed 
by FACS. N = 4 experiments per group. * = p < 0.05; *** = p < 0.001 
 
 
3.3.3 GATA2 is a key player for cell cycle progression in ECs 
 
 
In ECs, silencing of the bona fide miR-24 target GATA2, elevates apoptosis progression 
remarkably (figure 3.21). Apoptosis was described to be triggered by transcription factor-
dependent control of cell cycle (Field et al., 1996). To check for a direct relationship between 
repressed GATA2 protein level and proliferative status, GATA2 modulated ECs underwent 
cell cycle analysis by propidium iodide (PI) stain. In line with the aforementioned effect on 
apoptosis, cell cycle progression was disturbed in GATA2-deficient ECs compared to control 
group (figure 3.22). Resting cells in G0/G1 phase decreased (0.86 ± 0.008 vs. 1 ± 0.02; p < 
0.01), as well as DNA-synthesizing in S-phase (0.65 ± 0.01 vs. 1 ± 0.03; p < 0.001) and 
finally mitotically active ones (0.60 ± 0.03 vs. 1 ± 0.04 p < 0.001). Taken together, the 
GATA2 transcription factor also seems to be a key effector for cell cycle progression in 
endothelial cells. 
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Figure 3.22: Cell cycle analysis in GATA2 silenced ECs. Endothelial cells were transfected with gene specific 
siRNA (150 nM each) for 48 h. Afterwards samples underwent PI staining and were analyzed by 
FACS. N = 4 experiments per group. ** = p < 0.01; *** = p < 0.001 
 
 
3.3.4 Impairment in tube formation ability in ECs when silencing GATA2 
or PAK4 
 
 
Forced miR-24 expression induces apoptosis, ROS formation and leads to a disturbance in 
angiogenic signalling measured by decreased in vitro tube formation (figure 3.16). The 
identification of the miR-24 downstream effectors GATA2, H2A.X, PAK4 and RASA1 raised 
the question if single target knockdown also affects the formation of capillary-like structures 
on matrigel. Thus, siRNA experiments were performed and afterwards angiogenic response 
was investigated. The qualitative analysis reveals that again silencing GATA2 has the 
strongest effects on endothelial tube formation (figure 3.23). PAK4 knockdown also slightly 
impairs tube formation whereas inhibiting H2A.X or RASA1 does not alter capillary tube 
formation. 
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Figure 3.23: Tube formation assay on matrigel coated wells. HUVECs were siRNA-modulated (150 nM each) 
for 48 h. Then, 15000 cells were put on matrigel for up to 24 h. Qualitative pictures were taken at 
4-8 h. N = 3 experiments per group. 
 
 
3.3.5 PAK4 and RASA1 are downregulated under hypoxic conditions in 
ECs 
 
 
This work describes miR-24 induction by cardiac stress and through hypoxia. Certainly, 
hypoxia-driven transcriptome changes occur to counteract the changing environment. To test 
the hypothesis if the elevated miR-24 expression levels correlate with a parallel decrease in 
target protein, endothelial cells were exposed to hypoxia for 24 h. Total protein was isolated 
and subsequently Western Blot analysis for miR-24 targets GATA2, PAK4 and RASA1 was 
performed (figure 3.24). Indeed, miR-24 targets were deregulated by oxygen depletion but 
regulatory effects were diverse. While GATA2 expression was induced (1.32 ± 0.03 vs. 1 ± 
0.05; p = 0.001), PAK4 and RASA1 expression was repressed on protein level (PAK4: 0.52 ± 
0.10 vs. 1 ± 0.13; p < 0.05; RASA1: 0.69 ± 0.09 vs. 1 ± 0.05; p < 0.05). 
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Figure 3.24: Hypoxia regulated expression of miR-24 targets in ECs. HUVECs were exposed to normoxia or 
hypoxia (1%) for 24 h, harvested and lysed. 15-35 µg total protein was loaded onto 12% (v/v) 
SDS-Polyacrylamide gels and SDS-PAGE was performed. Gels were blotted onto PVDF-
membranes, blocked with 5% (w/v) skim milk powder, incubated with appropriate primary 
antibodies, secondary antibodies linked to HRP and developed using chemiluminescent reaction. 
GAPDH was used as a loading control. For each target, Western Blot results were normalized and 
validated statistically. N = 4 experiments each. * = p < 0.05; *** = p < 0.001 
 
 
3.4. Affymetrix and ChIP data indicate GATA2-regulated genes related 
to angiogenic processes 
 
 
The direct miR-24 target GATA2 is a key mediator for endothelial biology. Different 
experiments showed the necessity for GATA2-dependent transcriptional regulation. GATA2 
silencing resulted in apoptosis, cell cycle disturbance and decreased angiogenic response. 
Thus, transcriptional control in promoter regions of target genes should be responsible for 
these observations. Identification of possible GATA2 target genes is facilitated by whole 
genome transcriptome approaches using Affymetrix gene chip analysis.  
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By this method, global mRNA changes are monitored and can be compared in groups. Further 
in vitro assays such as chromatin immunoprecipitation (ChIP) may then validate GATA2-
bound DNA regions. 
 
 
3.4.1 Overexpression of murine Gata2 in ECs 
 
 
In vitro loss- and gain-of function experiments are an appropriate tool to define the impact for 
a gene of interest. Therefore, GATA2 was specifically down- or upregulated in ECs. By now, 
transient silencing of GATA2 has been applied (figure 3.20). For GATA2 overexpression, N-
terminal GFP-tagged murine GATA2 was cloned into adenoviral constructs (cooperation in 
biosafety level 2 with group Prof. Engelhardt, Rudolf-Virchow-Center, University of 
Würzburg). Then, ECs were infected with viral particles for 24 h. For control reasons, an YFP 
expressing control vector was also applied with the same multiplicity of infection (m.o.i.). 
Fluorescence microscopy revealed the subcellular localization of the GFP-GATA2 fusion 
protein solely in the nucleus (figure 3.25a). In contrast, control cells expressed YFP reporter 
protein ubiquitiously. 
 
Western Blot analysis further confirmed the overexpression of GFP-GATA2 in the nuclear 
fraction (figure 3.25b). The fusion protein could be detected at the estimated weight of 75 
kDa. Taken together, successfull GATA2 overexpression set the basis for comparison of 
transcriptome changes induced by repression or induction of transcription factor GATA2. 
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Figure 3.25: GATA2 overexpression in ECs. (a) ECs were infected with YFP control virus or GFP-GATA2 
adenovirus with m.o.i. 40. 24 h post infection fluorescence microscopy was performed. (b) Western 
Blot analysis for overexpression of GFP-GATA2. ECs were infected with control or GFP-GATA2 
virus for 24 h, harvested and lysed. An aliquot of nuclear fraction was loaded onto 12% (v/v) SDS-
Polyacrylamide gels and SDS-PAGE was performed. Gels were blotted onto PVDF-membranes, 
these blocked with 5% (w/v) skim milk powder, incubated with appropriate primary antibody, 
secondary antibody linked to HRP and developed using chemiluminescent reaction. N = 3 
experiments. 
 
 
3.4.2 Transcriptome analysis upon GATA2 modulation by Affymetrix 
gene chip 
 
 
Transcription factors are key proteins regulating the transcriptome. Naturally, these regulators 
are expressed dynamically. As a result, cells undergo permanent changes in their genome. 
Quite necessary, transcription factors are specific in their ability to recognize DNA binding 
sites. For GATA2, it is known that it binds to consensus [T/A(GATA)A/G] DNA sequences 
(Evans et al., 1988). Nevertheless, target genes in ECs are elusive. Thus, manipulating 
GATA2 expression level in ECs by either knockdown or overexpression should reflect 
GATA2´s impact on direct target gene regulation. Therefore, it is assumed that putative 
GATA2 target genes are reciprocally regulated when GATA2 is either repressed or induced. 
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In advance, ECs underwent silencing by liposomal siRNA transfection or adenoviral 
overexpression of GATA2. Then, total RNA was isolated and analyzed by Agilent capillary 
electrophoresis. RNA integrity number (RIN) can be investigated by this method. For 
subsequent Affymetrix gene chip analysis RINs should be comparable between groups and 
near to the maximum RIN of 10 which is indicated by distinct RNA peaks in the 
electropherogramme for 28 S and 18 S RNA. By way of example a gel electropherogramme is 
shown in figure 3.26 indicating a RIN of 9.9.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.26: Total RNA analysis with Agilent capillary gelelectrophoresis. Isolated total RNA was placed onto 
an Agilent RNA nano chip, mixed with fluorescent dye and run with the use of Agilent bioanalyzer 
software. The resulting electropherogramme indicated the presence of 28 S and 18 S RNA in a ratio 
of 1.9 giving a RIN of 9.9. 
 
 
For Affymetrix gene chip analysis following groups were compared: scr siRNA versus(vs) 
siRNA GATA2 and YFP control virus vs GFP-GATA2 virus. Isolated total RNAs had RINs 
between 9.5 and 10.0 (data not shown). Finally, 1 µg total RNA of each group was hybridized 
onto Affymetrix arrays in the department of Dr. Susanne Kneitz (IZKF Microarray Core 
Facility, University of Würzburg). Subsequently, data analysis was applied with the help of an 
R-programmed tool from Dr. Paolo Galuppo (Cardiology, University of Würzburg).  
 Results 
 
 95  
Firstly, data sets were screened for genes that were regulated > +1.5-/ < -1.5-fold. Then, data 
were further validated with the assumption, that GATA2 could regulate target mRNAs 
reciprocally if knocked down or induced by overexpression. With these restrictions, the 
putative GATA2 target genes BAMBI, ESM1 and NTN4 were identified (table 3.2). 
 
 
Table 3.2: Overview on reciprocally regulated genes upon GATA2 modulation by siRNA or viral 
overexpression. 
 
Gene assignment Fold Change (siRNA GATA2 vs scr siRNA) 
Fold Change (viral GATA2 
overexpression vs control 
virus) 
NM_012342 // BAMBI // 
BMP and activin membrane-
bound inhibitor homolog 
-1.52 1.60 
NM_007036 // ESM1 // 
endothelial cell-specific 
molecule 1 
1.54 -1.79 
NM_021229 // NTN4 //  
netrin 4  
1.51 -1.51 
 
 
Noteworthy, ESM1 and NTN4 have been described to be essential for angiogenesis (Shin et 
al., 2008; Lejmi et al., 2008). Thus, GATA2 can be considered as a key mediator for 
angiogenic signalling. Taken together, global transcriptome analysis in GATA2 modulated 
ECs revealed certain reciprocally regulated mRNAs. This might imply that their host genes 
are putatively regulated by GATA2. 
 
 
3.4.3 ChIP analysis for GATA2 
 
 
Chromatin-immunoprecipitation (ChIP) is a method to validate transcription factor binding 
sites in DNA. Initially, transcription factor and DNA are crosslinked. DNA:transcription 
factor complex is then sheared to fragments of about 200-1000 bp in length. Afterwards, 
immunoprecipitation is performed. Then transcription factor-bound DNA can be isolated. 
Mostly, precipitated DNA belongs to promoter regions of a gene which can be analyzed by 
PCR for example. ChIP analysis for GATA2 should further support the initial clue for direct 
regulation of BAMBI, ESM1 and NTN4.  
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ChIP analysis for GATA2 was performed in ECs resulting in precipitated GATA2-bound 
chromatin. Next, potential GATA2 binding sites in promoter regions of BAMBI, ESM1 and 
NTN4 were acquired in silico. Therefore, 2000 nucleotides upstream of exon 1 GATA2 
binding analysis was performed with Alggen Promo (http://alggen.lsi.upc.es/cgi-
bin/promo_v3/promo/promoinit.cgi?dirDB=TF_8.3, Messeguer et al., 2002; Farre et al., 
2003). Potential GATA2 binding sites for BAMBI, ESM1 and NTN4 are listed in table 3.3. 
Appropriate primers were designed spanning these sites. GATA2 immunoprecipitated 
chromatin then underwent PCR analysis with theses primers (figure 3.27). Resulting PCR 
products were enriched in samples generated with the GATA2 specific IP compared to 
samples incubated with mouse IgG. This indicates that GATA2 has regulative function 
towards endothelial BAMBI, ESM1 and NTN4. 
 
 
Table 3.3:  Predicted GATA2 binding sites in promoter region of BAMBI, ESM1 and NTN4. Transcription 
factor binding analysis was performed with Allgen Promo (http://alggen.lsi.upc.es). 
 
Gene symbol Predicted GATA2 binding 
site at upstream bp position 
BAMBI -1220, -1370 
ESM1 -540, -880, -1430, -1530, -1790 
NTN4 -110 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.27: Chromatin immunoprecipitation (ChIP) for GATA2 and analyzing PCR products. ECs were 
subjected to ChIP in three groups: GATA2 immunoprecipitation (IP) with specific GATA2 
antibody, mouse IgG control antibody and mock control (no antibody). Isolated chromatin was 
analzyed with primers detecting GATA2 binding sites in promoter regions of BAMBI, ESM1 and 
NTN4. Amplified PCR prodcuts were separated on 1.8 % (w/v) agarose gel. 
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3.4.4 Pro-angiogenic HMOX1 and SIRT1 are regulated on protein level 
by the miR-24 target GATA2 
 
 
Our previous data show that the miR-24 downstream effector GATA2 has an important role in 
regulating the endothelial transcriptome. Specifically, angiogenesis-related genes are either 
induced or repressed by GATA2 binding to respective promoter regions. Noteworthy, ECs 
overexpressing miR-24 show reduced GATA2 and HMOX1 levels (figures 3.13/18). HMOX1 
is, in addition to its important function for heme metabolism, a natural source of carbon 
monoxide thereby mediating pro-angiogenic properties (Dulak et al., 2008). To address the 
question if HMOX1 expression is effected by GATA2 modulation, Western Blots were 
performed upon GATA2 overexpression or silencing (figure 3.28). GATA2 knockdown 
resulted in decreased HMOX1 expression (0.41 ± 0.05 vs. 1 ± 0.05; p < 0.001) whereas 
inducing GATA2 forced elevated HMOX1 levels (1.63 ± 0.08 vs. 1 ± 0.11; p < 0.001). The 
reciprocal regulation indicates that GATA2 seems to be a transcriptional enhancer of 
HMOX1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.28: Representative Western Blots for HMOX1 in GATA2-modulated ECs. Control siRNA and siRNA 
GATA2 (150 nM each) were transfected in ECs for 48 h. In addition, ECs were transduced with 
adenoviral control virus and GFP-GATA2 virus (m.o.i. = 40). Then cells were harvested and lysed. 
Total protein was loaded onto 12% (v/v) SDS-Polyacrylamide gels and SDS-PAGE was performed. 
Gels were blotted onto PVDF-membranes, these were blocked with 5% (w/v) skim milk powder, 
incubated with appropriate primary antibody, secondary antibody linked to HRP and developed 
using chemiluminescent reaction. HMOX1 expression was normalized to GAPDH and validated 
statistically. N = 4 experiments per group. *** = p < 0.001 
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This finding also implicates that GATA2 is the mediator for miR-24 dependent HMOX1 
regulation. Antagonizing miR-24 in GATA2 deficient ECs should therefore not rescue 
HMOX1 expression. To test this hypothesis ECs underwent miR-24 and GATA2 modulation 
in parallel. In figure 3.29 HMOX1 and GATA2 expression are plotted for different treatment 
groups: HMOX1 expression is elevated in miR-24 deficient (anti-24) compared to GATA2 
silenced ECs (1 ± 0.04 vs. 0.68 ± 0.05; p < 0.01). Nevertheless, parallel antagonistic 
modulation of miR-24 and transient silencing of GATA2 could not rescue HMOX1 expression 
compared to control levels (0.71 ± 0.05 vs. 1 ± 0.04; p < 0.01). Taken together, HMOX1 
dysregulation induced by miR-24 is dependent on GATA2 function. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.29: HMOX1 and GATA2 protein level in miRNA and siRNA modulated ECs analyzed by Western 
Blot. miRNAs (100 nM each) and siRNAs (150 nM each) were transfected in ECs for 72 h. Then 
cells were harvested and lysed. Total protein was loaded onto 12% (v/v) SDS-Polyacrylamide gels 
and SDS-PAGE was performed. Gels were blotted onto PVDF-membranes, these were blocked 
with 5% (w/v) skim milk powder, incubated with appropriate primary antibody, secondary 
antibody linked to HRP and developed using chemiluminescent reaction. HMOX1 expression was 
normalized to GAPDH and validated statistically. N = 4 experiments per group. ** = p < 0.01 
 
 
Next to HMOX1, the histone deacetylase sirtuin1 (SIRT1) has been recently described as a 
potent regulator of angiogenesis (Potente et al., 2007). Indeed, bioinformatic analysis reveals 
GATA2 binding sites in SIRT1 promoter region. To validate GATA2-dependent regulation of 
SIRT1, GATA2-modulated ECs were analyzed for SIRT1 expression (figure 3.30). In line, 
SIRT1 expression was found to be downregulated in GATA2-deficient ECs (0.36 ± 0.08 vs. 1 
± 0.09; p < 0.01) whereas expression was increased in GATA2-overexpressing ECs (1.52 ± 
0.19 vs. 1 ± 0.26; p = n.s.) 
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Figure 3.30: Representative Western Blots for SIRT1 in GATA2-modulated ECs. Control siRNA and siRNA 
GATA2 (150 nM each) were transfected in ECs for 48 h. In addition, ECs were transduced with 
adenoviral control virus and GFP-GATA2 virus (m.o.i. = 40). Then cells were harvested and lysed. 
Total protein was loaded onto 12% (v/v) SDS-Polyacrylamide gels and SDS-PAGE was performed. 
Gels were blotted onto PVDF-membranes, these were blocked with 5% (w/v) skim milk powder, 
incubated with appropriate primary antibody, secondary antibody linked to HRP and developed 
using chemiluminescent reaction. SIRT1 expression was normalized to GAPDH and validated 
statistically. N = 4 experiments per group. ** = p < 0.01 
 
 
In conclusion, pro-angiogenic factors HMOX1 and SIRT1 are regulated on transcriptional 
level by endothelial transcription factor GATA2. Downregulation of GATA2 inhibits 
expression of HMOX1 and SIRT1 thus contributing to negative effects in angiogenic 
signalling. 
 
 
3.5 Bad phosphorylation status is regulated by the miR-24 target 
PAK4 
 
 
Identifying downstream effectors for miR-24 is essential to highlight underlying signal 
transduction. Besides miR-24 dependent regulation of HMOX1 anti-apoptotic phospho-Bad is 
dysregulated by increased miR-24 levels (figure 3.15). Of particular interest, the validated 
miR-24 target PAK4 has been reported to phosphorylate Bad at serine 112, which then 
functions anti-apoptotic (Gnesutta et al., 2001). This finding might also be true in ECs where 
PAK4 kinase was found to trigger apoptosis protection (figure 3.21).  
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To test for Bad phosphorylation status dependent on PAK4 expression ECs were modulated 
with PAK4-specific siRNA. Afterwards, Western Blot for unphosphorylated Bad and ELISA 
measurement for phospho-Bad (Ser112) was performed. As it can be seen in figure 3.31 
unphosphorylated Bad is not affected in PAK4-silenced ECs (1.09 ± 0.11 vs. 1 ± 0.22; p = 
n.s.). 
 
 
 
 
 
 
 
 
 
Figure 3.31: Bad protein level in siRNA modulated ECs analyzed by Western Blot. siRNAs (150 nM each) were 
transfected in ECs for 48 h. Then cells were harvested and lysed. Total protein was loaded onto 
12% (v/v) SDS-Polyacrylamide gels and SDS-PAGE was performed. Gels were blotted onto 
PVDF-membranes, these were blocked with 5% (w/v) skim milk powder, incubated with 
appropriate primary antibody, secondary antibody linked to HRP and developed using 
chemiluminescent reaction. Bad expression was normalized to GAPDH and validated statistically. 
N = 4 experiments per group. 
 
 
However, Bad phosphorylation decreases in PAK4 knockdown ECs measured by phospho-
Bad specific ELISA (0.45 ± 0.03 vs. 1 ± 0.21; p < 0.05; figure 3.32). Cumulatively, these 
experiments proof that PAK4 function is necessary to phosphorylate endothelial Bad protein. 
Mechanistically, miR-24-dependent PAK4 repression is responsible for reduced phospho-Bad 
levels observed in miR-24 overexpressing ECs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.32: Summary of phospho-BAD ELISA data (p112) normalized to total BAD protein values. Scrambled 
and PAK4 specific siRNA were transfected in ECs (150 nM each) for 48 h. Then cells were lysed 
and analyzed by phospho-BAD specific ELISA. N = 4 experiments per group. * = p < 0.05 
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3.6 In vivo treatment of myocardial infarction by a specific  
 miR-24 antagonist (antagomir) 
 
 
In case of MI, pathological cardiac injury results in altered gene expression. Derailed 
signalling pathways accompany cardiac remodelling processes. The exploration of miRNA 
biology offers a new regulative tool to counteract genomic changes. Whole gene networks are 
regulated by conductor miRNAs dynamically expressed upon diverse stimuli. More recently, 
novel therapeutic strategies were developed to decrease miRNA expression in vivo by 
chemically-modified miRNA-specific antagonists (antagomirs). In this work, the finding that 
MI induced miR-24 expression (figure 3.1) set the basis for in vivo treatment with antagomir-
24. Furthermore, describing and explaining a pro-apoptotic characteristic for miR-24 in ECs 
pointed out to investigate angiogenesis in vivo. To study the effects of miR-24 on 
vascularization in vivo, an experimental design was built spanning 14 days (figure 3.32). 
Initially, MI or matrigel plug implantation was applied in wildtype mice. Immediately 
thereafter antagomir-24 treatment was performed and was repeated two days later. For control 
reasons, an antagomir bearing a scrambled sequence was also injected. Matrigels were 
isolated one week after implantation whereas on day 14 heart function tests were performed 
with subsequent tissue analysis. 
 
 
 
 
 
 
 
 
 
 
Figure 3.33: Experimental design and treatment scheme of the antagomir-24 study. On day 0, MI or Matrigel 
plug implantation along with sham controls was performed in mice. Antagomir injection 
immediately followed and was repeated on day 2. Matrigels were isolated and analyzed one week 
after implantation. For MI-studies, heart function tests and tissue analysis were applied on day 14. 
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Noteworthy, two experiments were performed in advance of this study. First, it was proven 
that antagomirs are delivered effectively to ECs in vitro. Therefore ECs were incubated with 
Cy3-labeled antagomir. Cellular uptake was highly efficient (figure 3.34). 
 
 
 
 
 
 
 
 
 
Figure 3.34: Cellular uptake of Cy3-Antagomir in HUVECs. Confluent cells were incubated with Cy3-labelled 
Antagomir for 1-2 h. Afterwards cells were fixed and stained for endothelial CD31 (green) and 
nuclei (DAPI, blue). Fluorescent pictures were taken with 20x magnification. 
 
 
Next, titration experiments for antagomir concentration were applied since the aim was to 
target cardiovascular endothelial cells mainly. Low (5 mg/kg body weight) and high dose (80 
mg/kg body weight) Cy3-antagomir were injected retroorbitally in mice. Immuno-
histochemical analysis of heart tissue revealed that low-dose injection resulted in cellular 
uptake in cardiac vessels and the surrounding tissue whereas injection of a high dose led to a 
strong homogeneous stain of all cardiac cells including cardiomyocytes (figure 3.35). 
 
 
 
 
 
 
 
 
Figure 3.35: In vivo uptake of Cy3-antagomir in heart tissue. Two doses of Cy3-antagomir were injected 
retroorbitally in mice. Hearts were isolated, sliced and stained for CD31 (green) and nuclei (DAPI, 
blue). 
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3.6.1 Antagomir-24 efficiently lowers cardiac miR-24 expression 
 
 
The efficient delivery of antagomirs into the heart has been shown before thus being a 
prerequisite for therapeutic therapy in cardiac stress conditions (Thum et al., 2008). 
Nevertheless, in this study, antagomir-24 treatment was investigated quantitatively 14 d after 
intervention to check for knockdown of cardiac miR-24. Therefore, heart tips were subjected 
to RNA analysis with subsequent miRNA RT-PCR. As shown in figure 3.36, antagomir-24 
lowers miR-24 expression in comparison to placebo control (10± 8.27 vs. 50000± 9290; p < 
0.001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.36: Ratio of miR24/RNU6b in scrambled antagomir or antagomir-24 treated murine hearts. 
Antagomir treatment followed twice after intervention. 14 d after coronary ligation, heart tips 
underwent total RNA isolation and miRNA detection. N = 7 animals per group. *** = p < 0.001 
 
 
3.6.2 Heart function tests after MI 
 
 
We first characterized basic cardiac parameters in the different study groups. For control 
reasons, an antagomir against a scrambled miRNA sequence (placebo/ctrl) was also injected. 
Analysis of cardiac function by echocardiography 14 days after initial intervention proved 
that MI led to an impairment of cardiac function measured by decreased fractional shortening 
in scrambled antagomir treated animals compared to sham (12.63 % ± 0.75 % vs. 36.12 % ± 
2.79 %; p < 0.001, figure 3.37a). In addition, an increase in lung wet weight (150.32 mg ± 
4.61 mg vs. 98.5 mg ± 5.17 mg; p < 0.001, figure 3.37b) and systolic (0.48 cm ± 0.02 cm vs. 
0.22 cm ± 0.017 cm; p < 0.001, figure 3.37c) as well as diastolic left ventricular diameter 
(0.55 cm ± 0.02 cm vs. 0.34 cm ± 0.016 cm; p < 0.001, figure 3.37d) was observed.  
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These observations were consistent to normal cardiac disease progression after MI. 
Remarkably, injecting antagomir-24 as an immediate interventional treament after MI at day 0 
and 2, partly rescued cardiac function when comparing parameters to scrambled antagomir 
treated group. First of all, fractional shortening was improved by antagomir-24 treatment 
(20.88 % ± 4.03 % vs. 12.63 % ± 0.75 %; p < 0.01, figure 3.37a). Additionally, pulmonary 
congestion decreased slightly (132.35 mg ± 7.16 mg vs. 150.32 mg ± 4.61 mg; p = n.s., figure 
3.37b). The increase in left ventricular systolic (0.36 cm ± 0.04 cm vs. 0.48 cm ± 0.02 cm; p < 
0.05, figure 3.37c) and diastolic dilatation (0.45 cm ± 0.03 cm vs. 0.55 cm ± 0.02; p < 0.05, 
figure 3.37d) was also attenuated. 
 
a  b 
 
 
 
 
 
 
 
 
c   d 
 
 
 
 
 
 
 
Figure 3.37: Basic heart parameters derived from mice subjected to antagomir-24 study 14 days after 
intervention. Three groups are indicated: sham, scrambled antagomir and antagomir-24. (a) 
Fractional shortening (FS) is lowered after MI. Antagomir-24 treatment increases FS compared to 
placebo. (b) Lung wet weight is increased after MI. Repression of miR-24 indicates prevention of 
pulmonary congestion. (c+d) Systolic and diastolic left ventricular diameters (LVs/LVd) are 
elevated due to MI. Eliminating miR-24 lowers the extension of LVs and LVd diameter. N = 4-7 
animals per group. * = p < 0.05; ** = p < 0.01; *** = p < 0.001 
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In conclusion, therapeutic antagomir-24 treatment after MI indicates a global improvement in 
cardiac function. Necessarily, underlying cardiac molecular mechanisms and general 
structural alterations have to be determined. 
 
 
3.6.3 Cardiac angiogenesis is improved upon antagomir-24 treatment 
 
 
Myocardial infarction leads to a hypoxic insult and upregulation of miR-24 in EC. In this 
work, in vitro data suggest a role for miR-24-dependent negative regulation of angiogenic 
signalling in endothelial cells. Antagonizing miR-24 expression might thus improve 
angiogenic response upon myocardial infarction in vivo. To test this hypothesis, mice 
underwent MI and were treated with antagomir-24. Finally, heart tissue from control 
scrambled antagomir or antagomir-24 treated animals was collected, sliced to appropriate 
sections and analyzed for CD31 expression, an endothelial cell marker indicating capillaries 
or vessels. In addition, sections were also stained for cardiomyocyte Troponin I (TnI) and 
nuclei (figure 3.38a). Remarkably, antagomir-24-receiving animals are characterized by an 
increased capillary density indicated by elevated CD31 staining (arbitrary units, a.u.) in 
border (12.13 ± 0.38 vs. 6.96 ± 0.25; p < 0.001, figure 3.38b) and infarct zone (10.50 ± 0.61 
vs. 4.96 ± 0.39; p < 0.001, figure 3.38b) in comparison to scrambled antagomir treated 
animals. However, capillar density remains unchanged in remote myocardium (8.63 ± 0.14 vs. 
8.17 ± 0.40; p = n.s., figure 3.38b). Taken together, these data proof a pro-angiogenic effect of 
therapeutic antagomir-24 treatment in diseased hearts. 
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Figure 3.38: Immunohistochemical analysis of murine heart tissue derived from antagomir-24 study. (a) Hearts 
from scrambled antagomir (ctrl) and antagomir-24 (Ant-24) treated mice were collected, sliced to 
10 µm sections and stained for CD31 (green), Troponin I (TnI, red) and nuclei (DAPI, blue). (B) 
Statistical summary of CD31-positive capillaries present in remote, infarct and border zone. N = 4 
animals per group. *** = p < 0.001 
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3.6.4 Implantation of matrigel plugs to characterize global 
neovascularization in vivo 
 
 
Basically, antagomir technique delivers cholesterol-bound antisense miRNAs to every organ 
except the brain. As shown before, antagonizing miR-24 in a murine disease model of 
myocardial infarction improves cardiac angiogenesis. The effect of antagomir-24 therapy on 
global neovascularization has not been monitored yet. To address this question a matrigel-
based assay to detect angiogenesis in vivo was applied (Akhtar et al., 2002). 
 
Matrigel plus were injected subcutaneously in mice in advance to antagomir-24 treatment. 
After one week, matrigels were collected and analyzed. Whole matrigels were divided into 
two pieces. One half underwent hemoglobin detection, the other part was analyzed by 
immunohistochemistry. Hemoglobin-specific ELISA validated that plugs derived from 
antagomir-24 treated mice showed an increased hemoglobin content compared to scrambled 
antagomir treated group (265.07 µg/mg ± 51.34 µg/mg vs. 88.65 µg/mg ± 34.89 µg/mg; p < 
0.05; figure 3.39). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.39: Hemoglobin (Hb) ELISA to quantify neovascularization in a matrigel plug assay. Matrigels were 
injected subcutaneously in mice. Control and antagomir-24 treatment followed and was repeated 
two days later. After one week matrigels were isolated and underwent hemoglobin-specific ELISA. 
Values were normalized to total protein content and validated statistically. N = 4 animals per group. 
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Immunohistochemical analysis of matrigel plugs further confirmed the pro-angiogenic 
property of antagomir-24 treatment. Sliced matrigel plugs were stained for endothelial CD31 
surface marker and nuclei (figure 3.40). Qualitatively, antagomir-24 treatment increased 
capillar density in implanted matrigels. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.40: Representative cyroscetions of implanted matrigel plugs to characterize angiogenesis. 14 d after 
matrigel implantation and treatment with control (scrambled antagomir) or antagomir-24 plugs 
were isolated and sliced. Endothelial staining (CD31, green) and nuclei stain (DAPI, blue) 
followed. 
 
 
In conclusion, antagomir-24 treatment promotes neovascularization in vivo and thus may  
be beneficial in treatment of ischemic cardiovascular disease. 
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4. Discussion 
 
 
The work presented here suggests a miR-24 based mechanism contributing to the regulation of 
capillary density in the infarcted heart (figure 4.1). Hypoxia or myocardial infarction 
increases endothelial miR-24 expression triggering endothelial cell apoptosis and vascular 
defects. Mechanistically, GATA2, H2A.X, RASA1 and PAK4 were validated as direct miR-
24 targets in endothelium. Further downstream signalling pathways were identified for 
GATA2 and PAK4. GATA2-dependent transcriptional regulation was found for diverse target 
genes including HMOX1 and SIRT1. MiR-24-induced repression of PAK4 directly decreases 
the phosphorylation status of Bad thus contributing to apoptosis. In a mouse model of MI, 
blocking of miR-24 by a specific antagonist (antagomir) enhances capillary density in the 
heart and preserves cardiac function. In conclusion, endothelial miR-24 serves as a pro-
apoptotic miRNA acting as a critical regulator of endothelial cell apoptosis and capillary 
density of the infarcted heart. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1: Scheme for the biological function of endothelial miR-24. Hypoxia or myocardial infarction 
induces expression of endothelial miR-24. As a consequence, miR-24 targets GATA2, H2A.X, 
PAK4 and RASA1 are repressed. PAK4 kinase activity is impaired leading to decreased level of 
anti-apoptotic phospho-Bad. Repression of GATA2 downregulates anti-apoptotic HMOX1 and 
deregulates the transcription of further angiogenic genes. Cumulatively, induction of endothelial 
miR-24 supports apoptosis and impairs capillary density. 
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4.1 MiR-24 deregulation in cardiac disease 
 
 
The endogenous expression of miR-24 increases in murine hearts after myocardial infarction 
(figure 3.1). MicroRNAs regulated after myocardial infarction have also been investigated 
earlier (van Rooij et al., 2008). However, in this previous publication, miR-24 has not yet 
been characterized. There are two genomic loci for miR-24 (mature miRs are identical, but 
miR-24-1* and miR-24-2* differ in sequence), which cluster together with miR-23/27a/b, and 
thus form a very complex miRNA family. Specifically, van Rooij et al. report a 
downregulation of miR-24-2* in the border zone of infarcted myocardium. Thus, two 
important facts have to be taken into account when the two findings are compared: First, only 
the mature miR-24 expression was investigated in the present work. Here, no data regarding 
the expression level of miR-24-1* or miR-24-2* were generated. No experiments to screen for 
changes in pre-miRNA expression were performed. However, further evidence for an 
upregulation in infarcted murine heart was gained by a collaboration with the RNA laboratory 
of Thomas Tuschl, Rockefeller University, New York. The Tuschl group performed miRNA 
in situ hybridization of cryosectioned hearts and found a strong miR-24 expression in 
infarcted versus sham control hearts (unpublished). Enhanced miR-24 signals indicate that a 
consistent upregulation is present in the infarct area 14 days after MI. A time course for miR-
24 expression during progression of cardiac disease has not been performed so far. However, 
we suggest that miR-24 induction starts early after MI based on the heart cell fractionation 
experiments 2d after MI (figure 3.6). 
 
The cellular source for miR-24 upregulation signal remains unclear but there are some first 
findings in the literature; miR-24 expression was attributed to microvascular cells derived 
from CD31+-sorting of different organs in mouse (Larsson et al., 2009). Therefore, it can be 
assumed that cardiac endothelial cells contribute by large to enhanced miR-24 signal upon MI. 
This hypothesis is also supported by different observations made in the current work. 
Fractionation of infarcted and control heart tissue into cardiomyocytes and endothelial cells 
revealed a selective miR-24 upregulation in endothelial cells 2 d after infarction whereas the 
expression level in cardiomyocytes remained basically unchanged (figure 3.6).  
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In addition, hypoxic atmosphere serving as a model for reduced oxygen supply post MI 
induces miR-24 expression specifically in endothelial cells in vitro (figure 3.3). However, no 
direct evidence was found for potential HIF1α dependent transcriptional regulation as it has 
been suggested earlier in cancer cell lines (Kulshreshta et al., 2007) or recently in lung and 
pulmonary arteries (Chan et al., 2010). One could speculate that endothelial miR-24 is 
regulated by different hypoxia-related transcription factors or other stress sensors because 
contribution of reactive oxygen species (ROS) towards miR-24 expression was recently 
reported (Takagi et al., 2010). Hepatocyte cells exposed to ROS inducing H2O2 were 
characterized by elevated miR-24 expression. This in turn modulated the expression of 
metabolizing enzymes like HNF4α and caused a defect in cell cycle progression indicating the 
need of tightly balanced miR-24 expression. The exact mechanism of miR-24 regulation in 
endothelial cells by hypoxia remains to be determined. 
 
Enhanced miR-24 expression levels post MI rise the question if the clustered miR-23/27a/b 
also are subject to transcriptional regulation in infarcted hearts. To address this issue, 
collaboration partners in the Tuschl laboratory also performed in situ hybridization for 
clustered miRNAs in cardiac tissue after MI. Indeed, they found a parallel upregulation of 
clustered miRNAs in the infarcted zone (unpublished). This in turn indicates that the miR-23-
27-24 cluster may act coordinatively in the infarcted heart, although different post-
transcriptional regulation has been observed within this miRNA cluster (Sun F et al., 2009; 
Buck et al., 2010). Synergistic effects of this miRNA cluster have also been reported for the 
regulation of Smads during hepatocytic differentiation (Rogler et al., 2009). The presented 
mechanism established a pivotal role of the miR-23b cluster for TGF-beta signalling with high 
expression levels shutting down the pathway. A previous functional study also suggests 
synergistic effects regarding apoptosis. Overexpression of clustered miR-23a-27a-24-2 
sensitized HEK293 cells to apoptosis either by the extrinsic or intrinsic apoptosis pathway 
(Chhabra et al., 2009). Nevertheless, functional studies for the other members miR-
23a/b/27a/b have not been addressed in this work. Therefore, putative effects of other 
members of this miRNA family on e.g. endothelial cell apoptosis or other endothelial 
functions cannot be ruled out. Analyzing the impact of modulated endothelial miR-
23a/b/27a/b expression should be investigated in further studies. Nevertheless, cooperative 
function in a miRNA cluster is not obligatory.  
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Recently, it has been shown that the miR-23a-27a-24-2 cluster is upregulated upon 
hypertrophic stimuli like aldosterone or isoproterenol in cardiomyocytes (Lin et al., 2009). 
Noteworthy, silencing of miR-23a only prevents aldosterone or isoproterenol induced 
cardiomyocyte hypertrophy whereas antagonizing miR-27a or miR-24 had no effects. In line 
with these observations, van Rooij et al. reported that adenoviral miR-24 overexpression 
induces cardiomyocyte hypertrophy (van Rooij et al., 2006). Additionally, enhanced miR-24 
expression was found in failing human hearts indicating that miR-24 has a role in progression 
and manifestation of cardiac failure, although the cellular source of this regulation was not 
examined in this work. Taken together, these investigations emphasize that miR-24 
dysregulation may have potential impact in other cardiac cells than endothelial cells which 
has not been addressed in this work. Besides these adverse effects for miR-24 on cardiac 
remodeling, interesting findings were made while exploring the miRNA expression panel 
upon ischemic preconditioning (IPC) (Yin et al., 2009). During IPC, that might serve as a 
cardioprotective approach, miR-1, miR-21 and miR-24 expression is induced. Parallel 
injection of these miRNAs led to a reduced infarct area upon ischemia/reperfusion which 
demonstrates that upregulation of miR-24 can also guide defense mechanisms prior to cardiac 
stress. However, the current work emphasizes that increased miR-24 expression induced by 
MI exerts negative effects on cardiac endothelial cell biology contributing to adverse cardiac 
remodeling. 
 
 
4.2 Induction of endothelial cell apoptosis by miR-24 
 
 
Myocardial infarction or hypoxia induces endothelial miR-24 expression (figure 3.1). 
Mimicking this situation in vitro modulates apoptosis outcome because miR-24 
overexpressing ECs suffer from more apoptotic events (figure 3.9). Therefore, endothelial 
miR-24 can be viewed as a pro-apoptotic miRNA. In contrast, antagonizing miR-24, even 
under hypoxic conditions, counteracts endothelial apoptosis (figure 3.10). Additionally, ROS 
generation increases in parallel further amplifying cellular stress signalling (figure 3.16). By 
this, EC biology is crucially disturbed as defined by impaired capillary tube formation in 
vitro. The importance of miRNAs for angiogenesis has been described by Suarez et al.  
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Silencing of the miRNA processing enzyme Dicer in ECs abolished capillary tube formation 
due to unprocessed, not functional miRNAs (Suarez et al., 2007). This clearly indicates that 
miRNAs are necessary for capillary formation. Interestingly, elevated miR-24 levels affected 
apoptosis in ECs only (figure 3.9). Other cardiac cell types such as cardiomyocytes or cardiac 
fibroblasts were unaffected. A possible explanation for this observation is the variance of 
protein expression patterns and thus potential miR-24 targets in these cell types. 
Cardiomyocytes, cardiac fibroblasts and endothelial cells have per se different functional 
relevance in the cardiac system. Thus, cellular transcriptome differs greatly with respect to 
functionality. In turn, this impacts on respective miRNA actions which is crucially dependent 
on its specific target availability within a given cell type. Taken together, endothelial cells 
seem to have a transcriptome “fitting” best for miR-24 induced apoptosis formation in 
comparison to other cardiac cells. Of great importance, the pro-apoptotic character of miR-24 
in ECs is quite strong since overexpression triggers apoptosis even in the presence of serum. 
The presence of serum normally protects cells and its withdrawal sensitizes cells towards 
apoptosis which is also in part dependent on miRNA function (Asada et al., 2008). The 
linkage of miRNAs towards the specific regulation of EC apoptosis has also recently been 
reported. The exposure of ECs to shear stress upregulated miR-21 (Weber et al., 2010). 
Increased miR-21 expression inhibited endothelial apoptosis although data from our group 
also show impairment of oxidative stress defense mechanisms in circulating angiogenic cells 
(unpublished). In this work, repression of endogenous miR-24 displayed anti-apoptotic 
character only. This emphasizes that derepression of direct miR-24 targets is responsible for 
anti-apoptotic signalling.  
 
Further investigations characterizing proliferation or migratory capacity in miR-24 
overexpressing ECs should be performed. Due to the proapoptotic effects of miR-24 in 
endothelial cells, it is likely that also other important characteristics of EC biology are 
affected. In fibroblasts, miR-24 inhibits proliferation and cell cycle via downregulation of 
E2F2 and Myc, whereas depleting miR-24 expression forced proliferation (Lal et al., 2009). 
Target recognition studies revealed interactions of miR-24 with “seedless” nucleotide 
elements in the 3´-UTR suggesting an alternative miRNA modus operandi.  
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Such different target regulation mechanisms were also found in cancer cells where miR-24 
displayed target recognition elements in the coding sequence of FAF1 thus abolishing 
apoptosis (Qin et al., 2010).  
 
The proapoptotic and antiangiogenic effects of miR-24 in mature endothelium raise the 
question if developmental processes in endothelial cells are also affected when miR-24 
expression is modulated. To dissect miRNA-dependent developmental processes, the 
zebrafish model is often used. MiRNAs are injected as either precursors or antagonists 
(morpholinos) into the developing zebrafish embryo. In a periode of two or three days after 
injection the developing embryo is monitored. Thus, to gain insights into the role of miR-24 
for vascular development, zebrafish experiments have been performed in cooperation (AG 
Prof. Brand, Cell and Developmental Biology, University Würzburg; laboratory moved over 
to Imperial College London recently). Transgenic zebrafishes bearing a flk-driven GFP 
reporter (flk:GFP), thus marking the vasculature, were modulated by injection of miRNA 
precursors. Indeed, enhanced miR-24 expression disturbed the formation of the vascular 
network indicated by lack of vessel branching and hemorrhage compared to control miRNA 
injected embryos (figure 4.1 and personal communication). The impairment of vascular 
development demonstrates that miR-24 can already influence EC biology during early stages 
in vivo. It is assumable that endothelial apoptosis, as described in this work, is triggered by 
enhanced miR-24 expression in the developing zebrafish and thus impairs vascularization 
processes.  
 
In parallel, amplifying the disturbances in vascular formation, erythropoiesis could be 
disturbed which was described for miR-24 in erythroleukemic K562 cells by interfering with 
ALK4 receptor mediating erythroid differentiation (Wang et al., 2008). In contrast, miR-24 
seems to negatively regulate apoptosis in the neural retina (Walker and Harland, 2009). In the 
developing Xenopus laevis, antagonizing miR-24 caused marked apoptosis in the eye by 
derepressing pro-apoptotic factors like Caspase-9. Thus, besides effecting vascular 
development demonstrated in zebrafish, also loss of miR-24 may exerts specific target 
derepression in other organs regulating critical cellular events.  
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Taken together, endothelial miR-24 influences cellular outcome in a pro-apoptotic manner and 
impairs the formation of new capillaries. The underlying molecular mechanisms are linked to 
the downregulation of target genes which should be considered as key players for EC biology. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2: Effect of miR-24 overexpression in flk1:GFP transgenic zebrafish. Control (ctr) or precursor-
miRNA-24 (premir-24) were injected into developing zebrafish embryos. 48 h post fertilization, 
vascular structures were monitored. Arrows indicate sites of vascular defects observed in miR-24 
mutant embryos (figure provided by AG Prof. Brand, Bettina Kirchmaier, Cell and Developmental 
Biology, University Würzburg). 
 
 
4.3 Target-specific regulation for miR-24 in ECs 
 
 
The use of in silico target prediction tools has accelerated the exploration of direct endothelial 
miR-24 targets. Target databases like targetscan (www.targetscan.org) were screened for 
endothelial expressed downstream effectors of miR-24. Recently, a comprehensive database 
comparing miRNA expression versus mRNA expression in different tissues has been 
introduced further assisting in miRNA target finding (Ritchie et al., 2010). Combining 
miRNA modulation with proteomics would be an interesting alternative to screen for global 
protein changes reflecting potential miRNA targets. 
 Discussion 
 116 
This work describes that endothelial miR-24 represses the protein level of GATA2, H2A.X, 
PAK4 and RASA1 (figure 3.18). Targets are abundantly expressed in cultured ECs as well as 
in cardiac tissue monitored by immunohistochemistry (data not shown). Mechanistically, 
downstream signalling was deciphered by different assays. Downregulation of GATA2, 
PAK4 and RASA1 mediates miR-24 apoptosis progression analyzed by transient silencing of 
these factors in ECs (figure 3.21). Capillary formation in vitro is disturbed by silencing of 
GATA2 and PAK4 only (figure 3.23). This highlights a general concept of combined miRNA 
target effects. Single target repression does not obligatory reflect miRNA-induced effects. The 
sum of global proteome changes is crucial since one single miRNA orchestrates often 
complete gene networks. Repressive miRNA effects are mostly modest with reduction rates of 
20-30% in protein. In turn, this fine-tuning balances different cellular events. Probably, miR-
24 has other endothelial targets that do not support apoptosis or angiogenesis defects. By way 
of example, p27/Kip1 expression was found to be repressed upon miR-24 overexpression in 
ECs (data not shown). The p27/Kip1 protein functions as a cell-cycle inhibitor potent of 
forcing cellular proliferation in cancer cells when depleted (Roy et al., 2008), which did not 
match to the aforementioned apoptotic phenotype. However the net effect of altered targets 
drive the phenotypic alterations. 
 
One of the most important endothelial miR-24 targets based on the results in this work, is the 
zinc-finger transcription factor GATA2. Downregulation of GATA2 impairs EC function 
measured by increased apoptosis rate, disturbance in cell cycle progression and finally 
decreased capillary formation (figures 3.21/22/23). Linkage of GATA2 to these processes has 
been reported in different settings. In line with the current work, reduced GATA2 expression 
coincidences with decreased cell survival in embryonic stem cells in vitro (Tsai and Orkin, 
1997). Moreover, GATA2 reduction in haploinsufficient animals was attributed to lower 
amounts of hematopoietic progenitors and in parallel to increased apoptotic events by 
reduction of anti-apoptotic Bcl-x (Rodrigues et al., 2005). Noteworthy, increased levels of 
GATA2 also support apoptotic signalling in a B-cell line by inducing pro-apoptotic alpha 
globin (Brecht et al., 2005). This indicates that GATA2 deregulation may impact on apoptosis 
in both ways. As aforementioned for miR-24 action, transcriptional activity of GATA2 is also 
dependent on target gene accessibility thus explaining cell-type specific effects. Furthermore, 
transcriptive (upstream) regulation sets another level for GATA2-guided signal pathways. 
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Although miRNA-mediated post-transcriptional control reported in this work is possible and 
also seen for miR-451 in zebrafish erythroid maturation (Pase et al., 2009), potential other 
regulative motifs in the enhancer/promotor region of GATA2 contribute to direct 
transcriptional regulation. For instance, GATA2 occupies sites in its own promoter thereby 
establishing a positive feedback loop (Martowicz et al., 2006; Wozniak et al., 2007). 
Remarkably, endothelial GATA2 is upregulated under hypoxic conditions (figure 3.24) which 
coincidences with hypoxia-induced VEGF expression regulating global angiogenesis (Marti 
and Risau, 1998). In addition, enhanced GATA2 expression has recently been shown to 
transduce angiogenic signalling by crosstalk with another transcription factor further 
emphasizing the pivotal angiogenic role of GATA2 (Mammoto et al., 2009). Besides its anti-
apoptotic, pro-angiogenic function, GATA2 also controls endothelial cell cycle progression 
since GATA2 knockdown induces G0/G1-arrest measured by DNA staining in this work 
(figure 3.22). Indeed, GATA2 expression has been linked to cell cycle control previously. 
Hematopoietic progenitor cells expressed GATA2 in an oscillating manner during cell cycle 
with highest expression in S-phase (Koga et al., 2007). Regarding the short half-life of a 
transcription factor oscillation is feasible but fast expression or dose changes have certainly 
profound effects on GATA2 target genes that are either transcriptionally induced or repressed.  
 
As shown in this work, GATA2 modulation experiments led to the identification of further 
downstream targets in ECs. Affymetrix gene chip analysis idenitified reciprocally regulated 
GATA2 target genes which then were further validated by ChIP analysis. Notably, BAMBI, 
ESMI and NTN4 have not been reported before as directly regulated by transcription factor 
GATA2. Nevertheless, ESM1 and NTN4 are deeply attributed to endothelial biology. During 
angiogenesis, endothel-specific molecule 1 (ESM1) is highly induced by angiogenic 
mediators VEGF-A and VEGF-C (Aitkenhead et al., 2002; Shin et al., 2008). Secreted netrin-
4 (NTN4) has also been proven as an active inductor of angiogenesis, even after ischemia in 
vivo and in the zebrafish model (Wilson et al., 2006). Controversially, endothelial NTN4 
knockdown increases tube formation ability on matrigel (Lejmi et al., 2008). This suggests 
pro-angiogenic property of NTN4 which is further reflected by the recent finding that GATA2 
silencing reduces NTN4 and then contributes to impaired tube formation in GATA2-deficient 
ECs. Next to the regulation of angiogenesis-related genes, GATA2 regulates heme 
oxygenase-1 (HMOX1) at the protein level (figure 3.28).  
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Loss-of function experiments in GATA2- and miR-24-deficient ECs demonstrated that miR-
24 target GATA2 is the critical regulator for HMOX1 repression in miR-24 overexpressing 
ECs (figure 3.29). HMOX1 has been described as a cytoprotective enzyme towards ischemic 
disease when administrated into the myocardium (Melo et al., 2002). Furthermore, carbon 
dioxide production by HMOX1 protects against EC apoptosis (Wang et al., 2007). 
Additionally, elevated HMOX1 expression reduced ROS levels in vascular ECs (Asija et al., 
2007). In contrast, HMOX1 downregulation induced by endothelial overexpression of miR-24 
expression induced maladaptive ROS as it has been shown in this work. Noteworthy, ROS 
generation is attributed to support cell apoptosis by facilitating cytochrome C release from 
mitochondrial intermembrane space (Petrosillo et al., 2003). Likewise, this scenario may also 
be present for miR-24 induced endothelial apoptosis. Besides HMOX1, histone deacteylase 
sirtuin1 (SIRT1) expression has been identified to be GATA2-dependent because SIRT1 
expression was markedly decreased in GATA2 deficient ECs (figure 3.30). Remarkably, 
SIRT1 has a central role in EC biology regulating angiogenic response in vitro and in vivo by 
post-translational modification of anti-angiogenic transcription factor Foxo1 (Potente et al., 
2007). Cumulatively, newly identified GATA2-regulated genes as well as effector proteins 
HMOX1 and SIRT1 emphasize a master function of endothelial transcription factor GATA2 
for endothelial homeostasis. 
 
Another important signal pathway identified in this work is the miR-24-induced repression of 
the anti-apoptotic kinase PAK4. Mechanistically, downregulation of endothelial PAK4 is 
responsible for decreased phospho-Bad expression observed in miR-24 overexpressing ECs 
(figures 3.15/32). This supports endothelial cell apoptosis which is accompanied by impaired 
tube formation in PAK4 silenced ECs. Indeed, previous reports have shown that PAK4 drives 
downstream phosphorylation of Bad thereby preventing its mitochondrial membrane binding 
which in turn is a prerequisite for apoptosis by cytochrome C release from the mitochondrial 
intermembrane space (Gnesutta et al., 2001; Hekman et al., 2006). In line, a defective 
vascular phenotype has also been observed for endothelial PAK4 knockdown before (Koh et 
al., 2008). Lessons from PAK4 knockout animals dying in the embryonic phase further 
revealed an essential role for developmental vessel formation which fits to the phenotype of 
aforementioned mutant zebrafish (Tian et al., 2009). It is likely that endothelial PAK4 not 
solely controls apoptotic decision by Bad phosphorylation.  
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Speculations on additional cellular tasks, like reported PKC-activated function for migration 
processes (Paliouras et al., 2009), links PAK4 kinase to further general cellular aspects which 
have not been adressed in the current work.  
 
Besides GATA2 and PAK4, endothelial miR-24 also targets RASA1 and H2A.X. 
Downstream analysis has not been performed for these factors but both proteins participate in 
miR-24 signalling. Notably, RASA1 knockouts also suffer from defective vasculogenesis and 
of clinical importance, as RASA1 mutations are regarded to guide capillary malformation-
arteriovenous malformation (Lapinski et al., 2007; Eerola et al., 2003). In a mechanistic view, 
RASA1 is negatively controlling mitogenic RAS activity by hydrolyzing GTP thus 
functioning as a tumor suppressor (Bos et al., 2007). However, endothelial RASA1 shows 
weak pro-apoptotic function and no effects on capillary tube formation were found (figures 
3.21/23). Endothelial modulation of miR-24 target H2A.X also revealed no severe functional 
changes measured by apoptosis analysis or capillary tube formation (figures 3.21/23). 
Interestingly, H2A.X mediates DNA strand repair by a miR-24 dependent mechanism in 
differentiated blood cells (Lal et al., 2009). Putatively, endothelial H2A.X executes similar 
functions. Therefore, repression would sensitize ECs to cellular stress mechanisms like 
apoptosis or ROS seen in this work.  
 
Altogether, endothelial cell characteristics are critically regulated by identified miR-24 
targets. Nevertheless, there are certainly more target proteins and signal mediators awaiting 
exploration. Despite the lack of comprehensive target overview, it should be emphasized that 
miR-24 signalling is maladaptive due to direct target repression and that antagonistic 
approaches may be favorable. 
 
 
4.4  Antagonizing miR-24 as a therapeutic option in 
treatment of cardiovascular disease 
 
 
The current working model suggests that blocking of elevated endothelial miR-24 expression 
counteracts endothelial detoriation in vitro. Theoretically, downstream target repression is 
abrogated and effects on apoptosis and vascularization are diminished.  
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Indeed, under basal and hypoxic conditions, anti-miRNA-24 transfection increases viable 
endothelial cell number (figure 3.9/10). Furthermore, repression of endogenous miR-24 
sustains and even slightly improves EC ability to form capillary tubes on matrigel (3.17). 
However, it is a great challenge to translate these findings into a therapeutic cardiovascular 
setting although translational miRNA research has been applied in different cardiac disease 
settings before. Usage of chemically modified antagonistic miRNA sequences, so-called 
”antagomirs”, markedly repressed endogenous miRNA expression in vivo and modulated 
disease recovery. By way of example, our group pioneered the first miRNA-based therapeutic 
approach in a cardiac hypertrophy model (Thum et al., 2008). Furthermore, antagonism of 
miR-92a improved vascularization in ischemic disease (Bonauer et al., 2009). In contrast, 
silencing of endogenous endothelial-specific miR-126 inhibited angiogenesis after ischemic 
insult (van Solingen et al., 2009). These findings indicate that miRNA downregulation can 
especially modulate angiogenic response. While Bonauer et al. applied a low dose for several 
times, van Solingen et al. applied a single high dose injection antagomir. In our study, 
titration experiments in comparing low (5 mg/kg) versus high (80 mg/kg) antagomir 
retroorbital application revealed that a low dose is sufficient to mainly target cardiac 
endothelial cells (figure 3.35). Therefore, antagomir was injected twice with 5 mg/kg after 
experimental MI to minimize antagomir off-side effects and effects on other cells such as 
cardiomyocytes. Analysis of miR-24 expression in placebo and antagomir-treated hearts 
validated an efficient repressive function of antagomir-24 in the cardiac system (figure 3.36). 
Certainly, other highly vascularized organs may also be affected but have not been in the 
scope of this study. To further exclude therapeutic side effects, other organs have to be 
intensively characterized to weigh positive versus negative effects of an antagomir-24 
treatment. 
 
Characterization of functional heart parameters after antagomir-24 treatment highlighted a 
general improvement in cardiac function (figure 3.37). Measurements for fractional 
shortening, left ventricular diameter and pulmonary congestion emphasized that cardiac 
function is preserved after MI-treatment with antagomir-24. Noteworthy, antagomir-24-
induced changes in cardiac function parameters point to a possible involvement of 
cardiomyocytes in the therapeutic response.  
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Induction of cardiomyocyte hypertrophy by miR-24 overexpression has been shown before 
(van Rooij et al., 2006). Nevertheless, application of low dose antagomir-24 should have 
precluded strong impact on none-endothelial cells. Taken together, a contribution of miR-24 
antagonism towards cardiomyocyte hypertrophy cannot be ruled out. 
 
The main idea for performing the antagomir-24 study resulted from the fact that miR-24 was 
upregulated after MI and triggered endothelial apoptosis. Taking into account that miR-24 
downregulation would positively influence on endothelial survival, it was assumed that miR-
24 repression is beneficial under ischemic disease conditions. In line, cardiac CD31 staining 
in placebo and antagomir-24 treated animals depicted a markedly enhanced capillary density 
in border and infarcted zone (figure 3.38). Enhanced angiogenesis after myocardial infarction 
is generally described by the release of growth factors like VEGF and induction in endothelial 
Flk-1 expression (Li et al., 1996). Therefore, blocking miR-24 expression is capable to 
support such vascular processes. In addition and also reflecting the proposed model, 
endothelial apoptosis might be blocked in antagomir treated hearts compared to placebo ones. 
Overall, increased cardiac capillary density contributes to improved cardiac function post 
antagomir-24 treatment. Further matrigel implantation experiments revealed a general 
improvement in vascularization by repression of miR-24 under basal conditions (3.39/40). 
This indicates that modulation of endogenous miR-24 expression may lead to side-effects 
related to cancer progression (for cancers that rely on angiogenesis). Indeed, miR-24 has been 
described as a tumor suppressor miRNA before (Mishra et al., 2009). Direct targeting of 
dihydrofolate reductase (DHFR) induced cell cycle arrest and blocked proliferation. Moreover 
and of importance, cancer tumor miRNA profiling revealed decreased miR-24 expression 
levels. Furthermore, DHFR single nucleotide polymorphisms in 3´-UTR comprising the miR-
24 binding site were attributed to chemodrug resistance (Mishra et al., 2007). These findings 
emphasize that miR-24 modulation guides angiogenic pathways in cancer disease. Therefore, 
in vivo application of antagomir-24 must be carefully considered. To overcome such diametral 
effects, meaning positive effects for capillary density in the heart but risk for cancer 
progression, antagomirs´ chemical characteristics need to be modified to develop cardiac 
specific approaches. Unspecific and systemic delivery should be substituted to a highly 
specific and efficient cell-type or organ delivery. 
 Discussion 
 122 
4.5 Concluding remarks 
 
 
The current work identified an endothelial miR-24 –related mechanism that may be translated 
into a potential cardiovascular therapeutic application. 
 
Hypoxia and myocardial infarction enhance miR-24 expression selectively in endothelial 
cells. Thereby, apoptosis in endothelial cells is induced and formation of capillary structures 
is abolished. Functional consequences are explained by the downregulation of important 
endothelial mediators GATA2, H2A.X, PAK4 and RASA1. MiR-24 antagonism prevented 
endothelial apoptosis and was applied in an in vivo model of myocardial infarction. 
Therapeutic intervention by injection of miR-24 antagonists preserved cardiac function and 
improved capillary density in the infarcted heart. 
 
Currently miRNA research covers many diseases and new therapeutic approaches may have 
great clinical relevance. Fundamental observations with respect to miRNA origin and 
mechanism are deciphered but many unsolved issues remain. For instance, upstream and 
downstream signalling differs for nearly every miRNA and needs to be deciphered in many 
cell types. Furthermore, translation into clinical scenarios is a future aim but careful 
consideration is needed since current antagomir approaches are systemic and not cell-type or 
organ specific and thus may have side-effects. Noteworthy, great efforts are underway to 
translate promising findings for the treatment of Hepatitis C infection in primates by 
repression of miR-122 to the clinic (Lanford et al., 2010) and indeed the first clinical study 
has recently started (Santaris, Denmark, personal communication). Thus, miRNA-dependent 
therapeutics will be in focus of future extensive characterization and clinical drug 
development. 
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Ang I: Angiopoietin I 
Ang II: Angiotensine II 
ANP: Atrial natriuretic peptide 
Anti-miR: Antagonistic miRNA 
bFGF: Basic fibroblast growth factor 
BNP: Brain natriuretic peptide 
APS:  Ammoniumpersulfate 
BAMBI: BMP and activin membrane-bound 
inhibitor homolog 
BSA:  Bovine serum albumine 
CAD: Coronary artery disease 
Caspases: Cysteinyl aspartate proteases 
CD31: Cluster of differentiation 31 
Cy3: Carbocyanine 3 
DAPI:  4´,6-diamidine-2-phenylindol 
DFA:  Desferrioxamine 
DISC: Death induced silencing complex 
DMEM:  Dulbecco´s modified eagle 
medium 
DMSO:  Dimethlysulfoxide 
DNA:  Desoxyribonuleic acid 
EDTA:  Ethylen diamine tetra-acetate 
ELISA:  Enzyme-linked immunosorbent 
assay 
EC:  Endothelial cell 
ECG: Electrocardiography 
ESM1: Endothelial cell-specific molecule 
1 
FACS:  Fluorescence-activated cell sorting 
FCS:  Fetal calf serum 
FITC: Fluoresceine isothiocyanate 
FS: Fractional shortening 
GAPDH:  Glyercolaldehyde-phosphate-
dehydrogenase 
GATA2: GATA-binding protein 2 
GFP: Green fluorescent protein 
H2A.X: Histone 2A family member X 
HEK293: Human embryonic kidney 293 
HEPES:  4-(2-hydroxyethyl)-1-
piperazineethane-sulfonic acid 
HIF-1α: Hypoxia-inducible factor 1α 
HMOX1: Heme oxygenase 1 
HRP:  Horseradish peroxidase 
HUVEC: Human umbilical vein endothelial 
cell 
LB:  Lysogeny broth 
LDL: Low-density lipoprotein 
LV: Left ventricle 
α-MHC: α-myosine heavy chain 
β-MHC: β-myosine heavy chain 
MACS:  Magnetic affinity based cell 
sorting 
MEM:  Minimum essential medium 
MI: Myocardial infarction 
NTN4: Netrin-4 
miRNA: microRNA 
nm:  nanometer 
nM:  nanomolar 
NP40:  Nonyl-
phenoxylpolyethoxylethanol 
NO: Nitric oxide 
PAK4: p21-activated kinase 4 
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PAGE:  Polyacrylamide gelelectrophoresis 
PBS:  Phosphate buffered saline 
Pen/Strep:  Penicilline/streptomycine 
PCR:  Polymerase chain reaction 
PI: Propidiume iodide 
PI3K: Phosphatidylinositol 3 kinase 
PKB: Protein kinase B 
PKC: Protein kinase C 
PVDF:  Polyvinyldifluoride 
PIPES:  1,4-(piperazinebis-ethane-sulfonic 
acid) 
Pre-miR: Precursor miRNA 
PVDF: Polyvinylidene fluoride 
RASA1: Ras p21 protein activator 
RISC: RNA-induced silencing complex 
RNA:  Ribonucleic acid 
RNase A:  Ribonuclease A 
ROS: Reactive oxygen species 
RT:  Room temperature 
RTK: Receptor tyrosine kinase 
RT-PCR: Real-time polymerase chain 
reaction 
Scr-miR: Scrambled miRNA 
SDS:  Sodiumdodecylsulfate 
siRNA: silencer RNA 
SIRT1: Sirtuin 1 
SOC:  Super optimal broth with 
catabolite repression 
TAC: Transverse aortic constriction 
TBP: TATA box binding protein 
TBST:  Tris buffered saline with triton 
TEMED:  Tetramethylendiamine 
TGF-β1: Transforming growth factor β1 
TNFα: Tumor necrosis factor α 
TnI: Troponin I 
TRIS:  Tris(hydroxymethyl)-
aminomethane 
VEGF: Vascular endothelial growth factor 
YFP:  Yellow fluorescent protein 
v/v:  volume per volume 
w/v:  weight per volume 
°C:  Degrees celsius 
µl:  microliter 
µM:  micromolar 
x g:  multiple of gravity 
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